<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cells</journal-id><journal-id journal-id-type="iso-abbrev">Cells</journal-id><journal-id journal-id-type="pmc-domain-id">2106</journal-id><journal-id journal-id-type="pmc-domain">cells</journal-id><journal-id journal-id-type="publisher-id">cells</journal-id><journal-title-group><journal-title>Cells</journal-title></journal-title-group><issn pub-type="epub">2073-4409</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11201516</article-id><article-id pub-id-type="pmcid-ver">PMC11201516.1</article-id><article-id pub-id-type="pmcaid">11201516</article-id><article-id pub-id-type="pmcaiid">11201516</article-id><article-id pub-id-type="pmid">38920700</article-id><article-id pub-id-type="doi">10.3390/cells13121071</article-id><article-id pub-id-type="publisher-id">cells-13-01071</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Tumor-Agnostic Therapy&#8212;The Final Step Forward in the Cure for Human Neoplasms?</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0009-1612-1732</contrib-id><name name-style="western"><surname>El-Sayed</surname><given-names initials="MM">Mohamed Mahmoud</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bianco</surname><given-names initials="JR">Julia Raffaella</given-names></name><xref rid="fn1-cells-13-01071" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0005-7324-2734</contrib-id><name name-style="western"><surname>Li</surname><given-names initials="Y">YiJing</given-names></name><xref rid="fn1-cells-13-01071" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fabian</surname><given-names initials="Z">Zsolt</given-names></name><xref rid="c1-cells-13-01071" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Kitatani</surname><given-names initials="K">Kazuyuki</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Chudakova</surname><given-names initials="DA">Daria A.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-cells-13-01071">School of Medicine and Dentistry, Faculty of Clinical and Biomedical Sciences, University of Central Lancashire, Preston PR1 2HE, UK; <email>mmelsayed@uclan.ac.uk</email> (M.M.E.-S.); <email>jrbianco@uclan.ac.uk</email> (J.R.B.); <email>yjli4@uclan.ac.uk</email> (Y.L.)</aff><author-notes><corresp id="c1-cells-13-01071"><label>*</label>Correspondence: <email>zfabian@uclan.ac.uk</email></corresp><fn id="fn1-cells-13-01071"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>20</day><month>6</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2024</year></pub-date><volume>13</volume><issue>12</issue><issue-id pub-id-type="pmc-issue-id">464885</issue-id><elocation-id>1071</elocation-id><history><date date-type="received"><day>01</day><month>5</month><year>2024</year></date><date date-type="rev-recd"><day>17</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>18</day><month>6</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>06</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>26</day><month>06</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-05-11 15:25:19.780"><day>11</day><month>05</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="cells-13-01071.pdf"/><abstract><p>Cancer accounted for 10 million deaths in 2020, nearly one in every six deaths annually. Despite advancements, the contemporary clinical management of human neoplasms faces a number of challenges. Surgical removal of tumor tissues is often not possible technically, while radiation and chemotherapy pose the risk of damaging healthy cells, tissues, and organs, presenting complex clinical challenges. These require a paradigm shift in developing new therapeutic modalities moving towards a more personalized and targeted approach. The tumor-agnostic philosophy, one of these new modalities, focuses on characteristic molecular signatures of transformed cells independently of their traditional histopathological classification. These include commonly occurring DNA aberrations in cancer cells, shared metabolic features of their homeostasis or immune evasion measures of the tumor tissues. The first dedicated, FDA-approved tumor-agnostic agent&#8217;s profound progression-free survival of 78% in mismatch repair-deficient colorectal cancer paved the way for the accelerated FDA approvals of novel tumor-agnostic therapeutic compounds. Here, we review the historical background, current status, and future perspectives of this new era of clinical oncology.</p></abstract><kwd-group><kwd>tumor-agnostic philosophy</kwd><kwd>pan-cancer mutations</kwd><kwd>biomarkers</kwd><kwd>next-generation sequencing</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-cells-13-01071"><title>1. Introduction</title><p>Cancer is among the leading causes of mortality in developed countries due to the high rate of morbidity and limited efficiency of contemporary therapeutic modalities. Indeed, lung cancer, for instance, accounts for an estimated 350 fatalities daily, making it the leading cause of cancer-related mortality across both sexes in 2022. From 2001 to 2017, an increase from 19% to 31% in 3-year survival outcome was observed. During this period, the median survival increased from 8 to 13 months [<xref rid="B1-cells-13-01071" ref-type="bibr">1</xref>]. Despite conventional chemotherapy being the primary treatment for non-small-cell lung cancer, the success rate was less than 5% [<xref rid="B2-cells-13-01071" ref-type="bibr">2</xref>].</p><p>Over the course of several decades, cancer management has predominantly relied on scrutinizing tumor tissue at the cellular and supracellular levels [<xref rid="B3-cells-13-01071" ref-type="bibr">3</xref>]. This has led to a site-specific approach in managing tumors, where guidelines are tailored, primarily, on the basis of their location within the human body. Accordingly, cancer research, clinical trials, and the development of anticancer drugs have, so far, hinged on histopathological classifications rather than addressing genetic alterations, highlighting the inherent limitations of these treatment regimes. Moreover, the lack of specificity of conventional therapies has been associated with adverse side effects and toxicity, while they may become ineffective over time as cancer cells develop drug resistance [<xref rid="B4-cells-13-01071" ref-type="bibr">4</xref>,<xref rid="B5-cells-13-01071" ref-type="bibr">5</xref>,<xref rid="B6-cells-13-01071" ref-type="bibr">6</xref>]. The limitations of conventional approaches urged a paradigm shift in developing new anticancer therapies that considers the unique molecular characteristics of cancer cells.</p><p>Accordingly, the landscape of cancer treatment has undergone a remarkable transformation with the rapid evolution of clinical genomic testing and simultaneous strides in precision cancer therapies. This has given rise to genomically targeted therapies and immune-boosting agents that represent a groundbreaking shift in cancer therapeutics.</p><p>Indeed, the repertoire of targeted therapies, designed to address specific molecular alterations, has witnessed an exponential surge in recent years [<xref rid="B7-cells-13-01071" ref-type="bibr">7</xref>]. The introduction of immunotherapy has propelled cancer treatment to a new dimension by harnessing the body&#8217;s own defenses to combat the disease [<xref rid="B8-cells-13-01071" ref-type="bibr">8</xref>]. Consequently, we find ourselves moving beyond the era of site-specific cancer management, witnessing the emergence of tissue-agnostic biomarkers spanning diverse cancer histologies. This shift has been primarily fueled by actionable alterations identified through next-generation sequencing and the development of drugs capable of precisely targeting these alterations.</p><p>While initially considered speculative, recent years have provided compelling evidence supporting the efficacy of biomarker-driven, tissue-agnostic therapeutics. Regulatory approvals have played a crucial role in validating this paradigm shift [<xref rid="B7-cells-13-01071" ref-type="bibr">7</xref>,<xref rid="B9-cells-13-01071" ref-type="bibr">9</xref>].</p></sec><sec id="sec2-cells-13-01071"><title>2. Tumor-Agnostic Philosophy</title><sec id="sec2dot1-cells-13-01071"><title>2.1. Advances in Understanding the Molecular Events of Tumor Development</title><p>Advancements in the preparation of histological samples and staining techniques for biological materials enabled researchers to offer a more intricate understanding of tumor structures. In the early 1800s, several scholars observed that neoplastic tumors consisted of cells with irregular shapes. This insight was initially articulated by Schleiden and M&#252;ller in 1838, and later corroborated by Schwann in 1839 [<xref rid="B10-cells-13-01071" ref-type="bibr">10</xref>]. They identified distinctive characteristics of neoplastic tumors, such as an increased rate of cell division, abnormal mitotic activity, enlarged cell nuclei, and a loss of cellular differentiation. Moreover, they noted additional tumor features like the surrounding stroma, blood vessels, and areas of necrosis, particularly within the cores of tumors. By the late 1800s, an increasing number of researchers leaned towards Virchow&#8217;s theory, that the root cause of the disease lay in cellular abnormalities (<xref rid="cells-13-01071-f001" ref-type="fig">Figure 1</xref>) [<xref rid="B11-cells-13-01071" ref-type="bibr">11</xref>].</p><p>During the 1970s, it became evident that the cells composing tumor masses display remarkable heterogeneity. They exhibit variations, such as differing resistance to drugs or sensitivity to signals prompting programmed cell death. Furthermore, over time, these cells become increasingly aggressive and acquire new capabilities, such as the ability to metastasize. While the &#8220;disease of genes&#8221; model of cancer recognized the role of mutations in initiating the disease, it failed to provide a comprehensive explanation for this progression. Consequently, it was inferred that there must exist a mechanism facilitating the emergence and accumulation of successive alterations.</p><p>The concept that viruses contribute to cancer development traces back to the research published by Peyton Rous in 1911 [<xref rid="B12-cells-13-01071" ref-type="bibr">12</xref>]. Rous identified a filterable agent, termed Rous sarcoma virus (RSV), in cell extracts from a chicken tumor capable of inducing tumors in healthy chickens. This groundbreaking discovery of a retrovirus laid the foundation for tumor virology, highlighting that certain cancers may have an infectious origin [<xref rid="B13-cells-13-01071" ref-type="bibr">13</xref>]. In the 1960s and 1970s, the first tumor viruses affecting humans were identified. The Epstein&#8211;Barr virus (EBV), also known as human herpes virus 4 (HHV-4), was first visualized in cells cultured from Burkitt&#8217;s lymphoma using electron microscopy, marking the inception of human tumor virology [<xref rid="B14-cells-13-01071" ref-type="bibr">14</xref>]. Subsequent immunofluorescence assays revealed heightened immune responses to EBV antigens in individuals with Burkitt&#8217;s lymphoma or nasopharyngeal carcinoma, and biopsy samples from these cancers exhibited the presence of EBV DNA [<xref rid="B15-cells-13-01071" ref-type="bibr">15</xref>].</p><p>By the 1960s, it became evident that cancer development is closely linked to genetic errors, which are passed on to descendant cells during subsequent divisions. This led to a shift in the interpretation of carcinogenesis from a cellular level to a molecular one, focusing on genetic abnormalities rather than cellular dysfunction [<xref rid="B16-cells-13-01071" ref-type="bibr">16</xref>]. The 1980s witnessed a surge in research focused on genes implicated in carcinogenesis. It became apparent that several genes identified in oncoviruses shared identical sequences with their cellular counterparts (e.g., SRC, initially discovered in avian DNA), eventually leading to the identification of cellular oncogenes [<xref rid="B17-cells-13-01071" ref-type="bibr">17</xref>].</p><p>In the early 1980s, orthologs of viral <italic toggle="yes">RAS</italic> oncogenes with point mutations were identified in DNA fragments from human cancer cells, marking a significant milestone in molecular oncology research [<xref rid="B18-cells-13-01071" ref-type="bibr">18</xref>,<xref rid="B19-cells-13-01071" ref-type="bibr">19</xref>]. This was followed by the discovery of cellular counterparts of further viral oncogenes, tumor drivers initially identified in retroviruses, including <italic toggle="yes">MYC</italic>, <italic toggle="yes">RAF</italic>, <italic toggle="yes">ERBB1</italic> (encoding Epidermal growth factor receptor [EGFR]), <italic toggle="yes">AKT</italic>, and <italic toggle="yes">SIS</italic> (encoding subunit B of the platelet-derived growth factor [PDGF]). Subsequent research revealed their key involvement in growth signaling pathways [<xref rid="B20-cells-13-01071" ref-type="bibr">20</xref>].</p><p>Research into chromosome abnormalities in cancer cells has revealed a striking finding: tumor cells may harbor an extensive array of mutations, possibly numbering in the thousands [<xref rid="B21-cells-13-01071" ref-type="bibr">21</xref>,<xref rid="B22-cells-13-01071" ref-type="bibr">22</xref>]. This substantial quantity prompted Loeb et al. to formulate the &#8220;mutator phenotype hypothesis,&#8221; suggesting that the conventional mutation rate in healthy cells falls short of explaining the abundance of mutations observed in cancer cells [<xref rid="B23-cells-13-01071" ref-type="bibr">23</xref>]. Consequently, mutations occurring in genes governing DNA synthesis fidelity or DNA repair (caretaker genes), as well as those encoding proteins involved in cell cycle regulation or apoptosis (gatekeeper genes), could significantly elevate the baseline mutation rate, potentially elucidating the multiple mutations found in tumor cells. The considerable surge in cancer risk as individuals age coincides with a shift from hematopoietic tumors, which tend to occur earlier in life, to epithelial carcinomas [<xref rid="B24-cells-13-01071" ref-type="bibr">24</xref>].</p><p>Genes implicated in the process of carcinogenesis are typically divided into three main categories: proto-oncogenes, tumor suppressor genes, and mutator genes. Proto-oncogenes are responsible for encoding proteins that stimulate cell division. When these genes undergo mutations, the resulting proteins can be overactivated, leading to uncontrolled cell proliferation. Conversely, tumor suppressor genes produce proteins that physiologically inhibit cell division and promote cell survival [<xref rid="B25-cells-13-01071" ref-type="bibr">25</xref>]. Mutator genes, on the other hand, are responsible for maintaining genome integrity, so upon their loss-of-function mutations, they induce chromosomal instability, which can result in mutations in proto-oncogenes and tumor suppressor genes. Additionally, mutator genes can lead to other mutations that confer a selective advantage for certain tumor cell clones to survive in their environment [<xref rid="B26-cells-13-01071" ref-type="bibr">26</xref>].</p><p>Current understanding suggests that the initiation of carcinogenesis typically requires gain-of-function mutations of proto-oncogenes and loss-of-function mutations of the tumor suppressor ones. Mutations in genes encoding proteins involved in apoptosis, DNA damage detection, and repair also play significant roles in oncogenesis. Cancer cells undergo a process of clonal selection, wherein the initial cells carry a variety of mutations, leading to diversity among their offspring [<xref rid="B27-cells-13-01071" ref-type="bibr">27</xref>]. While most genomic alterations have either neutral or detrimental effects on the cell phenotype, a select few confer a survival advantage. These advantageous clones proliferate and eventually dominate the tumor&#8217;s growth [<xref rid="B26-cells-13-01071" ref-type="bibr">26</xref>]. As tumor progression ensues, features that enhance cellular survival accumulate, such as genome instability, which increases the likelihood of additional mutations. Through clonal evolution, the most adapt clones emerge from the heterogeneous population of cancer cells to thrive within the tumor environment [<xref rid="B28-cells-13-01071" ref-type="bibr">28</xref>]. It is believed that cancer usually arises from multiple mutations in tumor-driver genes, with the accumulation of mutations being more critical than their specific sequence of appearance [<xref rid="B29-cells-13-01071" ref-type="bibr">29</xref>].</p></sec><sec id="sec2dot2-cells-13-01071"><title>2.2. Comparative Studies on the Molecular/Genetic Landscape of Individual Tumors</title><p>Advancements in our understanding of the carcinogenesis along with the development of high-throughput genomics inevitably led to the call for comprehensive investigations of the genetic landscapes of diverse neoplasms for mapping their molecular constellations [<xref rid="B30-cells-13-01071" ref-type="bibr">30</xref>]. Indeed, The Cancer Genome Atlas (TCGA) has conducted several pan-cancer genome studies, aiming to comprehensively analyze thousands of cancer genomes across multiple cancer types [<xref rid="B31-cells-13-01071" ref-type="bibr">31</xref>,<xref rid="B32-cells-13-01071" ref-type="bibr">32</xref>,<xref rid="B33-cells-13-01071" ref-type="bibr">33</xref>,<xref rid="B34-cells-13-01071" ref-type="bibr">34</xref>,<xref rid="B35-cells-13-01071" ref-type="bibr">35</xref>]. These studies have led to the extraction of 21 characteristic mutations from 30 types of cancers, providing a comprehensive landscape and dictionary of mutational signatures in major cancers [<xref rid="B31-cells-13-01071" ref-type="bibr">31</xref>]. Another systematic analysis of 3281 tumors from 12 cancer types to investigate the underlying mechanisms of cancer initiation and progression identified 127 significantly mutated genes involved in diverse cellular processes, including <italic toggle="yes">TP53</italic>, <italic toggle="yes">PTEN</italic>, <italic toggle="yes">APC</italic>, <italic toggle="yes">KRAS</italic>, and <italic toggle="yes">RB</italic> [<xref rid="B35-cells-13-01071" ref-type="bibr">35</xref>]. Identified genes were broadly classified into 20 categories, such as transcription factors/regulators, histone modifiers, transcription regulators, metabolic pathway elements, and genome integrity maintenance mediators [<xref rid="B36-cells-13-01071" ref-type="bibr">36</xref>].</p><p><italic toggle="yes">TP53</italic> emerged as the most frequently mutated gene in the pan-cancer cohort (42% of samples), with mutations being particularly prevalent in serous ovarian (95%) and serous endometrial carcinomas (89%). <italic toggle="yes">PIK3CA</italic> followed as the second most commonly mutated gene, observed frequently across most cancer types except ovarian serous carcinoma (OV), kidney renal clear cell carcinoma (KIRC), lung adenocarcinoma (LUAD), and acute myeloid leukemia (AML). Mutations in <italic toggle="yes">PIK3CA</italic> were notably enriched in luminal subtype tumors, notably in uterine corpus endometrial carcinoma (UCEC) (52%) and breast adenocarcinoma (BRCA) (33.6%). Interestingly, tumors lacking <italic toggle="yes">PIK3CA</italic> mutations often harbored mutations in <italic toggle="yes">PIK3R1</italic>, with significant occurrences in UCEC (31%) and glioblastoma multiforme (GBM) (11%) [<xref rid="B35-cells-13-01071" ref-type="bibr">35</xref>].</p><p>Chromatin remodeling genes displayed mutations across many cancer types, with histone-lysine N-methyltransferase genes (<italic toggle="yes">MLL2</italic>, <italic toggle="yes">MLL3</italic>, and <italic toggle="yes">MLL4</italic>) clustering notably in bladder, lung, and endometrial cancers. Additionally, mutations in <italic toggle="yes">ARID1A</italic> were frequent in bladder urothelial carcinoma (BLCA), UCEC, LUAD, and lung squamous cell carcinoma (LUSC), while <italic toggle="yes">ARID5B</italic> mutations were prevalent in UCEC (10%). Mutually exclusive <italic toggle="yes">KRAS</italic> and <italic toggle="yes">NRAS</italic> mutations were identified, with recurrent activating mutations observed commonly in colon and rectal carcinoma (COAD/READ) (30%, 5%, and 5% for <italic toggle="yes">KRAS</italic> (Gly 12), <italic toggle="yes">KRAS</italic> (Gly 13), and <italic toggle="yes">NRAS</italic> (Gln 61), respectively) [<xref rid="B35-cells-13-01071" ref-type="bibr">35</xref>].</p><p>Further intriguing insights have been uncovered by another large-scale survey (MSK-IMPACT) using prospective sequencing on tumors from over 10,000 cancer patients representing a diverse spectrum of solid tumor types [<xref rid="B30-cells-13-01071" ref-type="bibr">30</xref>]. The findings revealed that certain genes, previously deemed significant in TCGA studies, exhibited even higher mutation frequencies within the MSK-IMPACT dataset. Particularly notable was <italic toggle="yes">TP53</italic>, which displayed significantly elevated mutation rates across four tumor types (prostate cancer, kidney chromophobe carcinoma, glioblastoma, and gastric cancer) compared to TCGA. In prostate cancer alone, <italic toggle="yes">TP53</italic> mutations were over four times more prevalent in MSK-IMPACT (29%) than in TCGA (7%), consistent with prior observations linking <italic toggle="yes">TP53</italic> mutations to more aggressive disease [<xref rid="B37-cells-13-01071" ref-type="bibr">37</xref>].</p><p><italic toggle="yes">TP53</italic> emerged as the most frequently altered gene in the MSK-IMPACT dataset, affecting 41% of patients. Its mutations were notably prevalent in high-grade serous ovarian cancer (98%), esophageal adenocarcinoma (89%), and small-cell lung cancer (85%), often leading to functional inactivation through truncation or splicing disruption. Across 43 of the 62 primary tumor types studied, <italic toggle="yes">TP53</italic> alterations were present in over 10% of cases.</p><p>Following <italic toggle="yes">TP53</italic>, <italic toggle="yes">KRAS</italic> ranked as the second most frequently altered gene (15% of patients), with mutations predominantly observed in pancreatic adenocarcinoma (90%) and colon adenocarcinoma (44%). The G12 codon of <italic toggle="yes">KRAS</italic> stood out as the most frequently altered among the sequenced tumors, accounting for 80% of all <italic toggle="yes">KRAS</italic> mutations and 12% of individuals sequenced. Other commonly mutated loci included <italic toggle="yes">PIK3CAH1047</italic>, <italic toggle="yes">PIK3CAE545</italic>, and <italic toggle="yes">BRAFV600</italic>, each occurring in over 20 principal tumor types, indicating positive selection for these variants across diverse cancer lineages [<xref rid="B38-cells-13-01071" ref-type="bibr">38</xref>].</p><p>While some genes, like <italic toggle="yes">TP53</italic> and <italic toggle="yes">PIK3CA</italic>, displayed consistent mutation rates across multiple tumor types, others such as <italic toggle="yes">VHL</italic>, <italic toggle="yes">APC</italic>, and <italic toggle="yes">IDH1</italic> showed high mutation rates limited to only a few types of neoplasms. Certain gene fusions were also uniquely associated with particular cancer lineages, such as <italic toggle="yes">TMPRSS2-ERG</italic> in prostate cancer, <italic toggle="yes">EWSR1-FLI1</italic> in Ewing sarcoma, and <italic toggle="yes">DNAJB1-PRKACA</italic> in fibrolamellar hepatocellular carcinoma. However, excluding tumors with unusually high mutation rates, 97% of genes in the 410-gene panel showed mutations in at least five major tumor types, highlighting the potential benefits of comprehensive mutation profiling regardless of cancer lineage.</p><p>In addition to targeting the coding sequences of cancer-associated genes, MSK-IMPACT also captured the promoter region of <italic toggle="yes">TERT</italic>. Mutations occurring at two frequently recurring sites in the <italic toggle="yes">TERT</italic> promoter have been observed to generate new consensus binding sites for ETS family transcription factors. This leads to increased telomerase expression and decreased cell death. TERT promoter mutations were most commonly found in bladder cancer (70%), glioma (67%), thyroid cancer (60%), and melanoma (49%), particularly cutaneous melanoma. The researchers consistently noted a trend towards shorter survival among individuals with altered TERT promoters [<xref rid="B39-cells-13-01071" ref-type="bibr">39</xref>,<xref rid="B40-cells-13-01071" ref-type="bibr">40</xref>].</p></sec><sec id="sec2dot3-cells-13-01071"><title>2.3. Advances in Molecular Characterization of Patient Tumors</title><p>Advances in our understanding of the genetic mechanisms of tumor formation by large-scale genomic surveys for cancer-driver mutations, like TCGA and the International Cancer Genome Consortium (ICGC), paved the way for growing demands for high-throughput diagnostic tools for screening characterized molecular hallmarks of cancer in patient samples [<xref rid="B41-cells-13-01071" ref-type="bibr">41</xref>,<xref rid="B42-cells-13-01071" ref-type="bibr">42</xref>]. This fueled the implementation of novel technologies like next-generation sequencing (NGS) in the clinical practice of tumor diagnostics (<xref rid="cells-13-01071-f002" ref-type="fig">Figure 2</xref>). NGS allows for the sequencing of longer DNA sections faster than that of the current canonical sequencing technologies for a fraction of the cost. Using short segments of DNA or RNA, NGS uses libraries of these fragments tagged by adapter sequences that allows for efficient bidirectional amplification of all nucleotide fragments using standard primers generating both forward and reverse amplicons [<xref rid="B43-cells-13-01071" ref-type="bibr">43</xref>]. The process known as bridge amplification results in parallel amplification of each fragment of the sample. Sequencing is accomplished using the amplified fragments as template strands and polymerases that incorporate fluorescently labeled nucleotides to the growing strand. Fluorescently labeled nucleotides emit their characteristic signals upon incorporation. Their emission wavelengths and intensity are recorded to determine what nucleotide has been added to the growing strand. Synthesis takes place simultaneously along millions of templates in a common platform, and the emitted signal pattern is continuously recorded. This leads to the read of hundreds to thousands of fragment clusters at the same time, making the technology much more efficient than previous sequencing methods. Sequence information of the fragments finally lines up to reference genome sequences by dedicated algorithms to create the final sequence of the nucleotide sample tested (<xref rid="cells-13-01071-f002" ref-type="fig">Figure 2</xref>) [<xref rid="B43-cells-13-01071" ref-type="bibr">43</xref>].</p><p>NGS not only allows for broad mutation detection with faster speeds, allowing for early detection of neoplasms, but requires less patient sample material compared to other detection options [<xref rid="B44-cells-13-01071" ref-type="bibr">44</xref>]. The high-throughput nature of the NGS technology combined with the comprehensive catalog of cancer-driver genetic alterations allowed the innovation of NGS-based diagnostic panels that provide concise and affordable screening for cancer biomarkers in everyday clinical practice.</p><p>Indeed, over the past few years, several NGS-based cancer biomarker screening kits have been developed and introduced successfully to the hospital laboratory repertoire. One of the first FDA-approved functional screening panels (MSK-IMPACT) utilizing hybridization capture technology and next-generation sequencing was developed by the Memorial Sloan Kettering Cancer Center. This innovative panel has the power of not only screening for pathognomonic mutations within protein-coding regions but also detects copy number alterations, selected promoter mutations, and structural rearrangements across 410 onco- and tumor suppressor genes [<xref rid="B45-cells-13-01071" ref-type="bibr">45</xref>]. Without being limited to a given cancer type, the MSK-IMPACT panel has been successfully used in clinical settings for both aiding in patient&#8217;s enrollment to clinical trials and defining targeted drug therapies [<xref rid="B45-cells-13-01071" ref-type="bibr">45</xref>]. Since then, oncopanels have been developed further with different specifics and have become widely used in the current clinical practice (<xref rid="cells-13-01071-t001" ref-type="table">Table 1</xref>). Although NGS tends to be the most common approach to biomarker identification, it does not provide information on the biomarker status of target cells at the protein level. New advances in immunohistochemistry (IHC) can be used as another biomarker screening tool. Large-scale immunohistochemistry screening on tissue microarrays and tissue slice arrays has been proposed as a lower-cost and more efficient option with the aim to complement targeted therapy efforts [<xref rid="B46-cells-13-01071" ref-type="bibr">46</xref>].</p><p>Programmed death ligand 1 (PD-L1) binds to programmed death receptor 1 (PD-1) on lymphocytes, causing the lymphocytes to be inactivated. Some cancer cells have been seen to have an increase in PD-L1, resulting in host immune cells to be rendered inactive against cancer cells. PD-L1 immunohistochemistry assays are now in use to identify PD-L1-positive cancers. Currently, there are four main stains being worked on, 22C3, 28-8, SP142, and SP263, which differ in the antibodies used (<xref rid="cells-13-01071-t002" ref-type="table">Table 2</xref>) [<xref rid="B52-cells-13-01071" ref-type="bibr">52</xref>,<xref rid="B53-cells-13-01071" ref-type="bibr">53</xref>]. PD1 IHC has been of keen interest in triple-negative breast cancer and lung cancer [<xref rid="B52-cells-13-01071" ref-type="bibr">52</xref>,<xref rid="B53-cells-13-01071" ref-type="bibr">53</xref>,<xref rid="B54-cells-13-01071" ref-type="bibr">54</xref>].</p><p>It has been made very evident that the use of biomarkers is of great importance when it comes to early diagnosis and treatment options; therefore, there is a continuous need to make the discovery and identification of such biomarkers more efficient. In the detection of colorectal cancer (CRC), there is a very large influx of patient samples needed to be tested due to all individuals aged 50&#8211;75 in North America needing to be screened. Due to the large volume, more efficient and more cost-effective methods are advantageous. Currently, the common form of diagnosing CRC is through fecal occult blood testing, which tends to have a high false positive and false negative rate, or colonoscopies, which are quite invasive. High-throughput proteomic platforms allow for the screening of protein biomarkers. In high-throughput proteomic platforms, antibody mixtures are used to identify antigens on the protein that has been extracted from the biopsy. This method can be used in the detection of CRC via the use of aptamer-based screening. Stool is used as the sample and the results are verified using ELISA [<xref rid="B59-cells-13-01071" ref-type="bibr">59</xref>].</p><p>An emerging technique for the detection of biomarkers is electrical biosensors. Electrical biosensors allow you to identify a protein biomarker using molecular imprinting polymers (MIPs), which allow you to create a synthetic receptor for the biomarker you are looking for. The formation of these synthetic receptors has been shown to have more rapid and accurate identification of biomarkers [<xref rid="B60-cells-13-01071" ref-type="bibr">60</xref>]. Electrical biosensors have been showing fast and accurate readings at low detection levels, making them a very useful potential product in everyday care [<xref rid="B61-cells-13-01071" ref-type="bibr">61</xref>]. Electrical biosensors have already been used for both detecting well-known cancer biomarkers such as CEA and searching for new biomarkers like STEAP1, opening new frontiers in cancer diagnosis and management [<xref rid="B60-cells-13-01071" ref-type="bibr">60</xref>,<xref rid="B61-cells-13-01071" ref-type="bibr">61</xref>]. This technology can be very useful in the investigation of tumor-agnostic targets as well as opening the door to new targets through the ability to create a synthetic receptor, as natural receptors such as enzymes and antibodies can be high in cost as well as requiring strict conditions to function [<xref rid="B60-cells-13-01071" ref-type="bibr">60</xref>].</p></sec><sec id="sec2dot4-cells-13-01071"><title>2.4. Common Molecular Characteristics of Histopathologically Diverse Tumors</title><p>Using rapidly evolving contemporary high-throughput technologies, the tumor-agnostic approach became a clinical reality over recent years. By screening for characterized common tumor drivers, they provide information in continuously increasing details of the genetic constellation of individual tumors. These data shed light on biomarkers frequently occur in tumors that, formerly, were characterized as unrelated. Cell surface receptors are prominent examples of such tumor-agnostic markers (<xref rid="cells-13-01071-f003" ref-type="fig">Figure 3</xref>).</p><p>Indeed, neurotrophic tyrosine kinase receptors (NTRKs), for instance, have been found in several adult and pediatric malignances, including infantile fibrosarcoma, congenital mesoblastic nephroma, and papillary thyroid cancer [<xref rid="cells-13-01071-t001" ref-type="table">Table 1</xref>] [<xref rid="B62-cells-13-01071" ref-type="bibr">62</xref>]. In non-transformed tissues, NTRKs are involved in neuronal growth, differentiation, and survival. In transformed cells, however, NTRK encoding genes are often found to be fused with other genes, leading to their own constitutive upregulation and the consequent activation of their downstream effectors, including elements of the phospholipase C&#947;, mitogen-activated protein kinase (MAPK), and phosphatidylinositol 3 phosphate kinase signaling pathways [<xref rid="B63-cells-13-01071" ref-type="bibr">63</xref>,<xref rid="B64-cells-13-01071" ref-type="bibr">64</xref>].</p><p>The latter ones are particularly common targets for mutated cell surface receptors even beyond NTRKs. Anaplastic lymphoma kinase (ALK), a tyrosine kinase receptor mainly expressed in the brain, testis, and small intestines, also signals through the MAPK and PI3K pathways, regulating cell survival and proliferation [<xref rid="B65-cells-13-01071" ref-type="bibr">65</xref>]. <italic toggle="yes">ALK</italic> also seems to be prone to chromosomal rearrangements, resulting in fusion genes with recurring fusion partners like the nucleophosmin 1 gene (<italic toggle="yes">NPM1</italic>) or EMAP like 4 gene (<italic toggle="yes">EML4</italic>) [<xref rid="B66-cells-13-01071" ref-type="bibr">66</xref>,<xref rid="B67-cells-13-01071" ref-type="bibr">67</xref>]. <italic toggle="yes">NPM1</italic> produces chaperone proteins as wells as proteins that protect tumor suppressor protein ARF from being degraded by sequestering ARK into the nucleolus, while <italic toggle="yes">EML4</italic> is suspected to produce proteins involved in microtubule formation [<xref rid="B68-cells-13-01071" ref-type="bibr">68</xref>,<xref rid="B69-cells-13-01071" ref-type="bibr">69</xref>]. In these chimeras with its 5&#8242; region being lost, the 3&#8242; end of <italic toggle="yes">ALK</italic> usually remains intact, preserving its kinase and allowing ALK to be active without a ligand present, giving rise to constitutively active ALK activities. As a tumor-agnostic target, <italic toggle="yes">ALK</italic> rearrangements have been found in NSCLC, anaplastic large cell lymphoma, and breast cancer, among others [<xref rid="B62-cells-13-01071" ref-type="bibr">62</xref>,<xref rid="B70-cells-13-01071" ref-type="bibr">70</xref>,<xref rid="B71-cells-13-01071" ref-type="bibr">71</xref>].</p><p>Another receptor tyrosine kinase, ERBB2, also known as HER2, has also emerged as a powerful tumor-agnostic molecular signature. Although traditionally it has been known for its assignment with breast cancer, <italic toggle="yes">ERBB2</italic> overexpression, usually due to in-frame insertions and amplifications, has been identified in CRC and NSCLC alike [<xref rid="B71-cells-13-01071" ref-type="bibr">71</xref>,<xref rid="B72-cells-13-01071" ref-type="bibr">72</xref>,<xref rid="B73-cells-13-01071" ref-type="bibr">73</xref>]. ERBB2 is a member of the epidermal growth factor receptor family, primarily signaling through the MAPK cascade and phosphatidylinositol pathways, orchestrating the expression of genes involved in the regulation of cell cycle progression and survival [<xref rid="B74-cells-13-01071" ref-type="bibr">74</xref>]. Besides ERBB2, the RET receptor tyrosine kinase plays a similar role among the cell surface cohort of tumor-agnostic biomarkers. <italic toggle="yes">RET</italic> plays a central role in early human development, but in adult tissues, its functions are unclear [<xref rid="B75-cells-13-01071" ref-type="bibr">75</xref>]. <italic toggle="yes">RET</italic> fusions with other genes, commonly <italic toggle="yes">KIF5B</italic>, cause RET receptor tyrosine kinase to be constitutively active and have been frequently detected in NSCLC and papillary thyroid neoplasms [<xref rid="B76-cells-13-01071" ref-type="bibr">76</xref>]. In accordance with the tumor-agnostic philosophy, however, mutated <italic toggle="yes">RET</italic> variants were also found in neoplasms of breast tissue, widening the diagnostic and treatment repertoire for HER2-negative and -positive breast cancers which are resistant to current traditional treatment [<xref rid="B77-cells-13-01071" ref-type="bibr">77</xref>,<xref rid="B78-cells-13-01071" ref-type="bibr">78</xref>].</p><p>Abnormal signaling from cell surface receptors eventually converges on conserved signaling pathways, like the MAPK one, that play central roles in the regulation of the cell cycle. Thus, it is not surprising that rate-limiting elements of these signal transduction machineries are also commonly found to be mutated in histologically diverse neoplasms and, therefore, could serve as tumor-agnostic biomarkers. One of these proven candidates is <italic toggle="yes">KRAS</italic>, which produces a protein of the RAS family. KRAS undergoes a conformational change when bound to GTP that allows its interaction with GTPase-activating proteins (GAPs), resulting in its endogenous GTPase activity being amplified [<xref rid="B79-cells-13-01071" ref-type="bibr">79</xref>,<xref rid="B80-cells-13-01071" ref-type="bibr">80</xref>]. Several solid tumors, including NSCLC and colorectal cancers, are associated with <italic toggle="yes">KRAS</italic> mutations, of which the most common one is G12C missense mutations [<xref rid="B81-cells-13-01071" ref-type="bibr">81</xref>,<xref rid="B82-cells-13-01071" ref-type="bibr">82</xref>,<xref rid="B83-cells-13-01071" ref-type="bibr">83</xref>]. G12C produces a KRAS that is more favorably bound to GTP, rendering KRAS constitutively active [<xref rid="B84-cells-13-01071" ref-type="bibr">84</xref>]. Constitutive activation of KRAS will result in the upregulation of downstream components of the MAPK pathway, leading to the dysregulation of the cell cycle [<xref rid="B84-cells-13-01071" ref-type="bibr">84</xref>]. <italic toggle="yes">BRAF</italic>, a serine/threonine protein kinase that functions as a proximal effector of the MAPK pathway downstream of RAS, is also commonly mutated in histologically unrelated human tumors, making BRAF another tumor-agnostic target [<xref rid="B85-cells-13-01071" ref-type="bibr">85</xref>]. Indeed, although mutated <italic toggle="yes">BRAF</italic> has, traditionally, been associated with melanoma, it has also been identified in gliomas, NSCLC, colorectal tumors, head and neck neoplasms, and hepatocellular carcinomas [<xref rid="B71-cells-13-01071" ref-type="bibr">71</xref>,<xref rid="B85-cells-13-01071" ref-type="bibr">85</xref>,<xref rid="B86-cells-13-01071" ref-type="bibr">86</xref>]. <italic toggle="yes">BRAF</italic>&#8217;s most common cancer-causing missense mutation, V600E, renders BRAF to be constitutively active as a monomer, leading to abnormal firing of the critical intracellular machinery that governs cell cycle progression [<xref rid="B86-cells-13-01071" ref-type="bibr">86</xref>].</p><p>Tumor suppressor genes also play a central role in the regulation of cell division, so it is not surprising that their mutations are seen in almost all human neoplasms [<xref rid="B87-cells-13-01071" ref-type="bibr">87</xref>]. Indeed, <italic toggle="yes">TP53</italic>, which encodes for p53, a protein involved in cell cycle arrest and apoptosis, is one of the most commonly mutated genes in human neoplasms, predicting it to be an ideal tumor-agnostic target [<xref rid="B35-cells-13-01071" ref-type="bibr">35</xref>]. However, extensive research on <italic toggle="yes">TP53</italic> revealed more than 1000 diverse mutations, some of which are dominant negative ones that make the mutant variant interfere with wildtype p53, while other mutations are rather loss-of-function ones [<xref rid="B88-cells-13-01071" ref-type="bibr">88</xref>]. The extensive variety of mutations plays into the difficulty in using <italic toggle="yes">TP53</italic> as a direct tumor-agnostic target. The cell cycle regulator retinoblastoma protein (Rb), which blocks cell cycle progression via E2F, is also commonly mutated in diverse human tumors from the originally associated pediatric retinoblastoma to breast cancer or osteosarcoma [<xref rid="B89-cells-13-01071" ref-type="bibr">89</xref>,<xref rid="B90-cells-13-01071" ref-type="bibr">90</xref>]. E2F is a regulatory transcription factor that mediates cell cycle progression by controlling the expression of genes like cyclins [<xref rid="B91-cells-13-01071" ref-type="bibr">91</xref>]. Upon the CDK4/6-mediated phosphorylation of Rb, E2F is released, and the cell prepares for cell division by entering the S phase. Mutated <italic toggle="yes">RB</italic> fails to block E2F, allowing cells to progress through the cell cycle [<xref rid="B91-cells-13-01071" ref-type="bibr">91</xref>]. Interestingly, <italic toggle="yes">Rb</italic>, similar to <italic toggle="yes">TP53</italic>, also shows a high degree of mutational mosaicism, at least in part, due to the considerable quantity of CpG islands within the gene, making its direct pharmacological targeting particularly challenging [<xref rid="B92-cells-13-01071" ref-type="bibr">92</xref>,<xref rid="B93-cells-13-01071" ref-type="bibr">93</xref>]. Thus, current research is moving towards marking additional elements of the p53 and Rb pathways, like the negative p53 regulator MDM2 or the CDK4/6 that inhibits Rb, for potential use as tumor-agnostic biomarkers [<xref rid="B94-cells-13-01071" ref-type="bibr">94</xref>,<xref rid="B95-cells-13-01071" ref-type="bibr">95</xref>,<xref rid="B96-cells-13-01071" ref-type="bibr">96</xref>].</p><p>To prevent the accumulation of mutations in genes including the proto-onco- and tumor suppressor ones, maintenance of the genome integrity is critical. Thus, mutations of the mutator genes, including both caretaker genes, which are involved in DNA repair and genome stability, and gatekeeper genes, which are involved in apoptosis, are also widespread in transformed cells, making them potential tumor-agnostic targets [<xref rid="B97-cells-13-01071" ref-type="bibr">97</xref>]. Indeed, germline and acquired mutations in the emblematic member of the caretaker genes, breast cancer gene 1 and 2 (<italic toggle="yes">BRCA1</italic>/2), are ordinarily associated with breast cancer but have been documented in ovarian and prostate cancers as well [<xref rid="B98-cells-13-01071" ref-type="bibr">98</xref>,<xref rid="B99-cells-13-01071" ref-type="bibr">99</xref>,<xref rid="B100-cells-13-01071" ref-type="bibr">100</xref>]. The mutational pattern of <italic toggle="yes">BRCA1/2</italic>, however, poses challenges. Hereditary <italic toggle="yes">BRCA1/2</italic> mutations vary amongst ethnic groups studied, and there is no singular mutation associated with acquired <italic toggle="yes">BRCA1</italic>/2. In the Japanese population, L63X and Q934X of <italic toggle="yes">BRCA1</italic> are the most common mutations, while in the Ashkenazi Jewish population, 5382insC or 185delAG in <italic toggle="yes">BRCA1</italic> and 6174delT in <italic toggle="yes">BRCA2</italic> are the most prevalent [<xref rid="B101-cells-13-01071" ref-type="bibr">101</xref>,<xref rid="B102-cells-13-01071" ref-type="bibr">102</xref>]. <italic toggle="yes">BRCA1/2</italic> encodes for proteins involved in the repair of DNA double-strand breaks [<xref rid="B100-cells-13-01071" ref-type="bibr">100</xref>]. Thus, <italic toggle="yes">BRCA1/2</italic> mutations, along with mutations in other mutator genes like <italic toggle="yes">ATM</italic> and <italic toggle="yes">CHEK2</italic>, have been exploited as tumor-agnostic markers, but in a unique application [<xref rid="B87-cells-13-01071" ref-type="bibr">87</xref>]. <italic toggle="yes">ATM</italic> produces a protein kinase that, when activated, allows for the downstream signals of DNA repair activity to begin, including the activation of <italic toggle="yes">BRCA1/2</italic> and <italic toggle="yes">CHEK2</italic> [<xref rid="B103-cells-13-01071" ref-type="bibr">103</xref>]. <italic toggle="yes">CHEK2</italic> produces a protein which is rapidly phosphorylated upon DNA damage and prevents the cell from entering mitosis [<xref rid="B104-cells-13-01071" ref-type="bibr">104</xref>]. CHEK2 is also responsible for the activation of BRCA1 and BRCA2 [<xref rid="B104-cells-13-01071" ref-type="bibr">104</xref>]. Inhibition of the poly(adenosine diphosphate [ADP]&#8211;ribose) polymerases (PARPs), which are involved in single-strand break repairs, in neoplasms with <italic toggle="yes">BRCA1/2</italic>, <italic toggle="yes">ATM</italic> and <italic toggle="yes">CHEK2</italic> mutations causes single- and double-strand breaks at the replication forks which will, eventually, lead to the disassembly of the replication fork and, consequently, cell cycle arrest [<xref rid="B87-cells-13-01071" ref-type="bibr">87</xref>,<xref rid="B105-cells-13-01071" ref-type="bibr">105</xref>,<xref rid="B106-cells-13-01071" ref-type="bibr">106</xref>,<xref rid="B107-cells-13-01071" ref-type="bibr">107</xref>].</p></sec><sec id="sec2dot5-cells-13-01071"><title>2.5. Molecular Signatures of the Tumor Microenvironment for Tumor-Agnostic Targets</title><p>Besides the intracellular ones, breakthrough discoveries in tumor immunology shed light on molecular signatures that can serve as tumor-agnostic targets at supracellular levels as well. Indeed, with the rapidly growing attention to the role of the immune system in the development of neoplasms, molecules that are critical in the interaction between the immunocompetent cells and the tumor microenvironment emerged as primary targets for contemporary tumor-agnostic treatment regimes.</p><p>The tumor microenvironment (TME) is the complex and dynamic cellular environment where a tumor develops. It includes various immune cells such as T and B lymphocytes, tumor-associated macrophages, dendritic cells, natural killer cells, neutrophils, and myeloid-derived suppressor cells; stromal cells like cancer-associated fibroblasts, pericytes, and mesenchymal stromal cells; the extracellular matrix; and secreted molecules such as growth factors, cytokines, chemokines, and extracellular vesicles [<xref rid="B108-cells-13-01071" ref-type="bibr">108</xref>]. Additionally, it encompasses the blood and lymphatic vascular networks. These elements are interconnected and interact with the heterogeneous cancer cells. The TME significantly contributes to the acquisition and maintenance of cancer hallmarks, such as sustaining proliferative signaling, evading cell death, promoting angiogenesis, enabling invasion and metastasis, triggering tumor-promoting inflammation, and avoiding immune destruction [<xref rid="B109-cells-13-01071" ref-type="bibr">109</xref>]. Due to the pivotal role of the TME in tumor progression and its influence on the effectiveness of cancer treatments, strategies to target the TME have greatly expanded in recent years. These approaches mainly focus on targeting TAMs, DCs, T cells, tumor vasculature, extracellular matrix, and cancer-associated fibroblasts.</p><p>Within the TME, tumor-associated macrophages (TAMs) can quickly respond to local stimuli such as cytokines or therapeutic interventions, adopting a range of phenotypes from proinflammatory to anti-inflammatory states [<xref rid="B110-cells-13-01071" ref-type="bibr">110</xref>,<xref rid="B111-cells-13-01071" ref-type="bibr">111</xref>]. This plasticity is influenced by factors such as the stage of the disease, the affected tissue, and the host microbiota, collectively determining whether TAMs inhibit or promote tumorigenesis [<xref rid="B112-cells-13-01071" ref-type="bibr">112</xref>,<xref rid="B113-cells-13-01071" ref-type="bibr">113</xref>]. Targeting macrophages in therapy offers dual benefits: it can block TAMs from directly aiding cancer cell survival and can enhance the cross-presentation to CD8+ T cells, thereby increasing their antitumor efficacy [<xref rid="B113-cells-13-01071" ref-type="bibr">113</xref>]. There are a number of putative biomarkers to pharmacologically control TAM activities including CSF1 and chemokine receptors, costimulatory molecules like CD40, or elements of intracellular pathways like PI3K that all affect the antitumor phenotypes.</p><p>Three key characteristics of dendritic cells (DCs) are essential for eliciting a robust and sustained antitumor response: effective migration between lymphoid and non-lymphoid tissues, cross-presentation of tumor-associated antigens (TAAs) to CD8<sup>+</sup> cytotoxic T lymphocytes to initiate strong effector responses against the tumor, and the release of chemokines and cytokines to regulate the overall immune response and T-cell homing [<xref rid="B114-cells-13-01071" ref-type="bibr">114</xref>]. This makes DCs promising targets for cancer immunotherapy. Higher densities of DCs, particularly classic dendritic cells, within the TME are associated with improved prognosis in ovarian carcinoma, lung cancers, and breast cancers [<xref rid="B115-cells-13-01071" ref-type="bibr">115</xref>,<xref rid="B116-cells-13-01071" ref-type="bibr">116</xref>,<xref rid="B117-cells-13-01071" ref-type="bibr">117</xref>]. However, the TME can disrupt DC functions through various mechanisms. These include reduced production of chemoattractants (e.g., CCL4 and CCL5), which hampers DC recruitment to the tumor site, and decreased levels of survival signals like FMS-like tyrosine kinase 3 ligand (FLT3L), crucial for DC differentiation and viability [<xref rid="B118-cells-13-01071" ref-type="bibr">118</xref>]. These disruptions result in insufficient T-cell activation and may induce T-cell tolerance to TAAs [<xref rid="B118-cells-13-01071" ref-type="bibr">118</xref>].</p><p>Current cancer immunotherapies targeting T cells involve two main strategies: enhancing the antitumor activity of T cells by inhibiting immune checkpoints and boosting adaptive immunity through the adoptive transfer of genetically engineered T cells, such as those with chimeric antigen receptors (CARs) or modified T-cell receptors [<xref rid="B119-cells-13-01071" ref-type="bibr">119</xref>]. Several negative regulators, or checkpoint molecules, control T-cell activation to prevent immune system overactivity. The prototype of them is the pair of cytotoxic T lymphocytes programmed death receptor 1 (PD-1) and its ligand (PD-L1) (<xref rid="cells-13-01071-f004" ref-type="fig">Figure 4</xref>). Unlike the canonical tumor-driver biomarkers, neither PD-1 nor PD-L1 are mutated in the context of PD-L1-positive neoplasms. Still, distinct cancer types harboring apparently unrelated tumor-driver mutations have been demonstrated to be positive for PD-L1 expression, making the PD-1/PD-L1 axis an excellent tumor-agnostic target [<xref rid="B120-cells-13-01071" ref-type="bibr">120</xref>,<xref rid="B121-cells-13-01071" ref-type="bibr">121</xref>]. Elevated expression of PD-L1 of cancer cells paralyzes tumor-infiltrating lymphocytes through engaging their PD-1 receptor, resulting in suppression of both the innate and adaptive antitumor immunity. PD-L1 positivity has been documented in a wide range of neoplasms including head and neck cancers, NSCLC, and thyroid, tongue, and pancreatic cancers [<xref rid="B120-cells-13-01071" ref-type="bibr">120</xref>,<xref rid="B121-cells-13-01071" ref-type="bibr">121</xref>]. In many of these neoplasms, elevated PD-L1 expression is thought to be associated with the repression of miR-197, suggesting that the blockade of a transcriptional regulatory mechanism plays a part in the induction of PD-L1-encoding <italic toggle="yes">CD274</italic> in certain transformed cells [<xref rid="B121-cells-13-01071" ref-type="bibr">121</xref>]. <italic toggle="yes">BRAF</italic> mutation-positive colorectal cancers have also been shown to have increased PD-L1 expression, suggesting that the MAPK pathway is involved in the regulation of <italic toggle="yes">CD274</italic> expression in the intestinal epithelium [<xref rid="B122-cells-13-01071" ref-type="bibr">122</xref>,<xref rid="B123-cells-13-01071" ref-type="bibr">123</xref>]. Colorectal cancers, similar to endometrial and gastric tumors, frequently show accumulation of mutations in <italic toggle="yes">MLH1</italic>, <italic toggle="yes">MSH2</italic>, <italic toggle="yes">MSH6</italic> or <italic toggle="yes">PMS2</italic>, genes that encode elements of mismatch repair, typically resulting in a high degree of microsatellite instability [<xref rid="B73-cells-13-01071" ref-type="bibr">73</xref>]. Since these neoplasms have characteristic increases in the number of tumor-infiltrating lymphocytes, their PD-L1 status has fundamental importance in the tumor-agnostic design of their therapeutic approach [<xref rid="B124-cells-13-01071" ref-type="bibr">124</xref>,<xref rid="B125-cells-13-01071" ref-type="bibr">125</xref>,<xref rid="B126-cells-13-01071" ref-type="bibr">126</xref>].</p><p>In addition to PD-1/PDL-1, cytotoxic T-lymphocyte antigen-4 (CTLA-4) is another immune checkpoint effector that has recently emerged as a tumor-agnostic biomarker [<xref rid="B127-cells-13-01071" ref-type="bibr">127</xref>]. Physiologically, ligation of CTLA-4 by its ligand B7, expressed on antigen-presenting cells, triggers an inhibitory response of T-lymphocyte activity [<xref rid="B127-cells-13-01071" ref-type="bibr">127</xref>]. Thus, pharmacological targeting of the CTLA-4/B7 complex is believed to deliberate T-cell activity from cancer-mediated paralysis and serve as a potential tumor-agnostic target.</p><p>An alternative coreceptor that also participates in T-cell activation is lymphocyte activation gene-3 (LAG-3). LAG-3, a member of the immunoglobulin superfamily, is expressed on the surface of immune cells and actively suppresses T-cell proliferation and effector T-cell function [<xref rid="B128-cells-13-01071" ref-type="bibr">128</xref>]. LAG-3 is structurally and functionally similar to CD4, which ligates with various binding partners, including major histocompatibility complex class II. LAG-3 ligation greatly inhibits CD8<sup>+</sup> T cells due to their higher LAG-3 expression. Although LAG-3 is often co-expressed with PD-1 on tumor-infiltrating lymphocytes, they are distinct immune checkpoint inhibitors that can be regulated and expressed independently. Consequently, LAG-3 is often upregulated in various neoplasms, including melanoma, to mediate T-cell exhaustion [<xref rid="B128-cells-13-01071" ref-type="bibr">128</xref>,<xref rid="B129-cells-13-01071" ref-type="bibr">129</xref>]. Besides PD-1, CTLA4, and LAG3, other immune checkpoint molecules like TIM3 and TIGIT have also been identified as potential tumor-agnostic targets for T-cell-mediated cancer immunotherapy [<xref rid="B130-cells-13-01071" ref-type="bibr">130</xref>,<xref rid="B131-cells-13-01071" ref-type="bibr">131</xref>,<xref rid="B132-cells-13-01071" ref-type="bibr">132</xref>].</p><p>Compared to healthy tissues, tumor vasculature is often irregular and dysfunctional, exhibiting heterogeneous vascular permeability. This results from several morphological and functional changes, including high endothelial cell (EC) proliferation rates, reduced cellular tight junctions, abnormal pericyte coverage, and increased extracellular matrix (ECM) deposition [<xref rid="B133-cells-13-01071" ref-type="bibr">133</xref>]. These vascular abnormalities can lead to inefficient oxygen delivery, creating a hypoxic environment within the tumor, which is associated with increased cancer aggressiveness [<xref rid="B134-cells-13-01071" ref-type="bibr">134</xref>]. Additionally, the dysfunctional vessels can selectively block the infiltration of specific immune cells, such as cytotoxic T lymphocytes, and significantly hinder the delivery and distribution of therapeutic agents [<xref rid="B135-cells-13-01071" ref-type="bibr">135</xref>]. Consequently, targeting tumor vasculature has become a major focus in the study of the TME. Efforts have mainly concentrated on depleting vasculature using antiangiogenic therapies and enhancing drug and immune cell delivery through vessel normalization [<xref rid="B136-cells-13-01071" ref-type="bibr">136</xref>,<xref rid="B137-cells-13-01071" ref-type="bibr">137</xref>,<xref rid="B138-cells-13-01071" ref-type="bibr">138</xref>,<xref rid="B139-cells-13-01071" ref-type="bibr">139</xref>,<xref rid="B140-cells-13-01071" ref-type="bibr">140</xref>,<xref rid="B141-cells-13-01071" ref-type="bibr">141</xref>,<xref rid="B142-cells-13-01071" ref-type="bibr">142</xref>].</p><p>The extracellular matrix (ECM) is a complex network of proteins and macromolecules, such as collagens, glycoproteins, elastin, fibronectins, and proteoglycans, which cells secrete into the space between them [<xref rid="B143-cells-13-01071" ref-type="bibr">143</xref>]. ECM composition varies greatly among different organs, and in comparison to healthy tissues, tumor ECM is characterized by increased density, coverage, and stiffness. Within the tumor microenvironment, multiple cell types contribute to ECM production. Beyond providing structural support, the ECM plays a crucial role in regulating the behavior of both cancer cells and other cells within the TME. For example, heightened stiffness of the surrounding tissue can trigger the epithelial-to-mesenchymal transition in cancer cells, a process associated with increased tumor invasiveness, stemness, and metastasis [<xref rid="B144-cells-13-01071" ref-type="bibr">144</xref>]. Moreover, the abnormal accumulation of ECM interferes with therapeutic effectiveness by physically impeding the penetration of drugs and activating signaling pathways like integrin and focal adhesion kinase, which promote cell survival and resistance to chemotherapy [<xref rid="B145-cells-13-01071" ref-type="bibr">145</xref>]. Furthermore, specific patterns of ECM-related gene expression have been linked to poor patient prognosis and resistance to therapy across various cancer types [<xref rid="B146-cells-13-01071" ref-type="bibr">146</xref>,<xref rid="B147-cells-13-01071" ref-type="bibr">147</xref>,<xref rid="B148-cells-13-01071" ref-type="bibr">148</xref>]. In pediatric osteosarcoma, elevated expression of ECM remodeling genes like desmoplakin or SPARCL1 contributes to chemotherapy resistance [<xref rid="B146-cells-13-01071" ref-type="bibr">146</xref>], while in breast cancer, high levels of genes like TWIST are associated with a worse outcome [<xref rid="B147-cells-13-01071" ref-type="bibr">147</xref>,<xref rid="B148-cells-13-01071" ref-type="bibr">148</xref>]. Many research efforts have focused on strategies to degrade ECM components, such as using collagenases or hyaluronidases to improve drug distribution [<xref rid="B149-cells-13-01071" ref-type="bibr">149</xref>]. Alternatively, given the dynamic nature of ECM remodeling by enzymes produced within the TME, an unconventional therapeutic approach involves directly targeting the synthesis of ECM components. This could be achieved by inhibiting key signaling pathways like TGF&#946; or HIF1&#945;, which promote ECM production, or by targeting the modifying enzymes necessary for ECM component synthesis, secretion, and maturation [<xref rid="B150-cells-13-01071" ref-type="bibr">150</xref>,<xref rid="B151-cells-13-01071" ref-type="bibr">151</xref>].</p><p>Cancer-associated fibroblasts (CAFs) are pivotal in shaping the tumor microenvironment by producing ECM molecules. These fibroblasts facilitate tumor growth through several mechanisms. Not only do they deposit ECM, but they also produce matrix remodeling enzymes that promote tumor invasion, metastasis, and resistance to therapies. Furthermore, CAFs secrete various cytokines, exosomes, and growth factors, such as leukemia inhibitory factor (LIF) and growth differentiation factor 15 (GDF15), which further drive tumor growth and invasion [<xref rid="B152-cells-13-01071" ref-type="bibr">152</xref>,<xref rid="B153-cells-13-01071" ref-type="bibr">153</xref>,<xref rid="B154-cells-13-01071" ref-type="bibr">154</xref>]. The influence of CAFs extends beyond tumor cells to other TME components, including the vasculature and immune cells. For instance, CAF-derived VEGF stimulates angiogenesis, while cytokines like IL6, CXCL9, and TGF&#946; modulate T-cell responses [<xref rid="B155-cells-13-01071" ref-type="bibr">155</xref>,<xref rid="B156-cells-13-01071" ref-type="bibr">156</xref>]. This complex interaction network highlights the crucial role of CAFs in cancer progression and the dynamic nature of the TME.</p><p>Developments in our understanding of cellular transformation and the revolution in molecular biology-based diagnostic technologies led to the current paradigm shift in clinical oncology from the former histopathological classification of human neoplasms to the molecular aberration-focused approach we now know as the tumor-agnostic philosophy.</p></sec></sec><sec id="sec3-cells-13-01071"><title>3. Tumor-Agnostic Treatment Philosophy in Current Clinical Oncology</title><p>The identification of key tumor-driver mutations led to the concept of novel anticancer strategies on the basis of targeting common biomarkers of human neoplasms. Regulatory approvals underpinned this paradigm shift, with the FDA greenlighting new therapies tailored for tissue-agnostic indications [<xref rid="B7-cells-13-01071" ref-type="bibr">7</xref>,<xref rid="B9-cells-13-01071" ref-type="bibr">9</xref>].</p><sec id="sec3dot1-cells-13-01071"><title>3.1. Tumor-Agnostic Applications in Contemporary Clinical Practice</title><sec><title>Immunotherapies</title><p>Pembrolizumab, the first FDA-approved tumor-agnostic medicine, is a humanized monoclonal antibody that directly binds to PD-1 of T lymphocytes, interfering with the ligation of PD-L1 and preventing the tumor cell-mediated inhibition of PD-L1<sup>+</sup> lymphocytes [<xref rid="B126-cells-13-01071" ref-type="bibr">126</xref>,<xref rid="B157-cells-13-01071" ref-type="bibr">157</xref>]. In clinical trials, its use showed impressive results, with an objective response rate (ORR) of 40%, a disease control rate (DCR) of 90%, and progression-free survival of 78% in mismatch repair-deficient colorectal cancer patients [<xref rid="B158-cells-13-01071" ref-type="bibr">158</xref>]. In endometrial, small bowel, and gastric cancers, as well as in cholangiocarcinoma patients, the same measures showed 67%, 71%, and 71% for progression-free survival (PFS), ORR, and DCR, respectively [<xref rid="B157-cells-13-01071" ref-type="bibr">157</xref>,<xref rid="B158-cells-13-01071" ref-type="bibr">158</xref>]. Thus, it is not surprising that it was granted accelerated approval by the United States Food and Drug Administration (FDA) for patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) positive tumors in 2017 [<xref rid="B159-cells-13-01071" ref-type="bibr">159</xref>]. The approval was based on combined data from five single-arm trials, involving a total of 149 patients diagnosed with MSI-H/dMMR cancers, with the majority (90 patients) having colorectal cancer. Pembrolizumab exhibited manageable adverse reactions, and recent findings from the phase II KEYNOTE-158 study confirmed its robust and durable antitumor efficacy. A complete response was observed in a wide range of tumor types, including small intestine, gastric, ovarian, endometrial, and cholangiocarcinomas. The response was durable, with a 47.5-month median duration of the clinical response [<xref rid="B126-cells-13-01071" ref-type="bibr">126</xref>].</p><p>Following the approval in 2017, continuous evaluation of pembrolizumab has also revealed its efficiency in treating solid tumors with high metastatic tumor mutational burden (TMB-H) [<xref rid="B160-cells-13-01071" ref-type="bibr">160</xref>]. High TMB is defined as the occurrence of more than 10 somatic mutations per megabase and is seen in various histologically unrelated human neoplasms [<xref rid="B160-cells-13-01071" ref-type="bibr">160</xref>,<xref rid="B161-cells-13-01071" ref-type="bibr">161</xref>]. Based on the rationale that these tumors might be treated more efficiently using immune checkpoint inhibitors than targeting their complex and likely dynamic mutational pattern, pembrolizumab was granted a second accelerated approval by the FDA for patients with TMB-H-positive, unresectable, or metastatic solid tumors in 2020 [<xref rid="B160-cells-13-01071" ref-type="bibr">160</xref>,<xref rid="B161-cells-13-01071" ref-type="bibr">161</xref>].</p><p>The rapid and successful implementation of pembrolizumab in practical oncology has led to the development of additional monoclonal antibodies targeting biomarkers involved in the evasion of antitumor immune responses (<xref rid="cells-13-01071-t003" ref-type="table">Table 3</xref>). One of these candidates is PD-L1 itself, and humanized monoclonal anti-PD-L1 antibodies, e.g., atezolizumab, have already been developed to block PD-L1&#8217;s engagement with inhibitory T-cell proliferation regulators PD-1 and B7, thus preventing T-cell depletion and increasing T-cell-mediated immunity against neoplasms [<xref rid="B162-cells-13-01071" ref-type="bibr">162</xref>,<xref rid="B163-cells-13-01071" ref-type="bibr">163</xref>]. Atezolizumab has already received FDA approval as the first-line treatment for patients with metastatic non-small-cell lung cancer if they express high levels of PD-L1 or have PD-L1-stained tumor-infiltrating immune cells covering more than 10% of the tumor area and do not possess genomic mutations or rearrangements in epidermal growth factor receptor (<italic toggle="yes">EGFR</italic>) or <italic toggle="yes">ALK</italic>. Drug efficacy was evaluated in the IMpower110 clinical trial that compared platinum-based chemotherapy to atezolizumab and documented an impressive improvement in overall survival (OS), with a median OS of 20.2 months compared to the 12.1-month OS of patients receiving chemotherapy only [<xref rid="B164-cells-13-01071" ref-type="bibr">164</xref>].</p><p>In addition to PD-1/PDL-1, antibody-mediated targeting of cytotoxic T-lymphocyte antigen-4 (CTLA-4) has also been developed [<xref rid="B127-cells-13-01071" ref-type="bibr">127</xref>]. Targeted by the human monoclonal antibody ipilimumab, the antibody-mediated ligation of CTLA-4 blocks its interaction with its ligand B7, expressed on antigen-presenting cells, and the blockade of this interaction is believed to facilitate cytotoxic T-lymphocyte activity [<xref rid="B127-cells-13-01071" ref-type="bibr">127</xref>,<xref rid="B165-cells-13-01071" ref-type="bibr">165</xref>]. On that basis, in 2020, the FDA approved ipilimumab as the first-line treatment for patients with non-small-cell lung cancers in combination with nivolumab (another PD-1 inhibitor) if immunohistochemistry confirms PD-L1 expression &#8805;1% and tumor panel investigations show no presence of <italic toggle="yes">EGFR</italic> or <italic toggle="yes">ALK</italic> mutations [<xref rid="B166-cells-13-01071" ref-type="bibr">166</xref>]. Drug efficacy was observed through the CHECKMATE-227 trial, with an overall response rate of 36%. The trial also showed 23% of the patients surviving at least 5 years, which is remarkably significant considering the poor prognosis associated with non-small-cell lung cancers, where the 5-year survival rate is merely 7% [<xref rid="B166-cells-13-01071" ref-type="bibr">166</xref>,<xref rid="B167-cells-13-01071" ref-type="bibr">167</xref>].</p><p>Since CTLA-4 and PD-1 inhibitors act on immune checkpoint regulators in a complementary manner, it is not surprising that their use in combination frequently provokes immune-related adverse reactions. Although the majority of these side effects are mild to moderate and can be well managed with supportive treatments without discontinuing nivolumab and ipilimumab, there have been reports of fatalities due to autoimmune myocarditis, colitis, and myasthenia gravis associated with the use of them as well [<xref rid="B168-cells-13-01071" ref-type="bibr">168</xref>]. The clinical management of these severe side effects is particularly challenging due to the observation that their onset can occur even after drug clearance [<xref rid="B168-cells-13-01071" ref-type="bibr">168</xref>]. To address these challenges, a recent modeling study, based on multiomics investigations, found a close correlation between the number of InDel and point mutations of cancer cells, the amount of tumor-infiltrating lymphocytes, and the risk of immune-related adverse events, highlighting the importance of mutational evaluations of neoplasms before indicating combinatorial immune checkpoint therapies. This modeling also suggests that upon the elevated predicted risk of immune-related adverse events, a reduction in the dosage of immune checkpoint inhibitors circumvents the unfolding of their severe side effects [<xref rid="B169-cells-13-01071" ref-type="bibr">169</xref>].</p><p>The use of bispecific recombinant monoclonal antibodies, like tebotelimab, might be a solution to reduce the severe side effects of combinatorial immune checkpoint inhibitor therapies. Tebotelimab targets both PD-1 and LAG-3 either simultaneously or independently. Its bivalent design ensures individual blocking of PD-1 and LAG-3 from their respective ligands, irrespective of their co-expression. Binding to either PD-1 or LAG-3 promotes cell adherence, thereby increasing the local antibody concentration. Since tumor cells often compensate for the initial pharmacological blockade by inducing secondary checkpoint mediators, the bispecific nature of tebotelimab allows for the effective inhibition of the secondary checkpoint mediator on the same cell [<xref rid="B128-cells-13-01071" ref-type="bibr">128</xref>]. Tebotelimab induces greater T-cell activity and IFN-&#947; production than monophasic PD-1 or LAG-3 therapies alone or in combination, while exhibiting better tolerance. The potential benefit of dual inhibition of PD-1 and LAG-3 treatments in patients resistant to PD-1 inhibitors, however, is yet to be investigated [<xref rid="B128-cells-13-01071" ref-type="bibr">128</xref>].</p><p>Another plausible way to address the challenges that the use of immune checkpoint inhibitors might pose is the use of these medicines in combination with other agents that exploit distinct mechanisms of action (<xref rid="cells-13-01071-t004" ref-type="table">Table 4</xref>). Indeed, besides the rapid development of immune checkpoint-targeting medicines, direct tumor drivers have also served as subjects for targeted drug developments. This class of tumor-agnostic agents typically includes small-molecule pharmacological inhibitors that show a high degree of specificity to their dedicated tumor driver targets, so they can complement immune checkpoint-targeting monoclonal antibodies in combinatorial treatments. Indeed, a recent randomized phase III trial investigating the efficacy of the combination of PD-1, CTLA-4, and BRAF/MEK inhibitors dabrafenib and trametinib in melanoma patients showed significant clinical benefits [<xref rid="B170-cells-13-01071" ref-type="bibr">170</xref>].</p><p>Dabrafenib and trametinib have been developed to selectively inhibit mutated BRAF and mitogen-activated protein kinase 1 and 2 (<italic toggle="yes">MEK1</italic> and <italic toggle="yes">MEK2</italic>) through competitive ATP-binding site inhibition and allosteric blockade, respectively. <italic toggle="yes">BRAF</italic> mutations have high prevalence in melanomas, papillary thyroid cancers, and non-small-cell lung cancers, although it was also detected in gliomas and gastric cancers. Interestingly, BRAF inhibitors alone, paradoxically, activate the MAPK pathway, fueling the fear of secondary neoplasms. In combination, however, dabrafenib and trametinib effectively block the MAPK pathway and suppress the proliferation of BRAF V600E cells [<xref rid="B171-cells-13-01071" ref-type="bibr">171</xref>,<xref rid="B172-cells-13-01071" ref-type="bibr">172</xref>,<xref rid="B173-cells-13-01071" ref-type="bibr">173</xref>]. Accordingly, dabrafenib and trametinib has been approved for use in combination for patients with anaplastic thyroid cancer (ATC) harboring the V600E BRAF mutation, when no other satisfactory treatments are available [<xref rid="B174-cells-13-01071" ref-type="bibr">174</xref>].</p><p>Competitive ATP-binding inhibitors selective for mutated kinases have now been developed for various cytoplasmic and receptor kinases and have already found their way into everyday clinical practice. Larotrectinib, for instance, a highly selective NTRK inhibitor, has already been approved for patients with solid tumors harboring chimeric <italic toggle="yes">NTRK</italic> genes without a known acquired resistance mutation [<xref rid="B175-cells-13-01071" ref-type="bibr">175</xref>,<xref rid="B176-cells-13-01071" ref-type="bibr">176</xref>]. Clinical data suggest that Larotrectinib can pass the blood&#8211;brain barrier, an important aspect considering the prevalence of NTRK mutations among neoplasms [<xref rid="B177-cells-13-01071" ref-type="bibr">177</xref>]. Indeed, chimeric mutant <italic toggle="yes">NTRK</italic>s were found in a variety of adult and pediatric neoplasms including infantile fibrosarcoma, pediatric papillary thyroid carcinoma, and NSCLC, of which the latter ones can form metastases within the CNS [<xref rid="B175-cells-13-01071" ref-type="bibr">175</xref>,<xref rid="B177-cells-13-01071" ref-type="bibr">177</xref>]. Unfortunately, Larotrectinib is believed to have high affinity to P-Glycoprotein (P-GP), a well-characterized ABC transporter that is key to the efflux of the blood&#8211;brain barrier, suggesting a lower maximum concentration of the agent achievable within the CNS [<xref rid="B178-cells-13-01071" ref-type="bibr">178</xref>]. Other competitive ATP-binding NTRK inhibitors, like entrectinib, however, have weaker P-GP affinities, allowing higher brain-to-plasma concentration ratios [<xref rid="B178-cells-13-01071" ref-type="bibr">178</xref>]. Indeed, clinical data showed a complete response in patients with brain metastases of NTRK-positive lung cancer as well as significant disease reduction in NTRK-positive glioneuronal tumors following entrectinib exposure, highlighting its effectiveness against both primary and metastatic brain neoplasms [<xref rid="B179-cells-13-01071" ref-type="bibr">179</xref>]. Entrectinib, in addition, has inhibitory effects on both ALK and the receptor tyrosine kinase ROS proto-oncogene 1 (ROS1), extending its therapeutic applications beyond NTRK-mutated tumors [<xref rid="B62-cells-13-01071" ref-type="bibr">62</xref>,<xref rid="B180-cells-13-01071" ref-type="bibr">180</xref>]. Indeed, in clinical trials, efficacy has been documented in both NTRK-mutated and mutated ROS1-harboring neoplasms [<xref rid="B62-cells-13-01071" ref-type="bibr">62</xref>].</p><p>Recently, another highly selective ATP-competitive inhibitor for RET, selpercatinib, has been approved by the FDA for treating tumors positive for mutant <italic toggle="yes">RET</italic> alleles [<xref rid="B181-cells-13-01071" ref-type="bibr">181</xref>]. Positive responses to selpercatinib have been reported in various tumors including pancreatic adenocarcinoma, salivary, colorectal, ovarian, breast, and small intestine cancers, soft-tissue sarcomas, bronchial carcinoids, and cholangiocarcinomas alike [<xref rid="B181-cells-13-01071" ref-type="bibr">181</xref>]. Further details on the FDA-approved tumor-agnostic drugs are provided in <xref rid="cells-13-01071-t003" ref-type="table">Table 3</xref>.</p><table-wrap position="anchor" id="cells-13-01071-t003" orientation="portrait"><object-id pub-id-type="pii">cells-13-01071-t003_Table 3</object-id><label>Table 3</label><caption><p>FDA-approved tumor-agnostic medicines currently implemented in clinical practice. PD-1, programmed cell death protein 1; PD-L1, programmed death ligand 1; CTLA-4, Cytotoxic T-lymphocyte associated protein 4; NTRK, neurotrophic receptor tyrosine kinase; RET, Rearranged during Transfection; ORR, overall response rate; DOR, duration of response; 1-y PFS, 1-year progression-free survival; mDOR, median duration of the response.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target</th><th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Edvidence for Approval</th><th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Common Adverse Effects</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">FDA Approval</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Pembrolizumab</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">PD-1</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Combined data consisting of 149 patients enrolled across five single-arm studies. ORR: 39.6% (31.7&#8211;47.9%; 95% CI); mDOR &#8805; 6 months in 78% of patients</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Reported in &#8805;20% of patients including cough, fatigue, nausea, rash, pruritus, decrease appetite, arthralgia, diarrhea, and constipation</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">2017</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B159-cells-13-01071" ref-type="bibr">159</xref>,<xref rid="B182-cells-13-01071" ref-type="bibr">182</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Dostarlimab</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">PD-1</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Analysis derived from an ongoing, open label, single-arm multi-cohort phase I study. ORR: 43.5% (34.0&#8211;53.4%; 95% CI); mDOR: was not reached.</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Reported in &#8805;20% of patients including nausea, diarrhea, fatigue, anemia, and constipation</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">2021</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B183-cells-13-01071" ref-type="bibr">183</xref>,<xref rid="B184-cells-13-01071" ref-type="bibr">184</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Larotrectinib</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">NTRK</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Combined data consisting of 55 patients enrolled across three single-arm studies. ORR: 75% (61&#8211;85%; 95% CI); 1-y PFS: 55%; mDOR: was not reached.</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Reported in &#8805;20% of patients including nausea, dizziness, vomiting, increased AST, diarrhea, fatigue, increased ALT, cough, and constipation</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">2018</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B176-cells-13-01071" ref-type="bibr">176</xref>,<xref rid="B185-cells-13-01071" ref-type="bibr">185</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Entrectinib</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">NTRK</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Combined data consisting of 54 patients enrolled across three single-arm studies. ORR: 57% (43.2&#8211;70.8%; 95% CI); mDOR: 10 months (7.1-not estimable; 95% CI).</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Reported in &#8805;20% of patients including nausea, dizziness, vomiting, diarrhea, fatigue, edema, dysesthesia, dyspnea, myalgia, cognitive impairment, increase weight, vision disorders, arthralgia, vomiting, pyrexia, cough, and constipation</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">2019</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B186-cells-13-01071" ref-type="bibr">186</xref>,<xref rid="B187-cells-13-01071" ref-type="bibr">187</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Dabrafenib plus Trametinib</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">BRAFV600E</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
Combined data consisting of 167 patients (131 adults, 36 pediatric patients) enrolled across three single-arm studies. ORR adults: 41% (33&#8211;50%; 95% CI); ORR children: 25% (12&#8211;42%; 95% CI); DOR: &#8805;6 months for 78% of patients, &#8805;24 months for 44% of patients.
</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">rash, headache, hemorrhage, cough, myalgia, nausea, constipation, vomiting, diarrhea, pyrexia, fatigue, chills, peripheral edema, and arthralgia</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">2022</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B173-cells-13-01071" ref-type="bibr">173</xref>,<xref rid="B174-cells-13-01071" ref-type="bibr">174</xref>,<xref rid="B188-cells-13-01071" ref-type="bibr">188</xref>,<xref rid="B189-cells-13-01071" ref-type="bibr">189</xref>,<xref rid="B190-cells-13-01071" ref-type="bibr">190</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Selpercatinib</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">RET</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Analysis derived from a multi-cohort single-arm phase I/II study. ORR: 44% (28&#8211;60%; 95% CI); mDOR: 24.5 months (9.2-not evaluable; 95% CI).</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Reported in &#8805;20% of patients including dry mouth, edema, fatigue, hypertension, diarrhea, abdominal pain, constipation, rash, nausea, and headache</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">2022</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B181-cells-13-01071" ref-type="bibr">181</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Atezolizumab</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">PD-L1</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Analysis derived from a multicenter, randomized, open-label trial. ORR: 38% (29&#8211;48%; 95% CI); mDOR: 20.2 months (16.5-not evaluable; 95% CI).</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Reported in &#8805;20% of patients including fatigue, decrease appetite, nausea</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">2020</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B164-cells-13-01071" ref-type="bibr">164</xref>,<xref rid="B191-cells-13-01071" ref-type="bibr">191</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Nivolumab plus Ipilimumab</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">PD-1 and CTLA-4</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Analysis derived from a randomized, open label, muti-part trial. ORR: 36% (31&#8211;41%; 95% CI); mDOR: 23.2 months (15.2-32.2; 95% CI).</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Reported in &#8805;20% of patients including decreased appetite, musculoskeletal pain, diarrhea/colitis, dyspnea, fatigue, rash, cough, pruritis, nausea, and hepatitis</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">2020</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B166-cells-13-01071" ref-type="bibr">166</xref>,<xref rid="B192-cells-13-01071" ref-type="bibr">192</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Fam-trastuzumab deruxtecan-nxki</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">HER2</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Individual analyses for each trial consisting of 192 patients enrolled in one of three multicenter trials: <break/><break/>DESTINY-PanTumor02, ORR: 51.4% (41.7&#8211;61%; 95% CI); mDOR: 19.4 months (range 1.3, 27.9+).<break/><break/>DESTINY-Lung01, ORR: 52.9% (27.8&#8211;77%; 95% CI); mDOR: 6.9 months (range 4.0, 11.7+).<break/><break/>DESTINY-CRC02, ORR 46.9% (34.3&#8211;59.8%; 95% CI); mDOR: 5.5 months (range 1.3+, 9.7+)</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Reported in &#8805;20% of patients including vomiting, alopecia, constipation, decreased appetite, nausea, fatigue, leukopenia, cough, anemia, diarrhea, and thrombocytopenia</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">2024</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B193-cells-13-01071" ref-type="bibr">193</xref>,<xref rid="B194-cells-13-01071" ref-type="bibr">194</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Trastuzumab</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">HER2</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Analysis derived from a phase 3 clinical trial. ORR: 50% (<italic toggle="yes">p</italic> &lt; 0.001); mDOR: 9.1 months (<italic toggle="yes">p</italic> &lt; 0.001)</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Most important adverse event reported was cardiac dysfunction</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">1998</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B195-cells-13-01071" ref-type="bibr">195</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Gefitinib</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">EGFR</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Analysis derived from a randomized, double-blind, phase II, multicenter trial. ORR: 10.6% (6.0&#8211;16.8%; 95% CI); mDOR: 7.0 months (range 4.6&#8211;18.6+)</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Reported in &#8805;5% of patients including diarrhea, rash, and acne</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">2003</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B196-cells-13-01071" ref-type="bibr">196</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Imatinib</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">BCR/ABL</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Analysis derived from phase I and phase II clinical studies.<break/>OS: 90.8% (88.3&#8214;93.2%; 95% CI)</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Most reported adverse event includes edema, rash, gastrointestinal disturbances, and musculoskeletal complaints</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">2001</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B197-cells-13-01071" ref-type="bibr">197</xref>,<xref rid="B198-cells-13-01071" ref-type="bibr">198</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="anchor" id="cells-13-01071-t004" orientation="portrait"><object-id pub-id-type="pii">cells-13-01071-t004_Table 4</object-id><label>Table 4</label><caption><p>FDA-approved combination tumor-agnostic therapies. HRR, homologous recombination repair; PD-L1, Programmed death ligand 1; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Combination Therapies</th><th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Indications</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Nivolumab with Ipilimumab</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatocellular carcinoma, malignant pleural mesothelioma, melanoma</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B199-cells-13-01071" ref-type="bibr">199</xref>,<xref rid="B200-cells-13-01071" ref-type="bibr">200</xref>,<xref rid="B201-cells-13-01071" ref-type="bibr">201</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Pembrolizumab with lenvatinib </td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Endometrial carcinoma, renal cell carcinoma</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B202-cells-13-01071" ref-type="bibr">202</xref>,<xref rid="B203-cells-13-01071" ref-type="bibr">203</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Daratumumab and hyaluronidase-fihj with pomalidomide and dexamethasone</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple myeloma</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B204-cells-13-01071" ref-type="bibr">204</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Isatuximab-irfc, carfilzomib and dexamethasone</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple myeloma </td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B205-cells-13-01071" ref-type="bibr">205</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Nivolumab with cabozantinib </td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Renal cell carcinoma </td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B206-cells-13-01071" ref-type="bibr">206</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Pembrolizumab with axitinib</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Renal cell carcinoma</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B207-cells-13-01071" ref-type="bibr">207</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Avelumab with axitinib</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Renal cell carcinoma</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B208-cells-13-01071" ref-type="bibr">208</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Avelumab with chemotherapy</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Urothelial carcinoma</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B209-cells-13-01071" ref-type="bibr">209</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Atezolizumab with bevacizumab</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatocellular carcinoma</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B210-cells-13-01071" ref-type="bibr">210</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Atezolizumab with chemotherapy and bevacizumab</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-squamous, non-small-cell lung cancer</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B211-cells-13-01071" ref-type="bibr">211</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Atezolizumab, cobimetinib and vemurafenib</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">BRAF V600 unresectable or metastatic melanoma</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B212-cells-13-01071" ref-type="bibr">212</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Enfortumab vedotin-ejfv with pembrolizumab</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Urothelial cancer</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B213-cells-13-01071" ref-type="bibr">213</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Tremelimumab with durvalumab</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Hepatocellular carcinoma</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B214-cells-13-01071" ref-type="bibr">214</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Carfilzomib and daratumumab with dexamethasone</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Multiple myeloma</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B215-cells-13-01071" ref-type="bibr">215</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Lenalidomide with tafasitamab-cxix</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Diffuse large B-cell lymphoma</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B216-cells-13-01071" ref-type="bibr">216</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Lenalidomide with rituximab</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Follicular and marginal zone lymphoma</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B217-cells-13-01071" ref-type="bibr">217</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Pertuzumab, trastuzumab, and hyaluronidase-zzxf </td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">HER2-positive breast cancer</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B218-cells-13-01071" ref-type="bibr">218</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Ramucirumab with erlotinib</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Metastatic non-small-cell lung cancer</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B219-cells-13-01071" ref-type="bibr">219</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Olaparib with bevacizumab </td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Ovarian, fallopian tube, or primary peritoneal cancers</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B220-cells-13-01071" ref-type="bibr">220</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Ibrutinib with rituximab</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Chronic lymphocytic leukemia </td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B221-cells-13-01071" ref-type="bibr">221</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Encorafenib with cetuximab </td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Metastatic colorectal cancer with a BRAF V600E mutation</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B222-cells-13-01071" ref-type="bibr">222</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Relatimab with Nivolumab</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Melanoma</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B223-cells-13-01071" ref-type="bibr">223</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Tucatinib with trastuzumab</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Colorectal cancer</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B224-cells-13-01071" ref-type="bibr">224</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Durvalumab with chemotherapy </td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Endometrial cancer, biliary tract cancer, extensive-stage small-cell lung cancer </td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B225-cells-13-01071" ref-type="bibr">225</xref>,<xref rid="B226-cells-13-01071" ref-type="bibr">226</xref>,<xref rid="B227-cells-13-01071" ref-type="bibr">227</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Ponatinib with chemotherapy</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Philadelphia chromosome-positive acute lymphoblastic leukemia</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B228-cells-13-01071" ref-type="bibr">228</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Zanubrutinib with obinutuzumab</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Relapsed or refractory follicular lymphoma </td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B229-cells-13-01071" ref-type="bibr">229</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Nivolumab with cisplatin and gemcitabine</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Urothelial carcinoma</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B230-cells-13-01071" ref-type="bibr">230</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Osimertinib with platinum-based chemotherapy</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Epidermal growth factor receptor-mutated non-small-cell lung cancer</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B231-cells-13-01071" ref-type="bibr">231</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Pembrolizumab with chemoradiotherapy </td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">FIGO 2014 Stage III-IVA cervical cancer</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B232-cells-13-01071" ref-type="bibr">232</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Pembrolizumab with trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy </td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">HER2-positive gastric or gastroesophageal junction adenocarcinoma</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B233-cells-13-01071" ref-type="bibr">233</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Pembrolizumab with chemotherapy</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">HER2-negative gastric or gastroesophageal junction adenocarcinoma, biliary tract cancer, cervical cancer, high-risk early-stage TNBC, esophageal carcinoma, head and neck squamous cell carcinoma</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B234-cells-13-01071" ref-type="bibr">234</xref>,<xref rid="B235-cells-13-01071" ref-type="bibr">235</xref>,<xref rid="B236-cells-13-01071" ref-type="bibr">236</xref>,<xref rid="B237-cells-13-01071" ref-type="bibr">237</xref>,<xref rid="B238-cells-13-01071" ref-type="bibr">238</xref>,<xref rid="B239-cells-13-01071" ref-type="bibr">239</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Encorafenib with binimetinib </td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-small-cell lung cancer with a BRAF V600E mutation </td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B240-cells-13-01071" ref-type="bibr">240</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Trifluridine and tipiracil with bevacizumab</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Colorectal cancer</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B241-cells-13-01071" ref-type="bibr">241</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Dostarlimab-gxly with chemotherapy</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Endometrial cancer</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B242-cells-13-01071" ref-type="bibr">242</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Quizartinib with chemotherapy</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Acute myeloid leukemia</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B243-cells-13-01071" ref-type="bibr">243</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Tremelimumab with durvalumab and platinum-based chemotherapy</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-small-cell lung cancer</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B244-cells-13-01071" ref-type="bibr">244</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Brentuximab vedotin with chemotherapy</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Pediatric patients with classical Hodgkin lymphoma</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B245-cells-13-01071" ref-type="bibr">245</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Cemiplimab-rwlc with platinum-based chemotherapy</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-small-cell lung cancer </td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B246-cells-13-01071" ref-type="bibr">246</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Dabrafenib with trametinib</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Solid tumors with BRAF V600E mutation</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B174-cells-13-01071" ref-type="bibr">174</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Nivolumab with chemotherapy or with ipilimumab </td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Esophageal squamous cell carcinoma</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B247-cells-13-01071" ref-type="bibr">247</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Rituximab with chemotherapy</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Pediatric patients (&#8805;6 months to &lt;18 years) with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B248-cells-13-01071" ref-type="bibr">248</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Nivolumab with chemotherapy</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Gastric cancer, esophageal adenocarcinoma</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B249-cells-13-01071" ref-type="bibr">249</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Margetuximab-cmkb with chemotherapy</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">HER2-positive breast cancer</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B250-cells-13-01071" ref-type="bibr">250</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Naxitamab with granulocyte-macrophage colony-stimulating factor </td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">High-risk neuroblastoma in bone or bone marrow</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B251-cells-13-01071" ref-type="bibr">251</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Nivolumab with ipilimumab and chemotherapy </td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-small-cell lung cancer</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B252-cells-13-01071" ref-type="bibr">252</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Tucatinib with trastuzumab and capecitabine</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">HER2-positive breast cancer</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B253-cells-13-01071" ref-type="bibr">253</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Neratinib with capecitabine</td><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">HER2-positive breast cancer</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B254-cells-13-01071" ref-type="bibr">254</xref>]</td></tr></tbody></table></table-wrap></sec></sec><sec id="sec3dot2-cells-13-01071"><title>3.2. Future Perspectives</title><p>Besides the tyrosine kinase and immune checkpoint receptors, significant efforts have been made in developing agents targeting receptors belonging to other functional receptor classes. CD137 (also known as 4-1BB or tumor necrosis factor receptor superfamily member 9), for instance, is a costimulatory molecule transiently expressed on the surface of various leukocytes, including activated T cells and natural killer (NK) cells. Activation of CD137 depends on its ligation with CD137L, a trimer expressed on antigen-presenting cells. This interaction induces downstream pathways that are crucial for antitumor responses [<xref rid="B255-cells-13-01071" ref-type="bibr">255</xref>]. Upon CD137 activation, CD8<sup>+</sup> cytotoxic T cells receive potent signals promoting their proliferation, cytolytic effector functions, and survival, while CD137 ligation in NK cells fosters cytokine release and cytolytic functions [<xref rid="B256-cells-13-01071" ref-type="bibr">256</xref>,<xref rid="B257-cells-13-01071" ref-type="bibr">257</xref>]. Clinically, CD137 ligation seems to be particularly promising since data suggest that CD137L binding can restore the antitumor capacity of exhausted CD137<sup>+</sup> CD8<sup>+</sup> T cells, making CD137 a potential target for tumor-agnostic immunotherapy [<xref rid="B258-cells-13-01071" ref-type="bibr">258</xref>]. Unlike the first developed anti-CD137 IgG4 monoclonal antibody urelumab and the IgG2 monoclonal antibody utomilumab, which have severe hepatotoxicity and weaker agonistic functions, respectively, the novel human recombinant IgG4 monoclonal antibody, HuB6, demonstrated effective antitumor activity without systemic toxicity in distinct animal tumor models [<xref rid="B255-cells-13-01071" ref-type="bibr">255</xref>,<xref rid="B258-cells-13-01071" ref-type="bibr">258</xref>]. HuB6 has similar affinity for human 4-1BB to that of utomilumab but binds to a unique epitope within CD137 and shows greater agonistic activity. Despite being IgG4 recombinants, like urelumab, HuB6 exhibits higher safety profiles in vivo, which can be attributed to variations in epitope binding. Urelumab attaches to an epitope that orients its Fc domain for easy ligation with Fc&#947;R, potentially enhancing antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity [<xref rid="B258-cells-13-01071" ref-type="bibr">258</xref>]. However, stronger immune cell activation, especially in non-tumor tissues, can trigger autoimmune responses leading to severe hepatotoxicity. In contrast, utomilumab binds to an epitope closer to the cell surface, positioning the antibody parallel to the membrane, thereby hindering its interaction with Fc&#947;R, potentially leading to its limited agonistic function. HuB6, on the other hand, presents with moderate interaction with Fc&#947;R, ranging between urelumab and utomilumab [<xref rid="B258-cells-13-01071" ref-type="bibr">258</xref>]. This moderate binding provides sufficient affinity to induce downstream signaling and immune activation without overstimulating the immune system. Furthermore, IgG4 generally elicits a greater interaction with immune cells via Fc&#947;R interaction than IgG2, which may enhance the agonistic activity of HuB6 despite its similar affinity for human 4-1BB to utomilumab [<xref rid="B258-cells-13-01071" ref-type="bibr">258</xref>]. In addition to being an efficacious monotherapy, HuB6 also exerted an enhanced antitumor effect in combination with other immunotherapies, such as anti-PD-1, indicating broader clinical applications. This promising antitumor efficacy has led to HuB6&#8217;s approval for clinical trials investigating various malignant types in addition to colorectal cancer [<xref rid="B258-cells-13-01071" ref-type="bibr">258</xref>].</p><p>Understanding the correlation between the targeted epitopes and the clinical efficacy of monoclonal antibodies, like in the case of targeting CD137, is critical to improve the clinical outcome of these novel tumor-agnostic methodologies. Human epidermal growth factor receptor 2 (HER2), for instance, has been heavily studied as a target for monoclonal antibodies, since its overexpression is not only found in breast and gastric neoplasms, but it might be present in non-small-cell lung cancer and colorectal cancer as well [<xref rid="B259-cells-13-01071" ref-type="bibr">259</xref>]. In addition, <italic toggle="yes">HER2</italic> mutations have been associated with a more aggressive tumor progression in younger populations [<xref rid="B193-cells-13-01071" ref-type="bibr">193</xref>]. As part of these efforts, a bispecific monoclonal antibody, Zenocutuzumab, has also been recently developed for treating cancers with mutated <italic toggle="yes">HER2</italic>. Zenocutuzumab is a humanized immunoglobin that contains two distinct F<sub>ab</sub> arms targeting both HER2 and HER3, employing the so-called dock and block mechanism. The HER2-targeting arm initially binds to HER2 which, usually, is expressed more abundantly on the cell surface. This not only increases the local concentration of the antibody but also positions the HER3-targeting arm to block neuregulin 1 (NGRI) from binding to HER3. NRG1 primarily binds to HER2 and HER3, leading to heterodimer formations and subsequent stimulation of oncogenic signaling. Mutated <italic toggle="yes">NGR1</italic> has been associated with numerous malignancies including lung, breast, ovarian, prostate, and pancreas [<xref rid="B260-cells-13-01071" ref-type="bibr">260</xref>]. Thus, the Zenocutuzumab-mediated blockade of NGR1 ligation prevents the conformational change of HER3 required for heterotrimerization with HER2 and NGR1, consequently inhibiting downstream tumor-inducing signaling. So far, Zenocutuzumab has been tested in three patients suffering from <italic toggle="yes">NRG1</italic> fusion-positive cancers. Two of the patients with pancreatic cancer experienced tumor regression and continued the therapy for 19 and 11 months, respectively. The third patient with driver-negative non-small-cell lung cancer experienced a partial response [<xref rid="B260-cells-13-01071" ref-type="bibr">260</xref>]. The drug is overall well tolerated among the patients, with diarrhea being the most reported adverse drug reaction. As of April 2024, a global, multicenter phase I/II clinical trial is pending to evaluate the efficacy of Zenocutuzumab further.</p><p>Parallel HER2-directed antibodies are also being developed to serve as delivery vehicles for various anticancer compounds. Indeed, as of 2024, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic <italic toggle="yes">HER2</italic>-positive tumors, even if already pretreated or with no alternative treatment options available [<xref rid="B194-cells-13-01071" ref-type="bibr">194</xref>]. Trastuzumab deruxtecan is an antibody&#8211;drug conjugate consisting of a humanized anti-HER2 antibody linked with a potent cytotoxic drug via a cleavable, peptide-based linker. Once the drug binds to HER2-expressing tumor cells, the linker is cleaved, releasing the cytotoxic drug. The peptide-based linker is thought to be selectively cleaved by lysosomal enzymes, which are upregulated in the tumor microenvironment. This drug inhibits topoisomerase I through the stabilization of DNA&#8211;topoisomerase complexes, resulting in double-strand breaks and subsequent destruction of neoplasms. It is believed that the localized effect of the drug limits systemic toxicity in normal cells [<xref rid="B259-cells-13-01071" ref-type="bibr">259</xref>,<xref rid="B261-cells-13-01071" ref-type="bibr">261</xref>].</p><p>With our expanding knowledge of the molecular constellation of human neoplasms, new concepts continuously emerge for the development of novel therapeutic modalities. In addition to directly leveraging our immune surveillance against neoplasms, emerging therapeutic treatments focus on interfering with additional aspects of the cellular physiology, like apoptosis. One of these candidate targets is myeloid cell leukemia-a (MCL1), a member of the BCL2 family that regulates intrinsic apoptotic pathways via a series of signaling cascades or through mitochondrial apoptogenic factors [<xref rid="B262-cells-13-01071" ref-type="bibr">262</xref>]. Given the pivotal role of the BCL2 family, it is not surprising that its disruption would contribute to tumorigenesis and drug resistance. Indeed, MCL1 is often upregulated in various solid tumors, particularly in melanomas where its increased expression correlates with poor response to cancer therapies due to upregulation of Myeloid-derived suppressor cells (MDSCs) [<xref rid="B262-cells-13-01071" ref-type="bibr">262</xref>]. An increased number of MDSCs are believed to contribute to the immune evasion of tumor cells by altering the tumor microenvironment through the secretion of immunosuppressive agents such as interleukin-10, VEGF, and reactive oxygen species and increased expression of cell surface receptors that suppress T-cell activity [<xref rid="B262-cells-13-01071" ref-type="bibr">262</xref>]. On this basis, recent investigations into BH3 mimetics, a new class of drug consisting of small-molecule inhibitors that selectively inhibits anti-apoptotic members through mimicking the action of pro-apoptotic family members, have shed light on potential therapeutic use of targeting apoptosis regulators like MCL1. Indeed, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="S64315">S64315</ext-link>, an MCL1 inhibitor, has gained attention for its hypothesized ability to decrease MDSC frequency through impeding MCL1 expression. Studies have shown that <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="S64315">S64315</ext-link> monotherapy reduces MDSC frequency in mouse models, leading to improved CD8<sup>+</sup> T-cell function. Moreover, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="S64315">S64315</ext-link> demonstrated greater efficacy in combination therapy with anti-PD-1, effectively inhibiting melanoma growth and enhancing T-cell activity. However, further research is needed to delineate optimal treatment strategies using MCL1 inhibitors, since their current generation shows dose-dependent cardiac toxicity due to high expression levels of MCL1 in cardiomyocytes [<xref rid="B262-cells-13-01071" ref-type="bibr">262</xref>].</p><p>Focusing on the TME, many macrophage-targeted therapies are currently in clinical trials for various tumor types. Inhibition of the CSF1 receptor is believed to deplete TAMs and/or modify their functions within the TME, while a pharmacological blockade of CC-motif chemokine ligand 2 (CCL2) or CC-chemokine receptor 2 (CCR2) might prevent TAM recruitment into the TME [<xref rid="B263-cells-13-01071" ref-type="bibr">263</xref>,<xref rid="B264-cells-13-01071" ref-type="bibr">264</xref>]. CD47/SIRP&#945; complex antagonists are also in the test phase to enhance the TAM-mediated phagocytosis of cancer cells as well as inhibitors of PI3K&#947; and TREM2 proteins to reprogram TAMs toward antitumor phenotypes [<xref rid="B265-cells-13-01071" ref-type="bibr">265</xref>,<xref rid="B266-cells-13-01071" ref-type="bibr">266</xref>].</p><p>Pharmacological intervention of TAM physiology is predicted to affect TME on an intercellular level as well. Indeed, administration of costimulatory molecules, like CD40, is expected to enhance reactivity of the immune system via T-cell activation [<xref rid="B267-cells-13-01071" ref-type="bibr">267</xref>]. To further support T-cell reactivity against tumor cells, strategies to manipulate DCs are also in the development pipeline, including the use of FLT3L to promote DC expansion and survival in vivo or the modulation of DC activity with GM-CSF [<xref rid="B268-cells-13-01071" ref-type="bibr">268</xref>,<xref rid="B269-cells-13-01071" ref-type="bibr">269</xref>]. To expand the DC population, the use of DC vaccines to enhance antitumor immunity is also under investigation [<xref rid="B270-cells-13-01071" ref-type="bibr">270</xref>].</p><p>Targeting cancer-associated fibroblasts as part of a strategy for tumor-agnostic anticancer therapy is also the focus of current studies. One promising approach involves inhibiting fibroblast activation protein (FAP), given that FAP-expressing CAFs are linked to immunosuppression in various preclinical models and human samples [<xref rid="B156-cells-13-01071" ref-type="bibr">156</xref>,<xref rid="B271-cells-13-01071" ref-type="bibr">271</xref>,<xref rid="B272-cells-13-01071" ref-type="bibr">272</xref>]. Additionally, since CAF activation and function are regulated by signaling pathways such as Hedgehog, NF&#954;B, CXCR4, FGFR, and TGF&#946;, specific inhibitors targeting these pathways are currently being evaluated in clinical trials [<xref rid="B273-cells-13-01071" ref-type="bibr">273</xref>]. Alternative strategies to depleting CAFs include reprogramming or normalizing them using vitamin D or vitamin A. For example, treating pancreatic cancer preclinical models with a vitamin D analog has been shown to revert CAFs to their quiescent stellate cell state, thereby enhancing antitumor efficacy [<xref rid="B274-cells-13-01071" ref-type="bibr">274</xref>]. Moreover, recent studies have highlighted that targeting a specific subset of CAFs expressing CD10 and GPR77 can increase chemotherapy sensitivity in breast cancer models [<xref rid="B275-cells-13-01071" ref-type="bibr">275</xref>]. These diverse approaches underscore the potential of CAF-targeted therapies in improving cancer treatment outcomes.</p></sec></sec><sec sec-type="discussion" id="sec4-cells-13-01071"><title>4. Discussion</title><p>In recent years, there has been a striking rejuvenation in cancer treatment, characterized by a profound shift in therapeutic strategies from targeting specific tumors or molecular traits to concentrating on specific molecules irrespective of tumor origin. Throughout this transformative period, the trajectory of cancer treatment was intimately intertwined with the relentless progress of diagnostic technologies, from the inception of microscopy in pathology to the cutting-edge tools of modern molecular biology [<xref rid="B276-cells-13-01071" ref-type="bibr">276</xref>,<xref rid="B277-cells-13-01071" ref-type="bibr">277</xref>].</p><p>The journey into the realm of precision oncology began in the late 1980s when the discovery of human epidermal growth factor-2 (HER2) overexpression or amplification in breast cancer emerged as a pivotal breakthrough. Initially identified through immunohistochemistry (IHC) and subsequently confirmed by in situ hybridization (ISH) techniques, this revelation paved the way for the development of trastuzumab, a humanized antibody targeting HER2. Its groundbreaking approval by the Food and Drug Administration (FDA) in 1998 marked a significant milestone in cancer treatment [<xref rid="B278-cells-13-01071" ref-type="bibr">278</xref>,<xref rid="B279-cells-13-01071" ref-type="bibr">279</xref>]. Following this achievement, strides were made in the development of targeted therapies. Noteworthy examples include imatinib, which inhibits the BCR/ABL tyrosine kinase in chronic myeloid leukemia (CML), and gefitinib, targeting the epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC).</p><p>A pivotal advancement in reshaping cancer treatment paradigms came with the landmark achievement of the first human genome sequencing in 2001. Yet it was the subsequent emergence of NGS techniques around the same period that truly revolutionized the field, enabling rapid, cost-effective, and extensive parallel sequencing of DNA and RNA [<xref rid="B279-cells-13-01071" ref-type="bibr">279</xref>,<xref rid="B280-cells-13-01071" ref-type="bibr">280</xref>]. The widespread integration of modern molecular biology methodologies has provided deeper insights into the intricate molecular landscape of cancer, uncovering a myriad of mutations, some driving selective growth advantages while others remain bystanders. This vast pool of molecular data has undeniably enriched the field of oncology. However, it has also introduced complexities, as distinguishing between driver and non-driver mutations is not always straightforward, and not all driver mutations are amenable to targeted therapies. Nevertheless, in certain cancer types, the identification of molecular subgroups based on specific driver mutations has led to the development of tailored targeted therapies, resulting in significant prognostic improvements [<xref rid="B280-cells-13-01071" ref-type="bibr">280</xref>,<xref rid="B281-cells-13-01071" ref-type="bibr">281</xref>,<xref rid="B282-cells-13-01071" ref-type="bibr">282</xref>,<xref rid="B283-cells-13-01071" ref-type="bibr">283</xref>,<xref rid="B284-cells-13-01071" ref-type="bibr">284</xref>].</p><p>The advent of immunotherapy has introduced a formidable new weapon against cancer as well. In select cases, immunotherapy has demonstrated remarkable and enduring responses [<xref rid="B285-cells-13-01071" ref-type="bibr">285</xref>,<xref rid="B286-cells-13-01071" ref-type="bibr">286</xref>], highlighting its potential to engage the immune system and evoke robust tumor responses, including through interactions involving amino acid residues [<xref rid="B287-cells-13-01071" ref-type="bibr">287</xref>].</p><p>The expansive growth of precision oncology and immune oncology has ushered in two distinct currents in cancer research: combination therapies and molecular-specific/tumor-agnostic treatments. Recognizing that most cancers arise from a complex interplay of molecular irregularities, investigators have delved into combination therapies, such as pairing chemotherapy with targeted agents, chemotherapy with immunotherapy, or various combinations of immunotherapy agents. The objective is to heighten treatment efficacy and circumvent potential resistance mechanisms, yielding promising outcomes across diverse cancer types [<xref rid="B288-cells-13-01071" ref-type="bibr">288</xref>,<xref rid="B289-cells-13-01071" ref-type="bibr">289</xref>,<xref rid="B290-cells-13-01071" ref-type="bibr">290</xref>,<xref rid="B291-cells-13-01071" ref-type="bibr">291</xref>]. However, while combination therapies have demonstrated notable advantages, their success may not solely stem from synergistic drug interactions. Instead, it could be attributed to a broader treatment spectrum, encompassing different patient subgroups that are responsive to various therapeutic approaches. This approach, however, may entail a &#8220;loss of precision&#8221;, potentially leading to overtreatment among certain patient subsets [<xref rid="B280-cells-13-01071" ref-type="bibr">280</xref>,<xref rid="B292-cells-13-01071" ref-type="bibr">292</xref>].</p><p>On the contrary, molecular-specific/tumor-agnostic therapies have emerged primarily in response to two specific clinical dilemmas. Firstly, they address cases where a tumor exhibits a molecular abnormality for which a targeted therapy exists but is typically used for other tumor types. Secondly, they cater to instances where rare mutations/abnormalities with potential treatment options are identified across various tumor types, including those considered rare or ultra-rare. However, both scenarios often involve small sample sizes, making the traditional approach of single-histology trials impractical. Consequently, there has been a rise in off-label use of molecularly targeted agents, resulting in numerous promising case reports. Yet these reports are inherently biased, as negative outcomes from individual cases tend to be underreported. To address these challenges, master protocols have been devised, particularly histology-agnostic/aberration-specific basket and &#8220;n-of-1&#8221; trials encompassing multiple subgroups or studies involving patients with similar or diverse diseases to assess the efficacy of one or more therapies [<xref rid="B293-cells-13-01071" ref-type="bibr">293</xref>,<xref rid="B294-cells-13-01071" ref-type="bibr">294</xref>,<xref rid="B295-cells-13-01071" ref-type="bibr">295</xref>,<xref rid="B296-cells-13-01071" ref-type="bibr">296</xref>,<xref rid="B297-cells-13-01071" ref-type="bibr">297</xref>,<xref rid="B298-cells-13-01071" ref-type="bibr">298</xref>]. These protocols have gained considerable traction and have been embraced by regulatory authorities in recent years. They offer a pathway to overcome the limitations posed by small sample sizes, facilitating more rigorous evaluation of novel therapies [<xref rid="B279-cells-13-01071" ref-type="bibr">279</xref>,<xref rid="B280-cells-13-01071" ref-type="bibr">280</xref>,<xref rid="B281-cells-13-01071" ref-type="bibr">281</xref>,<xref rid="B294-cells-13-01071" ref-type="bibr">294</xref>,<xref rid="B299-cells-13-01071" ref-type="bibr">299</xref>,<xref rid="B300-cells-13-01071" ref-type="bibr">300</xref>].</p><p>Basket trials epitomize a master protocol approach, scrutinizing the effectiveness of a solitary drug across patients afflicted with diverse diseases but united by a shared molecular anomaly, operating through parallel sub-studies. Rooted in the traditional phase I dose escalation design, these trials pioneer inclusive enrollment, disregarding tissue type, to establish a recommended dosage&#8212;a strategy historically employed to pave the way for subsequent phase studies targeting specific histologies. Embracing the notion that biomarkers can prognosticate the response to targeted therapy regardless of tumor histology is pivotal for the advancement of tissue-agnostic treatments [<xref rid="B301-cells-13-01071" ref-type="bibr">301</xref>]. Basket trials not only enable the examination of drugs within molecularly defined subgroups but also validate the predictive prowess of biomarkers. Furthermore, they unravel contextual nuances, recognizing histology as a crucial variable: the disease-specific milieu surrounding a targetable mutation may influence drug efficacy [<xref rid="B302-cells-13-01071" ref-type="bibr">302</xref>]. Variations in tumor types can redefine the significance of molecular anomalies owing to diverse oncogenic pathways and resistance mechanisms. Moreover, histology-specific factors, such as tumor microenvironments, intricately shape drug delivery and immunosurveillance [<xref rid="B303-cells-13-01071" ref-type="bibr">303</xref>].</p><p>Despite their significance, basket trials encounter notable challenges. Their rarity often translates into small sample sizes, undermining the robustness of conclusions drawn. Subgroups may suffer from scant participant numbers, further complicating result reliability [<xref rid="B281-cells-13-01071" ref-type="bibr">281</xref>]. Predominantly conducted as phase I/II trials, they primarily focus on activity and safety, sidelining efficacy assessments. While randomized controlled trials remain indispensable for drug approval, in the case of exceedingly rare conditions or drugs demonstrating promising early efficacy, a randomized approach may prove impractical or dispensable for registration [<xref rid="B303-cells-13-01071" ref-type="bibr">303</xref>,<xref rid="B304-cells-13-01071" ref-type="bibr">304</xref>,<xref rid="B305-cells-13-01071" ref-type="bibr">305</xref>]. Basket trials offer substantial value in exploring rare cancers or mutations characterized by a single, low-complexity driver mutation. Conversely, common cancers exhibit a multifaceted molecular landscape, governed by numerous genomic, transcriptomic, and proteomic alterations, intricately shaping therapeutic responses [<xref rid="B281-cells-13-01071" ref-type="bibr">281</xref>].</p><p>The &#8220;n-of-1&#8221; trial design, a recent addition to oncology research, aims to delve into personalized, molecular-driven treatment strategies tailored to each patient [<xref rid="B280-cells-13-01071" ref-type="bibr">280</xref>]. In this innovative approach, patients are administered a bespoke combination therapy that aligns with their unique molecular profile, necessitating the involvement of an expert tumor molecular board to accurately interpret individual patient data [<xref rid="B296-cells-13-01071" ref-type="bibr">296</xref>]. As personalized precision strategies become increasingly intricate in the evolving landscape of oncology, it becomes imperative to integrate real-world data, expansive registries, and comprehensive observational trials [<xref rid="B297-cells-13-01071" ref-type="bibr">297</xref>,<xref rid="B298-cells-13-01071" ref-type="bibr">298</xref>]. This integration is vital for elevating the standard of evidence required for future approvals in the field.</p></sec><sec id="sec5-cells-13-01071"><title>5. Glossary</title><p>ELISAs&#8212;enzyme-linked immunosorbent assays&#8212;are an immunologic assay used to detect antibodies, antigens, and proteins. In sandwich ELISA, the plate is first coated with the capture antibody and then the sample is added to the plate, and any antigen in the sample will then bind to the capture antibody [<xref rid="B306-cells-13-01071" ref-type="bibr">306</xref>]. A detection antibody is then added which is labeled with an enzyme that will convert to a color for detection [<xref rid="B306-cells-13-01071" ref-type="bibr">306</xref>]. There are other types of ELISA, including competitive, indirect, and direct, which differ in the methods of detection [<xref rid="B306-cells-13-01071" ref-type="bibr">306</xref>].</p><p>Objective/Overall response rates&#8212;the proportion of patients in the trial who responded to the agent being measured.</p><p>Disease control rates&#8212;the percentage of patients whose disease has remained stable or has decreased over a period.</p><p>Duration of response&#8212;the length of time during which a tumor responds to the treatment without further growth or progression.</p><p>Progression-free survival&#8212;the length of time during which a person lives without disease progression, such as tumor growth or metastasis.</p><p>Median duration of the response&#8212;the length of time from initial treatment until half of the patients that responded have experienced disease progression or death.</p><p>Disease control rate&#8212;the percentage of patients with advance disease whose treatment has led to complete response (disappearance of all signs of neoplasm), partial response, (significant decrease in tumor size), or disease stabilization (no significant increase in tumor size).</p><p>Overall survival&#8212;the length of time from the start of a treatment regimen until clinical endpoint (i.e., death, disease progression) compared to those in a control group.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">ALK</td><td align="left" valign="middle" rowspan="1" colspan="1">anaplastic lymphoma kinase </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ATC</td><td align="left" valign="middle" rowspan="1" colspan="1">anaplastic thyroid cancer</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CEA</td><td align="left" valign="middle" rowspan="1" colspan="1">carcinoembryonic antigen</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CRC</td><td align="left" valign="middle" rowspan="1" colspan="1">colorectal cancer</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CTLA-4</td><td align="left" valign="middle" rowspan="1" colspan="1">cytotoxic T-lymphocyte-associated protein 4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DCs</td><td align="left" valign="middle" rowspan="1" colspan="1">dendritic cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DCR</td><td align="left" valign="middle" rowspan="1" colspan="1">disease control rate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">dMMR</td><td align="left" valign="middle" rowspan="1" colspan="1">mismatch repair-deficient</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DOR</td><td align="left" valign="middle" rowspan="1" colspan="1">duration of response</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EGFR</td><td align="left" valign="middle" rowspan="1" colspan="1">epidermal growth factor receptor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EML4</td><td align="left" valign="middle" rowspan="1" colspan="1">EMAP-like 4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FDA</td><td align="left" valign="middle" rowspan="1" colspan="1">United States Food and Drug Administration </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FLT3L</td><td align="left" valign="middle" rowspan="1" colspan="1">FMS-like tyrosine kinase 3 ligand</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GDF15</td><td align="left" valign="middle" rowspan="1" colspan="1">growth differentiation factor 15</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HER2</td><td align="left" valign="middle" rowspan="1" colspan="1">human epidermal growth factor receptor 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">HRR</td><td align="left" valign="middle" rowspan="1" colspan="1">homologous recombination repair </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IHC</td><td align="left" valign="middle" rowspan="1" colspan="1">immunohistochemistry</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">InDel</td><td align="left" valign="middle" rowspan="1" colspan="1">insertions and deletions</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LIFl</td><td align="left" valign="middle" rowspan="1" colspan="1">leukemia inhibitory factor 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MAPK</td><td align="left" valign="middle" rowspan="1" colspan="1">Mitogen-activated protein kinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MCL1</td><td align="left" valign="middle" rowspan="1" colspan="1">myeloid cell leukemia-1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">mDOR</td><td align="left" valign="middle" rowspan="1" colspan="1">median duration of the response</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MDSC</td><td align="left" valign="middle" rowspan="1" colspan="1">myeloid-derived suppressor cells </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MEK1 and MEK2</td><td align="left" valign="middle" rowspan="1" colspan="1">mitogen-activated protein kinase 1 and 2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MIP</td><td align="left" valign="middle" rowspan="1" colspan="1">molecular imprinting polymers </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MSI-H</td><td align="left" valign="middle" rowspan="1" colspan="1">metastatic microsatellite instability-high</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NGR1</td><td align="left" valign="middle" rowspan="1" colspan="1">HER3-targeting arm to block neuregulin 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NGS</td><td align="left" valign="middle" rowspan="1" colspan="1">Next-generation sequencing </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NK</td><td align="left" valign="middle" rowspan="1" colspan="1">natural killer cell</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NPM1</td><td align="left" valign="middle" rowspan="1" colspan="1">nucleophosmin 1 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">non-small-cell lung cancer</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NTRK</td><td align="left" valign="middle" rowspan="1" colspan="1">neurotrophic receptor tyrosine kinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ORR</td><td align="left" valign="middle" rowspan="1" colspan="1">objective response rate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">OS</td><td align="left" valign="middle" rowspan="1" colspan="1">overall survival</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PD-1</td><td align="left" valign="middle" rowspan="1" colspan="1">programmed death receptor 1 </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PD-L1</td><td align="left" valign="middle" rowspan="1" colspan="1">programmed death ligand 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PFS</td><td align="left" valign="middle" rowspan="1" colspan="1">progression-free survival</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">P-GP</td><td align="left" valign="middle" rowspan="1" colspan="1">P-Glycoprotein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">RET</td><td align="left" valign="middle" rowspan="1" colspan="1">rearranged during transfection</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ROS1</td><td align="left" valign="middle" rowspan="1" colspan="1">receptor tyrosine kinase ROS proto-oncogene 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TAAs</td><td align="left" valign="middle" rowspan="1" colspan="1">tumor-associated antigens</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TAMs</td><td align="left" valign="middle" rowspan="1" colspan="1">tumor-ssociated macrophages</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TNBC</td><td align="left" valign="middle" rowspan="1" colspan="1">triple-negative breast cancer</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TCGA</td><td align="left" valign="middle" rowspan="1" colspan="1">The Cancer Genome Atlas Program</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TME</td><td align="left" valign="middle" rowspan="1" colspan="1">tumor microenvironment</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TLR</td><td align="left" valign="middle" rowspan="1" colspan="1">Toll-like receptor </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TMB-H</td><td align="left" valign="middle" rowspan="1" colspan="1">high metastatic tumor mutational burden</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-cells-13-01071"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Cancer statistics, 2022</article-title><source>CA Cancer J. Clin.</source><year>2022</year><volume>72</volume><fpage>7</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.3322/caac.21708</pub-id><pub-id pub-id-type="pmid">35020204</pub-id></element-citation></ref><ref id="B2-cells-13-01071"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schiller</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>D.</given-names></name><name name-style="western"><surname>Belani</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sandler</surname><given-names>A.</given-names></name><name name-style="western"><surname>Krook</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Eastern Cooperative Oncology</surname><given-names>G.</given-names></name></person-group><article-title>Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer</article-title><source>N. Engl. J. Med.</source><year>2002</year><volume>346</volume><fpage>92</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa011954</pub-id><pub-id pub-id-type="pmid">11784875</pub-id></element-citation></ref><ref id="B3-cells-13-01071"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russell</surname><given-names>W.O.</given-names></name></person-group><article-title>The Pathologic Diagnosis of Cancer-A Crescendo of Importance in Current and Future Therapies: Ward Burdick Award Lecture</article-title><source>Am. J. Clin. Pathol.</source><year>1980</year><volume>73</volume><fpage>3</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1093/ajcp/73.1.3</pub-id><pub-id pub-id-type="pmid">6986079</pub-id></element-citation></ref><ref id="B4-cells-13-01071"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Debela</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Muzazu</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Heraro</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Ndalama</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Mesele</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Haile</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Kitui</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Manyazewal</surname><given-names>T.</given-names></name></person-group><article-title>New approaches and procedures for cancer treatment: Current perspectives</article-title><source>SAGE Open Med.</source><year>2021</year><volume>9</volume><fpage>20503121211034366</fpage><pub-id pub-id-type="doi">10.1177/20503121211034366</pub-id><pub-id pub-id-type="pmid">34408877</pub-id><pub-id pub-id-type="pmcid">PMC8366192</pub-id><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="expression-of-concern" ext-link-type="pmc" xlink:href="PMC11523150"/></element-citation></ref><ref id="B5-cells-13-01071"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Di</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Surgical treatment and prognosis of focal brainstem gliomas in children: A 7 year single center experience</article-title><source>Medicine</source><year>2020</year><volume>99</volume><fpage>e22029</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000022029</pub-id><pub-id pub-id-type="pmid">32899058</pub-id><pub-id pub-id-type="pmcid">PMC7478697</pub-id></element-citation></ref><ref id="B6-cells-13-01071"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakraborty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>T.</given-names></name></person-group><article-title>The difficulties in cancer treatment</article-title><source>Ecancermedicalscience</source><year>2012</year><volume>6</volume><fpage>ed16</fpage><pub-id pub-id-type="doi">10.3332/ecancer.2012.ed16</pub-id><pub-id pub-id-type="pmid">24883085</pub-id><pub-id pub-id-type="pmcid">PMC4024849</pub-id></element-citation></ref><ref id="B7-cells-13-01071"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chakravarty</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kundra</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rudolph</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yaeger</surname><given-names>R.</given-names></name><name name-style="western"><surname>Soumerai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nissan</surname><given-names>M.</given-names></name></person-group><article-title>OncoKB: A precision oncology knowledge base</article-title><source>JCO Precis. Oncol.</source><year>2017</year><volume>2017</volume><fpage>PO.17.00011</fpage><pub-id pub-id-type="doi">10.1200/PO.17.00011</pub-id><pub-id pub-id-type="pmid">28890946</pub-id><pub-id pub-id-type="pmcid">PMC5586540</pub-id></element-citation></ref><ref id="B8-cells-13-01071"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Decker</surname><given-names>W.K.</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>R.F.</given-names></name><name name-style="western"><surname>Sanabria</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Angelo</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Guimar&#227;es</surname><given-names>F.</given-names></name><name name-style="western"><surname>Burt</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Kheradmand</surname><given-names>F.</given-names></name><name name-style="western"><surname>Paust</surname><given-names>S.</given-names></name></person-group><article-title>Cancer immunotherapy: Historical perspective of a clinical revolution and emerging preclinical animal models</article-title><source>Front. Immunol.</source><year>2017</year><volume>8</volume><fpage>829</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2017.00829</pub-id><pub-id pub-id-type="pmid">28824608</pub-id><pub-id pub-id-type="pmcid">PMC5539135</pub-id></element-citation></ref><ref id="B9-cells-13-01071"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subbiah</surname><given-names>V.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>J.</given-names></name><name name-style="western"><surname>Konda</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Spira</surname><given-names>A.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>J.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ohe</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ohashi</surname><given-names>K.</given-names></name></person-group><article-title>Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): A phase 1/2, open-label, basket trial</article-title><source>Lancet Oncol.</source><year>2022</year><volume>23</volume><fpage>1261</fpage><lpage>1273</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(22)00541-1</pub-id><pub-id pub-id-type="pmid">36108661</pub-id><pub-id pub-id-type="pmcid">PMC11702314</pub-id></element-citation></ref><ref id="B10-cells-13-01071"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garrison</surname><given-names>F.</given-names></name></person-group><article-title>The history of cancer</article-title><source>Bull. New York Acad. Med.</source><year>1926</year><volume>2</volume><fpage>179</fpage><pub-id pub-id-type="pmid">19311535</pub-id><pub-id pub-id-type="pmcid">PMC2387432</pub-id></element-citation></ref><ref id="B11-cells-13-01071"><label>11.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Steinhaus</surname><given-names>J.</given-names></name></person-group><source>Malignant Neoplasms. Their Morphology and Structure from the Standpoint of Experimental Pathology and Pathologic Anatomy. Polish [Nowotwory Z&#322;osliwe. Ich Morfologia i Budowa ze Stanowiska Patologii Doswiadczalnej i Anatomii Patologicznej]</source><publisher-name>Bookstore E. Wende i S-KA, Krakowskie Przedmiescie 9</publisher-name><publisher-loc>Warszawa, Poland</publisher-loc><year>1918</year></element-citation></ref><ref id="B12-cells-13-01071"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rous</surname><given-names>P.</given-names></name></person-group><article-title>A sarcoma of the fowl transmissible by an agent separable from the tumor cells</article-title><source>J. Exp. Med.</source><year>1911</year><volume>13</volume><fpage>397</fpage><pub-id pub-id-type="doi">10.1084/jem.13.4.397</pub-id><pub-id pub-id-type="pmid">19867421</pub-id><pub-id pub-id-type="pmcid">PMC2124874</pub-id></element-citation></ref><ref id="B13-cells-13-01071"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Vogt</surname><given-names>P.K.</given-names></name></person-group><article-title>100 years of Rous sarcoma virus</article-title><source>J. Exp. Med.</source><year>2011</year><volume>208</volume><fpage>2351</fpage><lpage>2355</lpage><pub-id pub-id-type="doi">10.1084/jem.20112160</pub-id><pub-id pub-id-type="pmid">22110182</pub-id><pub-id pub-id-type="pmcid">PMC3256973</pub-id></element-citation></ref><ref id="B14-cells-13-01071"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Epstein</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Achong</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Barr</surname><given-names>Y.M.</given-names></name></person-group><article-title>Virus particles in cultured lymphoblasts from Burkitt&#8217;s lymphoma</article-title><source>Lancet</source><year>1964</year><volume>283</volume><fpage>702</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(64)91524-7</pub-id><pub-id pub-id-type="pmid">14107961</pub-id></element-citation></ref><ref id="B15-cells-13-01071"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nonoyama</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kawai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pagano</surname><given-names>J.</given-names></name></person-group><article-title>Detection of Epstein-Barr virus DNA in human tumors</article-title><source>Bibl. Haematol.</source><year>1975</year><volume>40</volume><fpage>577</fpage><lpage>583</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000397575</pub-id><pub-id pub-id-type="pmid">169825</pub-id></element-citation></ref><ref id="B16-cells-13-01071"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jackson-Grusby</surname><given-names>L.</given-names></name></person-group><article-title>Modeling cancer in mice</article-title><source>Oncogene</source><year>2002</year><volume>21</volume><fpage>5504</fpage><lpage>5514</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1205603</pub-id><pub-id pub-id-type="pmid">12154411</pub-id></element-citation></ref><ref id="B17-cells-13-01071"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stehelin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Varmus</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Vogt</surname><given-names>P.K.</given-names></name></person-group><article-title>DNA related to the transforming gene (s) of avian sarcoma viruses is present in normal avian DNA</article-title><source>Nature</source><year>1976</year><volume>260</volume><fpage>170</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1038/260170a0</pub-id><pub-id pub-id-type="pmid">176594</pub-id></element-citation></ref><ref id="B18-cells-13-01071"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Der</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Krontiris</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>G.M.</given-names></name></person-group><article-title>Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1982</year><volume>79</volume><fpage>3637</fpage><lpage>3640</lpage><pub-id pub-id-type="doi">10.1073/pnas.79.11.3637</pub-id><pub-id pub-id-type="pmid">6285355</pub-id><pub-id pub-id-type="pmcid">PMC346478</pub-id></element-citation></ref><ref id="B19-cells-13-01071"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimizu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Goldfarb</surname><given-names>M.</given-names></name><name name-style="western"><surname>Suard</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Perucho</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kamata</surname><given-names>T.</given-names></name><name name-style="western"><surname>Feramisco</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stavnezer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fogh</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wigler</surname><given-names>M.H.</given-names></name></person-group><article-title>Three human transforming genes are related to the viral ras oncogenes</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1983</year><volume>80</volume><fpage>2112</fpage><lpage>2116</lpage><pub-id pub-id-type="doi">10.1073/pnas.80.8.2112</pub-id><pub-id pub-id-type="pmid">6572964</pub-id><pub-id pub-id-type="pmcid">PMC393767</pub-id></element-citation></ref><ref id="B20-cells-13-01071"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malumbres</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barbacid</surname><given-names>M.</given-names></name></person-group><article-title>RAS oncogenes: The first 30 years</article-title><source>Nat. Rev. Cancer</source><year>2003</year><volume>3</volume><fpage>459</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1038/nrc1097</pub-id><pub-id pub-id-type="pmid">12778136</pub-id></element-citation></ref><ref id="B21-cells-13-01071"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loeb</surname><given-names>L.A.</given-names></name></person-group><article-title>Microsatellite instability: Marker of a mutator phenotype in cancer</article-title><source>Cancer Res.</source><year>1994</year><volume>54</volume><fpage>5059</fpage><pub-id pub-id-type="pmid">7923117</pub-id></element-citation></ref><ref id="B22-cells-13-01071"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loeb</surname><given-names>L.A.</given-names></name></person-group><article-title>A mutator phenotype in cancer</article-title><source>Cancer Res.</source><year>2001</year><volume>61</volume><fpage>3230</fpage><lpage>3239</lpage><pub-id pub-id-type="pmid">11309271</pub-id></element-citation></ref><ref id="B23-cells-13-01071"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loeb</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Loeb</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>J.P.</given-names></name></person-group><article-title>Multiple mutations and cancer</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2003</year><volume>100</volume><fpage>776</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1073/pnas.0334858100</pub-id><pub-id pub-id-type="pmid">12552134</pub-id><pub-id pub-id-type="pmcid">PMC298677</pub-id></element-citation></ref><ref id="B24-cells-13-01071"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DePinho</surname><given-names>R.A.</given-names></name></person-group><article-title>The age of cancer</article-title><source>Nature</source><year>2000</year><volume>408</volume><fpage>248</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1038/35041694</pub-id><pub-id pub-id-type="pmid">11089982</pub-id></element-citation></ref><ref id="B25-cells-13-01071"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bishop</surname><given-names>J.M.</given-names></name></person-group><article-title>The molecular genetics of cancer</article-title><source>Science</source><year>1987</year><volume>235</volume><fpage>305</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1126/science.3541204</pub-id><pub-id pub-id-type="pmid">3541204</pub-id></element-citation></ref><ref id="B26-cells-13-01071"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Negrini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gorgoulis</surname><given-names>V.G.</given-names></name><name name-style="western"><surname>Halazonetis</surname><given-names>T.D.</given-names></name></person-group><article-title>Genomic instability&#8212;An evolving hallmark of cancer</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2010</year><volume>11</volume><fpage>220</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1038/nrm2858</pub-id><pub-id pub-id-type="pmid">20177397</pub-id></element-citation></ref><ref id="B27-cells-13-01071"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nowell</surname><given-names>P.C.</given-names></name></person-group><article-title>The Clonal Evolution of Tumor Cell Populations: Acquired genetic lability permits stepwise selection of variant sublines and underlies tumor progression</article-title><source>Science</source><year>1976</year><volume>194</volume><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1126/science.959840</pub-id><pub-id pub-id-type="pmid">959840</pub-id></element-citation></ref><ref id="B28-cells-13-01071"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merlo</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Pepper</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Maley</surname><given-names>C.C.</given-names></name></person-group><article-title>Cancer as an evolutionary and ecological process</article-title><source>Nat. Rev. Cancer</source><year>2006</year><volume>6</volume><fpage>924</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1038/nrc2013</pub-id><pub-id pub-id-type="pmid">17109012</pub-id></element-citation></ref><ref id="B29-cells-13-01071"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fearon</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Vogelstein</surname><given-names>B.</given-names></name></person-group><article-title>A genetic model for colorectal tumorigenesis</article-title><source>Cell</source><year>1990</year><volume>61</volume><fpage>759</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(90)90186-I</pub-id><pub-id pub-id-type="pmid">2188735</pub-id></element-citation></ref><ref id="B30-cells-13-01071"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zehir</surname><given-names>A.</given-names></name><name name-style="western"><surname>Benayed</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Syed</surname><given-names>A.</given-names></name><name name-style="western"><surname>Middha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chakravarty</surname><given-names>D.</given-names></name><name name-style="western"><surname>Devlin</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients</article-title><source>Nat. Med.</source><year>2017</year><volume>23</volume><fpage>703</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1038/nm.4333</pub-id><pub-id pub-id-type="pmid">28481359</pub-id><pub-id pub-id-type="pmcid">PMC5461196</pub-id></element-citation></ref><ref id="B31-cells-13-01071"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexandrov</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Nik-Zainal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wedge</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Aparicio</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Behjati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Biankin</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Bignell</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Bolli</surname><given-names>N.</given-names></name><name name-style="western"><surname>Borg</surname><given-names>A.</given-names></name><name name-style="western"><surname>B&#248;rresen-Dale</surname><given-names>A.-L.</given-names></name></person-group><article-title>Signatures of mutational processes in human cancer</article-title><source>Nature</source><year>2013</year><volume>500</volume><fpage>415</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1038/nature12477</pub-id><pub-id pub-id-type="pmid">23945592</pub-id><pub-id pub-id-type="pmcid">PMC3776390</pub-id></element-citation></ref><ref id="B32-cells-13-01071"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ciriello</surname><given-names>G.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Aksoy</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Senbabaoglu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sander</surname><given-names>C.</given-names></name></person-group><article-title>Emerging landscape of oncogenic signatures across human cancers</article-title><source>Nat. Genet.</source><year>2013</year><volume>45</volume><fpage>1127</fpage><lpage>1133</lpage><pub-id pub-id-type="doi">10.1038/ng.2762</pub-id><pub-id pub-id-type="pmid">24071851</pub-id><pub-id pub-id-type="pmcid">PMC4320046</pub-id></element-citation></ref><ref id="B33-cells-13-01071"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zack</surname><given-names>T.I.</given-names></name><name name-style="western"><surname>Schumacher</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Cherniack</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Saksena</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tabak</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.-Z.</given-names></name><name name-style="western"><surname>Wala</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mermel</surname><given-names>C.H.</given-names></name></person-group><article-title>Pan-cancer patterns of somatic copy number alteration</article-title><source>Nat. Genet.</source><year>2013</year><volume>45</volume><fpage>1134</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1038/ng.2760</pub-id><pub-id pub-id-type="pmid">24071852</pub-id><pub-id pub-id-type="pmcid">PMC3966983</pub-id></element-citation></ref><ref id="B34-cells-13-01071"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lawrence</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Stojanov</surname><given-names>P.</given-names></name><name name-style="western"><surname>Polak</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kryukov</surname><given-names>G.V.</given-names></name><name name-style="western"><surname>Cibulskis</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sivachenko</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mermel</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>S.A.</given-names></name></person-group><article-title>Mutational heterogeneity in cancer and the search for new cancer-associated genes</article-title><source>Nature</source><year>2013</year><volume>499</volume><fpage>214</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1038/nature12213</pub-id><pub-id pub-id-type="pmid">23770567</pub-id><pub-id pub-id-type="pmcid">PMC3919509</pub-id></element-citation></ref><ref id="B35-cells-13-01071"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kandoth</surname><given-names>C.</given-names></name><name name-style="western"><surname>McLellan</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Vandin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>K.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>McMichael</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Wyczalkowski</surname><given-names>M.A.</given-names></name></person-group><article-title>Mutational landscape and significance across 12 major cancer types</article-title><source>Nature</source><year>2013</year><volume>502</volume><fpage>333</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1038/nature12634</pub-id><pub-id pub-id-type="pmid">24132290</pub-id><pub-id pub-id-type="pmcid">PMC3927368</pub-id></element-citation></ref><ref id="B36-cells-13-01071"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dees</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Kandoth</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wendl</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Schierding</surname><given-names>W.</given-names></name><name name-style="western"><surname>Koboldt</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Mooney</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Callaway</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Dooling</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mardis</surname><given-names>E.R.</given-names></name></person-group><article-title>MuSiC: Identifying mutational significance in cancer genomes</article-title><source>Genome Res.</source><year>2012</year><volume>22</volume><fpage>1589</fpage><lpage>1598</lpage><pub-id pub-id-type="doi">10.1101/gr.134635.111</pub-id><pub-id pub-id-type="pmid">22759861</pub-id><pub-id pub-id-type="pmcid">PMC3409272</pub-id></element-citation></ref><ref id="B37-cells-13-01071"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Powell</surname><given-names>E.</given-names></name><name name-style="western"><surname>Piwnica-Worms</surname><given-names>D.</given-names></name><name name-style="western"><surname>Piwnica-Worms</surname><given-names>H.</given-names></name></person-group><article-title>Contribution of p53 to metastasis</article-title><source>Cancer Discov.</source><year>2014</year><volume>4</volume><fpage>405</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-0136</pub-id><pub-id pub-id-type="pmid">24658082</pub-id><pub-id pub-id-type="pmcid">PMC4063123</pub-id></element-citation></ref><ref id="B38-cells-13-01071"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Asthana</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Chapman</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Kandoth</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Socci</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Solit</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Olshen</surname><given-names>A.B.</given-names></name></person-group><article-title>Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity</article-title><source>Nat. Biotechnol.</source><year>2016</year><volume>34</volume><fpage>155</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1038/nbt.3391</pub-id><pub-id pub-id-type="pmid">26619011</pub-id><pub-id pub-id-type="pmcid">PMC4744099</pub-id></element-citation></ref><ref id="B39-cells-13-01071"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>P.</given-names></name></person-group><article-title>TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>8712</fpage><pub-id pub-id-type="doi">10.18632/oncotarget.6007</pub-id><pub-id pub-id-type="pmid">26556853</pub-id><pub-id pub-id-type="pmcid">PMC4890999</pub-id></element-citation></ref><ref id="B40-cells-13-01071"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piscuoglio</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>M.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Edelweiss</surname><given-names>M.</given-names></name><name name-style="western"><surname>Geyer</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Macedo</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Inagaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Papanastasiou</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Martelotto</surname><given-names>L.G.</given-names></name></person-group><article-title>Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression</article-title><source>J. Pathol.</source><year>2016</year><volume>238</volume><fpage>508</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1002/path.4672</pub-id><pub-id pub-id-type="pmid">26832993</pub-id><pub-id pub-id-type="pmcid">PMC4962788</pub-id></element-citation></ref><ref id="B41-cells-13-01071"><label>41.</label><element-citation publication-type="gov"><article-title>The Cancer Genome Atlas Program (TCGA)</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cancer.gov/ccg/research/genome-sequencing/tcga" ext-link-type="uri">https://www.cancer.gov/ccg/research/genome-sequencing/tcga</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-03-07">(accessed on 7 March 2024)</date-in-citation></element-citation></ref><ref id="B42-cells-13-01071"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bajari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Andric</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gerthoffert</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lepsa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nahal-Bose</surname><given-names>H.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Ferretti</surname><given-names>V.</given-names></name></person-group><article-title>The International Cancer Genome Consortium Data Portal</article-title><source>Nat. Biotechnol.</source><year>2019</year><volume>37</volume><fpage>367</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1038/s41587-019-0055-9</pub-id><pub-id pub-id-type="pmid">30877282</pub-id></element-citation></ref><ref id="B43-cells-13-01071"><label>43.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Illumina</collab></person-group><source>An Introduction to Next-Generation Sequencing Technology</source><publisher-name>Illumina Inc.</publisher-name><publisher-loc>San Diego, CA, USA</publisher-loc><year>2017</year></element-citation></ref><ref id="B44-cells-13-01071"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bestvina</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Waters</surname><given-names>D.</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>L.</given-names></name><name name-style="western"><surname>Emond</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lafeuille</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Hilts</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lefebvre</surname><given-names>P.</given-names></name><name name-style="western"><surname>He</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vanderpoel</surname><given-names>J.</given-names></name></person-group><article-title>Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer</article-title><source>J. Med. Econ.</source><year>2024</year><volume>27</volume><fpage>292</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1080/13696998.2024.2314430</pub-id><pub-id pub-id-type="pmid">38391239</pub-id></element-citation></ref><ref id="B45-cells-13-01071"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>Zehir</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Benayed</surname><given-names>R.</given-names></name><name name-style="western"><surname>Syed</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chandramohan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Won</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>S.N.</given-names></name></person-group><article-title>Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology</article-title><source>J. Mol. Diagn.</source><year>2015</year><volume>17</volume><fpage>251</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1016/j.jmoldx.2014.12.006</pub-id><pub-id pub-id-type="pmid">25801821</pub-id><pub-id pub-id-type="pmcid">PMC5808190</pub-id></element-citation></ref><ref id="B46-cells-13-01071"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marchetti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Di Lorito</surname><given-names>A.</given-names></name><name name-style="western"><surname>Felicioni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Buttitta</surname><given-names>F.</given-names></name></person-group><article-title>An innovative diagnostic strategy for the detection of rare molecular targets to select cancer patients for tumor-agnostic treatments</article-title><source>Oncotarget</source><year>2019</year><volume>10</volume><fpage>6957</fpage><lpage>6968</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.27343</pub-id><pub-id pub-id-type="pmid">31857850</pub-id><pub-id pub-id-type="pmcid">PMC6916754</pub-id></element-citation></ref><ref id="B47-cells-13-01071"><label>47.</label><element-citation publication-type="webpage"><article-title>FoundationOne CDx Technical Information</article-title><year>2017</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://info.foundationmedicine.com/hubfs/FMI%20Labels/FoundationOne_CDx_Label_Technical_Info.pdf" ext-link-type="uri">https://info.foundationmedicine.com/hubfs/FMI%20Labels/FoundationOne_CDx_Label_Technical_Info.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B48-cells-13-01071"><label>48.</label><element-citation publication-type="webpage"><article-title>Oncomine&#8482; Dx Target Test</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.thermofisher.com/document-connect/document-connect.html?url=https://assets.thermofisher.com/TFS-Assets%2FCSD%2FFlyers%2Fodxtt-eu-oncologist-flyer.pdf" ext-link-type="uri">https://www.thermofisher.com/document-connect/document-connect.html?url=https://assets.thermofisher.com/TFS-Assets%2FCSD%2FFlyers%2Fodxtt-eu-oncologist-flyer.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B49-cells-13-01071"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conroy</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Pabla</surname><given-names>S.</given-names></name><name name-style="western"><surname>Glenn</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Burgher</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nesline</surname><given-names>M.</given-names></name><name name-style="western"><surname>Papanicolau-Sengos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Andreas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Giamo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lenzo</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Hyland</surname><given-names>F.C.L.</given-names></name><etal/></person-group><article-title>Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors</article-title><source>J. Mol. Diagn.</source><year>2018</year><volume>20</volume><fpage>95</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.jmoldx.2017.10.001</pub-id><pub-id pub-id-type="pmid">29061374</pub-id></element-citation></ref><ref id="B50-cells-13-01071"><label>50.</label><element-citation publication-type="gov"><article-title>OmniSeq Insight&#8212;Clinical Test&#8212;NIH Genetic Testing Registry (GTR)&#8212;NCBI</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/gtr/tests/593389/" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/gtr/tests/593389/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B51-cells-13-01071"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eifert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pantazi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>R.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cingolani</surname><given-names>P.</given-names></name><name name-style="western"><surname>Heyer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lvova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ring</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tse</surname><given-names>J.Y.</given-names></name><etal/></person-group><article-title>Clinical application of a cancer genomic profiling assay to guide precision medicine decisions</article-title><source>Per. Med.</source><year>2017</year><volume>14</volume><fpage>309</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.2217/pme-2017-0011</pub-id><pub-id pub-id-type="pmid">28890729</pub-id><pub-id pub-id-type="pmcid">PMC5580078</pub-id></element-citation></ref><ref id="B52-cells-13-01071"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirsch</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>McElhinny</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stanforth</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ranger-Moore</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jansson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kulangara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Richardson</surname><given-names>W.</given-names></name><name name-style="western"><surname>Towne</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hanks</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vennapusa</surname><given-names>B.</given-names></name><etal/></person-group><article-title>PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project</article-title><source>J. Thorac. Oncol.</source><year>2017</year><volume>12</volume><fpage>208</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2016.11.2228</pub-id><pub-id pub-id-type="pmid">27913228</pub-id></element-citation></ref><ref id="B53-cells-13-01071"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsao</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Kockx</surname><given-names>M.</given-names></name><name name-style="western"><surname>Beasley</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Borczuk</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Botling</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bubendorf</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chirieac</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>T.Y.</given-names></name><etal/></person-group><article-title>PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project</article-title><source>J. Thorac. Oncol.</source><year>2018</year><volume>13</volume><fpage>1302</fpage><lpage>1311</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2018.05.013</pub-id><pub-id pub-id-type="pmid">29800747</pub-id><pub-id pub-id-type="pmcid">PMC8386299</pub-id></element-citation></ref><ref id="B54-cells-13-01071"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rugo</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Loi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schneeweiss</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barrios</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Iwata</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dieras</surname><given-names>V.</given-names></name><name name-style="western"><surname>Winer</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Kockx</surname><given-names>M.M.</given-names></name><etal/></person-group><article-title>PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer</article-title><source>J. Natl. Cancer Inst.</source><year>2021</year><volume>113</volume><fpage>1733</fpage><lpage>1743</lpage><pub-id pub-id-type="doi">10.1093/jnci/djab108</pub-id><pub-id pub-id-type="pmid">34097070</pub-id><pub-id pub-id-type="pmcid">PMC8634452</pub-id></element-citation></ref><ref id="B55-cells-13-01071"><label>55.</label><element-citation publication-type="webpage"><article-title>PD-L1 IHC 22C3 PharmDx</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.agilent.com/en-ca/products/pharmdx/pd-l1-ihc-22c3-pharmdx-testing" ext-link-type="uri">https://www.agilent.com/en-ca/products/pharmdx/pd-l1-ihc-22c3-pharmdx-testing</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B56-cells-13-01071"><label>56.</label><element-citation publication-type="webpage"><article-title>PD-L1 IHC 28-8 PharmDx Overview</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.agilent.com/en-ca/products/pharmdx/pd-l1-ihc-28-8-overview" ext-link-type="uri">https://www.agilent.com/en-ca/products/pharmdx/pd-l1-ihc-28-8-overview</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B57-cells-13-01071"><label>57.</label><element-citation publication-type="webpage"><article-title>VENTANA&#174; PD-L1 (SP142) Assay</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://diagnostics.roche.com/global/en/products/lab/pd-l1-sp142-assay-ventana-rtd001231.html" ext-link-type="uri">https://diagnostics.roche.com/global/en/products/lab/pd-l1-sp142-assay-ventana-rtd001231.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B58-cells-13-01071"><label>58.</label><element-citation publication-type="webpage"><article-title>VENTANA PD-L1 (SP263) Assay</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://diagnostics.roche.com/global/en/products/lab/pd-l1-sp263-ce-ivd-us-export-ventana-rtd001234.html" ext-link-type="uri">https://diagnostics.roche.com/global/en/products/lab/pd-l1-sp263-ce-ivd-us-export-ventana-rtd001234.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B59-cells-13-01071"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Vanarsa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Soomro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cicalese</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Duran</surname><given-names>V.</given-names></name><name name-style="western"><surname>Dasari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Pedroza</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kisiel</surname><given-names>J.B.</given-names></name><etal/></person-group><article-title>Comprehensive aptamer-based screen of 1317 proteins uncovers improved stool protein markers of colorectal cancer</article-title><source>J. Gastroenterol.</source><year>2021</year><volume>56</volume><fpage>659</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1007/s00535-021-01795-y</pub-id><pub-id pub-id-type="pmid">34117903</pub-id></element-citation></ref><ref id="B60-cells-13-01071"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carvalho</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gomes</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Moreira Rocha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Barroca-Ferreira</surname><given-names>J.</given-names></name><name name-style="western"><surname>Maia</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Guillade</surname><given-names>L.</given-names></name><name name-style="western"><surname>Correa-Duarte</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Passarinha</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>F.T.C.</given-names></name></person-group><article-title>Development of a novel electrochemical biosensor based on plastic antibodies for detection of STEAP1 biomarker in cancer</article-title><source>Bioelectrochemistry</source><year>2023</year><volume>152</volume><elocation-id>108461</elocation-id><pub-id pub-id-type="doi">10.1016/j.bioelechem.2023.108461</pub-id><pub-id pub-id-type="pmid">37192590</pub-id></element-citation></ref><ref id="B61-cells-13-01071"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreira</surname><given-names>F.T.C.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>M.</given-names></name><name name-style="western"><surname>Puga</surname><given-names>J.R.T.</given-names></name><name name-style="western"><surname>Sales</surname><given-names>M.G.F.</given-names></name></person-group><article-title>Screen-printed electrode produced by printed-circuit board technology. Application to Cancer Biomarker Detection by means of plastic antibody as sensing material</article-title><source>Sens. Actuators B Chem.</source><year>2016</year><volume>223</volume><fpage>927</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1016/j.snb.2015.09.157</pub-id><pub-id pub-id-type="pmid">30740000</pub-id><pub-id pub-id-type="pmcid">PMC6366552</pub-id></element-citation></ref><ref id="B62-cells-13-01071"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Desai</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Gauvain</surname><given-names>K.</given-names></name><name name-style="western"><surname>Basu</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Macy</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Maese</surname><given-names>L.</given-names></name><name name-style="western"><surname>Whipple</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Sabnis</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Foster</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Shusterman</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)</article-title><source>Neuro Oncol.</source><year>2022</year><volume>24</volume><fpage>1776</fpage><lpage>1789</lpage><pub-id pub-id-type="doi">10.1093/neuonc/noac087</pub-id><pub-id pub-id-type="pmid">35395680</pub-id><pub-id pub-id-type="pmcid">PMC9527518</pub-id></element-citation></ref><ref id="B63-cells-13-01071"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laetsch</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>DuBois</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Mascarenhas</surname><given-names>L.</given-names></name><name name-style="western"><surname>Turpin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Federman</surname><given-names>N.</given-names></name><name name-style="western"><surname>Albert</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Nagasubramanian</surname><given-names>R.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Rudzinski</surname><given-names>E.</given-names></name><name name-style="western"><surname>Feraco</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: Phase 1 results from a multicentre, open-label, phase 1/2 study</article-title><source>Lancet Oncol.</source><year>2018</year><volume>19</volume><fpage>705</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(18)30119-0</pub-id><pub-id pub-id-type="pmid">29606586</pub-id><pub-id pub-id-type="pmcid">PMC5949072</pub-id></element-citation></ref><ref id="B64-cells-13-01071"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okamura</surname><given-names>R.</given-names></name><name name-style="western"><surname>Boichard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sicklick</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Bazhenova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kurzrock</surname><given-names>R.</given-names></name></person-group><article-title>Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics</article-title><source>JCO Precis. Oncol.</source><year>2018</year><volume>2</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1200/PO.18.00183</pub-id><pub-id pub-id-type="pmcid">PMC6329466</pub-id><pub-id pub-id-type="pmid">30637364</pub-id></element-citation></ref><ref id="B65-cells-13-01071"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wasik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kelsh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Winkler</surname><given-names>C.</given-names></name></person-group><article-title>Anaplastic lymphoma kinase is required for neurogenesis in the developing central nervous system of zebrafish</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e63757</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0063757</pub-id><pub-id pub-id-type="pmid">23667670</pub-id><pub-id pub-id-type="pmcid">PMC3648509</pub-id></element-citation></ref><ref id="B66-cells-13-01071"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujimoto</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shiota</surname><given-names>M.</given-names></name><name name-style="western"><surname>Iwahara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Seki</surname><given-names>N.</given-names></name><name name-style="western"><surname>Satoh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>T.</given-names></name></person-group><article-title>Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5)</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1996</year><volume>93</volume><fpage>4181</fpage><lpage>4186</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.9.4181</pub-id><pub-id pub-id-type="pmid">8633037</pub-id><pub-id pub-id-type="pmcid">PMC39508</pub-id></element-citation></ref><ref id="B67-cells-13-01071"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>L.</given-names></name></person-group><article-title>The Structural Characterization of Tumor Fusion Genes and Proteins</article-title><source>Comput. Math. Methods Med.</source><year>2015</year><volume>2015</volume><fpage>912742</fpage><pub-id pub-id-type="doi">10.1155/2015/912742</pub-id><pub-id pub-id-type="pmid">26347798</pub-id><pub-id pub-id-type="pmcid">PMC4546970</pub-id></element-citation></ref><ref id="B68-cells-13-01071"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolli</surname><given-names>N.</given-names></name><name name-style="western"><surname>De Marco</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Martelli</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Bigerna</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pucciarini</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mannucci</surname><given-names>R.</given-names></name><name name-style="western"><surname>Manes</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pettirossi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pileri</surname><given-names>S.A.</given-names></name><etal/></person-group><article-title>A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF</article-title><source>Leukemia</source><year>2009</year><volume>23</volume><fpage>501</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1038/leu.2008.326</pub-id><pub-id pub-id-type="pmid">19005479</pub-id></element-citation></ref><ref id="B69-cells-13-01071"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heidebrecht</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Buck</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pollmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Siebert</surname><given-names>R.</given-names></name><name name-style="western"><surname>Parwaresch</surname><given-names>R.</given-names></name></person-group><article-title>Cloning and localization of C2orf2(ropp120), a previously unknown WD repeat protein</article-title><source>Genomics</source><year>2000</year><volume>68</volume><fpage>348</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1006/geno.2000.6301</pub-id><pub-id pub-id-type="pmid">10995578</pub-id></element-citation></ref><ref id="B70-cells-13-01071"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Camidge</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Dziadziuszko</surname><given-names>R.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mok</surname><given-names>T.</given-names></name><name name-style="western"><surname>Noe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nowicka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gadgeel</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Cheema</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pavlakis</surname><given-names>N.</given-names></name><name name-style="western"><surname>de Marinis</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study</article-title><source>J. Thorac. Oncol.</source><year>2019</year><volume>14</volume><fpage>1233</fpage><lpage>1243</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2019.03.007</pub-id><pub-id pub-id-type="pmid">30902613</pub-id></element-citation></ref><ref id="B71-cells-13-01071"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ettinger</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Aisner</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Akerley</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bauman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chirieac</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>D&#8217;Amico</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>DeCamp</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Dilling</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Dobelbower</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology</article-title><source>J. Natl. Compr. Cancer Netw.</source><year>2017</year><volume>15</volume><fpage>504</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.6004/jnccn.2017.0050</pub-id><pub-id pub-id-type="pmid">28404761</pub-id></element-citation></ref><ref id="B72-cells-13-01071"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cancer Genome Atlas</surname><given-names>N.</given-names></name></person-group><article-title>Comprehensive molecular portraits of human breast tumours</article-title><source>Nature</source><year>2012</year><volume>490</volume><fpage>61</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1038/nature11412</pub-id><pub-id pub-id-type="pmid">23000897</pub-id><pub-id pub-id-type="pmcid">PMC3465532</pub-id></element-citation></ref><ref id="B73-cells-13-01071"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cancer Genome Atlas</surname><given-names>N.</given-names></name></person-group><article-title>Comprehensive molecular characterization of human colon and rectal cancer</article-title><source>Nature</source><year>2012</year><volume>487</volume><fpage>330</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1038/nature11252</pub-id><pub-id pub-id-type="pmid">22810696</pub-id><pub-id pub-id-type="pmcid">PMC3401966</pub-id></element-citation></ref><ref id="B74-cells-13-01071"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Matsuoka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Funahashi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kitano</surname><given-names>H.</given-names></name></person-group><article-title>A comprehensive pathway map of epidermal growth factor receptor signaling</article-title><source>Mol. Syst. Biol.</source><year>2005</year><volume>1</volume><fpage>2005-0010</fpage><pub-id pub-id-type="doi">10.1038/msb4100014</pub-id><pub-id pub-id-type="pmid">16729045</pub-id><pub-id pub-id-type="pmcid">PMC1681468</pub-id></element-citation></ref><ref id="B75-cells-13-01071"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sawada</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ibi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kihara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Urushitani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nakanishi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Akaike</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shimohama</surname><given-names>S.</given-names></name></person-group><article-title>Neuroprotective mechanism of glial cell line-derived neurotrophic factor in mesencephalic neurons</article-title><source>J. Neurochem.</source><year>2000</year><volume>74</volume><fpage>1175</fpage><lpage>1184</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2000.741175.x</pub-id><pub-id pub-id-type="pmid">10693950</pub-id></element-citation></ref><ref id="B76-cells-13-01071"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subbiah</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cassier</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Siena</surname><given-names>S.</given-names></name><name name-style="western"><surname>Garralda</surname><given-names>E.</given-names></name><name name-style="western"><surname>Paz-Ares</surname><given-names>L.</given-names></name><name name-style="western"><surname>Garrido</surname><given-names>P.</given-names></name><name name-style="western"><surname>Nadal</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vuky</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lopes</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kalemkerian</surname><given-names>G.P.</given-names></name><etal/></person-group><article-title>Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>1640</fpage><lpage>1645</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01931-y</pub-id><pub-id pub-id-type="pmid">35962206</pub-id><pub-id pub-id-type="pmcid">PMC9388374</pub-id></element-citation></ref><ref id="B77-cells-13-01071"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paratala</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Yilmazel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Petrosky</surname><given-names>W.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schrock</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Gay</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dolfi</surname><given-names>S.C.</given-names></name><etal/></person-group><article-title>RET rearrangements are actionable alterations in breast cancer</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>4821</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-07341-4</pub-id><pub-id pub-id-type="pmid">30446652</pub-id><pub-id pub-id-type="pmcid">PMC6240119</pub-id></element-citation></ref><ref id="B78-cells-13-01071"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhuo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><etal/></person-group><article-title>HER2-positive breast cancer progresses rapidly after pyrotinib resistance: Acquired RET gene fusion and TP53 gene mutation are potential reasons</article-title><source>Anticancer Drugs</source><year>2023</year><volume>34</volume><fpage>1196</fpage><lpage>1201</lpage><pub-id pub-id-type="doi">10.1097/CAD.0000000000001506</pub-id><pub-id pub-id-type="pmid">36689646</pub-id></element-citation></ref><ref id="B79-cells-13-01071"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gideon</surname><given-names>P.</given-names></name><name name-style="western"><surname>John</surname><given-names>J.</given-names></name><name name-style="western"><surname>Frech</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lautwein</surname><given-names>A.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>R.</given-names></name><name name-style="western"><surname>Scheffler</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Wittinghofer</surname><given-names>A.</given-names></name></person-group><article-title>Mutational and kinetic analyses of the GTPase-activating protein (GAP)-p21 interaction: The C-terminal domain of GAP is not sufficient for full activity</article-title><source>Mol. Cell. Biol.</source><year>1992</year><volume>12</volume><fpage>2050</fpage><lpage>2056</lpage><pub-id pub-id-type="doi">10.1128/mcb.12.5.2050-2056.1992</pub-id><pub-id pub-id-type="pmid">1569940</pub-id><pub-id pub-id-type="pmcid">PMC364376</pub-id></element-citation></ref><ref id="B80-cells-13-01071"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giglione</surname><given-names>C.</given-names></name><name name-style="western"><surname>Parrini</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Baouz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bernardi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Parmeggiani</surname><given-names>A.</given-names></name></person-group><article-title>A new function of p120-GTPase-activating protein. Prevention of the guanine nucleotide exchange factor-stimulated nucleotide exchange on the active form of Ha-ras p21</article-title><source>J. Biol. Chem.</source><year>1997</year><volume>272</volume><fpage>25128</fpage><lpage>25134</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.40.25128</pub-id><pub-id pub-id-type="pmid">9312123</pub-id></element-citation></ref><ref id="B81-cells-13-01071"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fakih</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Kopetz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kuboki</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Munster</surname><given-names>P.N.</given-names></name><name name-style="western"><surname>Krauss</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Falchook</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Han</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Heinemann</surname><given-names>V.</given-names></name><name name-style="western"><surname>Muro</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Sotorasib for previously treated colorectal cancers with KRAS(G12C) mutation (CodeBreaK100): A prespecified analysis of a single-arm, phase 2 trial</article-title><source>Lancet Oncol.</source><year>2022</year><volume>23</volume><fpage>115</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(21)00605-7</pub-id><pub-id pub-id-type="pmid">34919824</pub-id></element-citation></ref><ref id="B82-cells-13-01071"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sacher</surname><given-names>A.</given-names></name><name name-style="western"><surname>LoRusso</surname><given-names>P.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>W.H.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Garralda</surname><given-names>E.</given-names></name><name name-style="western"><surname>Forster</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Santoro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Falcon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Paz-Ares</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation</article-title><source>N. Engl. J. Med.</source><year>2023</year><volume>389</volume><fpage>710</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2303810</pub-id><pub-id pub-id-type="pmid">37611121</pub-id></element-citation></ref><ref id="B83-cells-13-01071"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skoulidis</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Dy</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Price</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Falchook</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>J.</given-names></name><name name-style="western"><surname>Italiano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schuler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Borghaei</surname><given-names>H.</given-names></name><name name-style="western"><surname>Barlesi</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Sotorasib for Lung Cancers with KRAS p.G12C Mutation</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>384</volume><fpage>2371</fpage><lpage>2381</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2103695</pub-id><pub-id pub-id-type="pmid">34096690</pub-id><pub-id pub-id-type="pmcid">PMC9116274</pub-id></element-citation></ref><ref id="B84-cells-13-01071"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ostrem</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>U.</given-names></name><name name-style="western"><surname>Sos</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Shokat</surname><given-names>K.M.</given-names></name></person-group><article-title>K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions</article-title><source>Nature</source><year>2013</year><volume>503</volume><fpage>548</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1038/nature12796</pub-id><pub-id pub-id-type="pmid">24256730</pub-id><pub-id pub-id-type="pmcid">PMC4274051</pub-id></element-citation></ref><ref id="B85-cells-13-01071"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bignell</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stephens</surname><given-names>P.</given-names></name><name name-style="western"><surname>Edkins</surname><given-names>S.</given-names></name><name name-style="western"><surname>Clegg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Teague</surname><given-names>J.</given-names></name><name name-style="western"><surname>Woffendin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Garnett</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Bottomley</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Mutations of the BRAF gene in human cancer</article-title><source>Nature</source><year>2002</year><volume>417</volume><fpage>949</fpage><lpage>954</lpage><pub-id pub-id-type="doi">10.1038/nature00766</pub-id><pub-id pub-id-type="pmid">12068308</pub-id></element-citation></ref><ref id="B86-cells-13-01071"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smiech</surname><given-names>M.</given-names></name><name name-style="western"><surname>Leszczynski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kono</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wardell</surname><given-names>C.</given-names></name><name name-style="western"><surname>Taniguchi</surname><given-names>H.</given-names></name></person-group><article-title>Emerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks</article-title><source>Genes</source><year>2020</year><volume>11</volume><elocation-id>1342</elocation-id><pub-id pub-id-type="doi">10.3390/genes11111342</pub-id><pub-id pub-id-type="pmid">33198372</pub-id><pub-id pub-id-type="pmcid">PMC7697059</pub-id></element-citation></ref><ref id="B87-cells-13-01071"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joris</surname><given-names>S.</given-names></name><name name-style="western"><surname>Denys</surname><given-names>H.</given-names></name><name name-style="western"><surname>Collignon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rasschaert</surname><given-names>M.</given-names></name><name name-style="western"><surname>T&#8217;Kint de Roodenbeke</surname><given-names>D.</given-names></name><name name-style="western"><surname>Duhoux</surname><given-names>F.P.</given-names></name><name name-style="western"><surname>Canon</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Tejpar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mebis</surname><given-names>J.</given-names></name><name name-style="western"><surname>Decoster</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study</article-title><source>ESMO Open</source><year>2023</year><volume>8</volume><fpage>102041</fpage><pub-id pub-id-type="doi">10.1016/j.esmoop.2023.102041</pub-id><pub-id pub-id-type="pmid">37852034</pub-id><pub-id pub-id-type="pmcid">PMC10774963</pub-id></element-citation></ref><ref id="B88-cells-13-01071"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dearth</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Baroni</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Brachmann</surname><given-names>R.K.</given-names></name></person-group><article-title>Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers</article-title><source>Carcinogenesis</source><year>2007</year><volume>28</volume><fpage>289</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgl132</pub-id><pub-id pub-id-type="pmid">16861262</pub-id></element-citation></ref><ref id="B89-cells-13-01071"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trere</surname><given-names>D.</given-names></name><name name-style="western"><surname>Brighenti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Donati</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ceccarelli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Santini</surname><given-names>D.</given-names></name><name name-style="western"><surname>Taffurelli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Montanaro</surname><given-names>L.</given-names></name><name name-style="western"><surname>Derenzini</surname><given-names>M.</given-names></name></person-group><article-title>High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy</article-title><source>Ann. Oncol.</source><year>2009</year><volume>20</volume><fpage>1818</fpage><lpage>1823</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdp209</pub-id><pub-id pub-id-type="pmid">19556322</pub-id></element-citation></ref><ref id="B90-cells-13-01071"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friend</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Bernards</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rogelj</surname><given-names>S.</given-names></name><name name-style="western"><surname>Weinberg</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Rapaport</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Albert</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Dryja</surname><given-names>T.P.</given-names></name></person-group><article-title>A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma</article-title><source>Nature</source><year>1986</year><volume>323</volume><fpage>643</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1038/323643a0</pub-id><pub-id pub-id-type="pmid">2877398</pub-id></element-citation></ref><ref id="B91-cells-13-01071"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oshi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tokumaru</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rashid</surname><given-names>O.M.</given-names></name><name name-style="western"><surname>Nagahashi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Matsuyama</surname><given-names>R.</given-names></name><name name-style="western"><surname>Endo</surname><given-names>I.</given-names></name><name name-style="western"><surname>Takabe</surname><given-names>K.</given-names></name></person-group><article-title>The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2- Breast Cancer</article-title><source>Cells</source><year>2020</year><volume>9</volume><elocation-id>1643</elocation-id><pub-id pub-id-type="doi">10.3390/cells9071643</pub-id><pub-id pub-id-type="pmid">32650578</pub-id><pub-id pub-id-type="pmcid">PMC7407968</pub-id></element-citation></ref><ref id="B92-cells-13-01071"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tomar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sethi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sundar</surname><given-names>G.</given-names></name><name name-style="western"><surname>Quah</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Quah</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>P.S.</given-names></name></person-group><article-title>Mutation spectrum of RB1 mutations in retinoblastoma cases from Singapore with implications for genetic management and counselling</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0178776</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0178776</pub-id><pub-id pub-id-type="pmid">28575107</pub-id><pub-id pub-id-type="pmcid">PMC5456385</pub-id></element-citation></ref><ref id="B93-cells-13-01071"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rushlow</surname><given-names>D.</given-names></name><name name-style="western"><surname>Piovesan</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Prigoda-Lee</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Marchong</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Gallie</surname><given-names>B.L.</given-names></name></person-group><article-title>Detection of mosaic RB1 mutations in families with retinoblastoma</article-title><source>Hum. Mutat.</source><year>2009</year><volume>30</volume><fpage>842</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1002/humu.20940</pub-id><pub-id pub-id-type="pmid">19280657</pub-id></element-citation></ref><ref id="B94-cells-13-01071"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bouaoun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sonkin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ardin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hollstein</surname><given-names>M.</given-names></name><name name-style="western"><surname>Byrnes</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zavadil</surname><given-names>J.</given-names></name><name name-style="western"><surname>Olivier</surname><given-names>M.</given-names></name></person-group><article-title>TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data</article-title><source>Hum. Mutat.</source><year>2016</year><volume>37</volume><fpage>865</fpage><lpage>876</lpage><pub-id pub-id-type="doi">10.1002/humu.23035</pub-id><pub-id pub-id-type="pmid">27328919</pub-id></element-citation></ref><ref id="B95-cells-13-01071"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>LoRusso</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>N.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Laurie</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Davenport</surname><given-names>T.</given-names></name><name name-style="western"><surname>Teufel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lahmar</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study</article-title><source>Cancer Discov.</source><year>2023</year><volume>13</volume><fpage>1802</fpage><lpage>1813</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-23-0153</pub-id><pub-id pub-id-type="pmid">37269344</pub-id><pub-id pub-id-type="pmcid">PMC10401071</pub-id></element-citation></ref><ref id="B96-cells-13-01071"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Slamon</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Ro</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bondarenko</surname><given-names>I.</given-names></name><name name-style="western"><surname>Im</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Masuda</surname><given-names>N.</given-names></name><name name-style="western"><surname>Colleoni</surname><given-names>M.</given-names></name><name name-style="western"><surname>DeMichele</surname><given-names>A.</given-names></name><name name-style="western"><surname>Loi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>379</volume><fpage>1926</fpage><lpage>1936</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1810527</pub-id><pub-id pub-id-type="pmid">30345905</pub-id></element-citation></ref><ref id="B97-cells-13-01071"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deininger</surname><given-names>P.</given-names></name></person-group><article-title>Genetic instability in cancer: Caretaker and gatekeeper genes</article-title><source>Ochsner J.</source><year>1999</year><volume>1</volume><fpage>206</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">21845140</pub-id><pub-id pub-id-type="pmcid">PMC3145442</pub-id></element-citation></ref><ref id="B98-cells-13-01071"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cancer Genome Atlas Research</surname><given-names>N.</given-names></name></person-group><article-title>Integrated genomic analyses of ovarian carcinoma</article-title><source>Nature</source><year>2011</year><volume>474</volume><fpage>609</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1038/nature10166</pub-id><pub-id pub-id-type="pmid">21720365</pub-id><pub-id pub-id-type="pmcid">PMC3163504</pub-id></element-citation></ref><ref id="B99-cells-13-01071"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robinson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Van Allen</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lonigro</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Mosquera</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>B.</given-names></name><name name-style="western"><surname>Taplin</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Pritchard</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Attard</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Integrative Clinical Genomics of Advanced Prostate Cancer</article-title><source>Cell</source><year>2015</year><volume>162</volume><fpage>454</fpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.06.053</pub-id><pub-id pub-id-type="pmid">28843286</pub-id></element-citation></ref><ref id="B100-cells-13-01071"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riaz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Blecua</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Higginson</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Weinhold</surname><given-names>N.</given-names></name><name name-style="western"><surname>Norton</surname><given-names>L.</given-names></name><name name-style="western"><surname>Weigelt</surname><given-names>B.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Reis-Filho</surname><given-names>J.S.</given-names></name></person-group><article-title>Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>857</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-00921-w</pub-id><pub-id pub-id-type="pmid">29021619</pub-id><pub-id pub-id-type="pmcid">PMC5636842</pub-id></element-citation></ref><ref id="B101-cells-13-01071"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sekine</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nagata</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tsuji</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hirai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fujimoto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hatae</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nagata</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ushijima</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: Two common founder mutations of BRCA1 in Japanese population</article-title><source>Clin. Cancer Res.</source><year>2001</year><volume>7</volume><fpage>3144</fpage><lpage>3150</lpage><pub-id pub-id-type="pmid">11595708</pub-id></element-citation></ref><ref id="B102-cells-13-01071"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Metcalfe</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Poll</surname><given-names>A.</given-names></name><name name-style="western"><surname>Royer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Llacuachaqui</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tulman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>P.</given-names></name><name name-style="western"><surname>Narod</surname><given-names>S.A.</given-names></name></person-group><article-title>Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women</article-title><source>J. Clin. Oncol.</source><year>2010</year><volume>28</volume><fpage>387</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.25.0712</pub-id><pub-id pub-id-type="pmid">20008623</pub-id></element-citation></ref><ref id="B103-cells-13-01071"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bakkenist</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Kastan</surname><given-names>M.B.</given-names></name></person-group><article-title>DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation</article-title><source>Nature</source><year>2003</year><volume>421</volume><fpage>499</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1038/nature01368</pub-id><pub-id pub-id-type="pmid">12556884</pub-id></element-citation></ref><ref id="B104-cells-13-01071"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumpula</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Koivuluoma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Soikkonen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vorimo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Moilanen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Winqvist</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mantere</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kuismin</surname><given-names>O.</given-names></name><name name-style="western"><surname>Pylkas</surname><given-names>K.</given-names></name></person-group><article-title>Evaluating the role of CHEK2 p.(Asp438Tyr) allele in inherited breast cancer predisposition</article-title><source>Fam. Cancer</source><year>2023</year><volume>22</volume><fpage>291</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1007/s10689-023-00327-2</pub-id><pub-id pub-id-type="pmid">36653541</pub-id><pub-id pub-id-type="pmcid">PMC10276058</pub-id></element-citation></ref><ref id="B105-cells-13-01071"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fong</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Boss</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Yap</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Tutt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mergui-Roelvink</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mortimer</surname><given-names>P.</given-names></name><name name-style="western"><surname>Swaisland</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>A.</given-names></name><name name-style="western"><surname>O&#8217;Connor</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers</article-title><source>N. Engl. J. Med.</source><year>2009</year><volume>361</volume><fpage>123</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0900212</pub-id><pub-id pub-id-type="pmid">19553641</pub-id></element-citation></ref><ref id="B106-cells-13-01071"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cseh</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Fabian</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sumegi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Scorrano</surname><given-names>L.</given-names></name></person-group><article-title>Poly(adenosine diphosphate-ribose) polymerase as therapeutic target: Lessons learned from its inhibitors</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>50221</fpage><lpage>50239</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.16859</pub-id><pub-id pub-id-type="pmid">28430591</pub-id><pub-id pub-id-type="pmcid">PMC5564845</pub-id></element-citation></ref><ref id="B107-cells-13-01071"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cseh</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Fabian</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Quintana-Cabrera</surname><given-names>R.</given-names></name><name name-style="western"><surname>Szabo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eros</surname><given-names>K.</given-names></name><name name-style="western"><surname>Soriano</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Gallyas</surname><given-names>F.</given-names></name><name name-style="western"><surname>Scorrano</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sumegi</surname><given-names>B.</given-names></name></person-group><article-title>PARP Inhibitor PJ34 Protects Mitochondria and Induces DNA-Damage Mediated Apoptosis in Combination with Cisplatin or Temozolomide in B16F10 Melanoma Cells</article-title><source>Front. Physiol.</source><year>2019</year><volume>10</volume><fpage>538</fpage><pub-id pub-id-type="doi">10.3389/fphys.2019.00538</pub-id><pub-id pub-id-type="pmid">31133874</pub-id><pub-id pub-id-type="pmcid">PMC6514236</pub-id></element-citation></ref><ref id="B108-cells-13-01071"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quail</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>J.A.</given-names></name></person-group><article-title>Microenvironmental regulation of tumor progression and metastasis</article-title><source>Nat. Med.</source><year>2013</year><volume>19</volume><fpage>1423</fpage><lpage>1437</lpage><pub-id pub-id-type="doi">10.1038/nm.3394</pub-id><pub-id pub-id-type="pmid">24202395</pub-id><pub-id pub-id-type="pmcid">PMC3954707</pub-id></element-citation></ref><ref id="B109-cells-13-01071"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Binnewies</surname><given-names>M.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>E.W.</given-names></name><name name-style="western"><surname>Kersten</surname><given-names>K.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fearon</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Merad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Coussens</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Gabrilovich</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Ostrand-Rosenberg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hedrick</surname><given-names>C.C.</given-names></name></person-group><article-title>Understanding the tumor immune microenvironment (TIME) for effective therapy</article-title><source>Nat. Med.</source><year>2018</year><volume>24</volume><fpage>541</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0014-x</pub-id><pub-id pub-id-type="pmid">29686425</pub-id><pub-id pub-id-type="pmcid">PMC5998822</pub-id></element-citation></ref><ref id="B110-cells-13-01071"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>DeNardo</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Ruffell</surname><given-names>B.</given-names></name></person-group><article-title>Macrophages as regulators of tumour immunity and immunotherapy</article-title><source>Nat. Rev. Immunol.</source><year>2019</year><volume>19</volume><fpage>369</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0127-6</pub-id><pub-id pub-id-type="pmid">30718830</pub-id><pub-id pub-id-type="pmcid">PMC7339861</pub-id></element-citation></ref><ref id="B111-cells-13-01071"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mantovani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marchesi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Malesci</surname><given-names>A.</given-names></name><name name-style="western"><surname>Laghi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Allavena</surname><given-names>P.</given-names></name></person-group><article-title>Tumour-associated macrophages as treatment targets in oncology</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2017</year><volume>14</volume><fpage>399</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2016.217</pub-id><pub-id pub-id-type="pmid">28117416</pub-id><pub-id pub-id-type="pmcid">PMC5480600</pub-id></element-citation></ref><ref id="B112-cells-13-01071"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iida</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dzutsev</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bouladoux</surname><given-names>N.</given-names></name><name name-style="western"><surname>Weingarten</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Molina</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Salcedo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Back</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cramer</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor Microenvironment</article-title><source>Science</source><year>2013</year><volume>342</volume><fpage>967</fpage><lpage>970</lpage><pub-id pub-id-type="doi">10.1126/science.1240527</pub-id><pub-id pub-id-type="pmid">24264989</pub-id><pub-id pub-id-type="pmcid">PMC6709532</pub-id></element-citation></ref><ref id="B113-cells-13-01071"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cassetta</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pollard</surname><given-names>J.W.</given-names></name></person-group><article-title>Targeting macrophages: Therapeutic approaches in cancer</article-title><source>Nat. Rev. Drug Discov.</source><year>2018</year><volume>17</volume><fpage>887</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1038/nrd.2018.169</pub-id><pub-id pub-id-type="pmid">30361552</pub-id></element-citation></ref><ref id="B114-cells-13-01071"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perez</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>De Palma</surname><given-names>M.</given-names></name></person-group><article-title>Engineering dendritic cell vaccines to improve cancer immunotherapy</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>5408</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-13368-y</pub-id><pub-id pub-id-type="pmid">31776331</pub-id><pub-id pub-id-type="pmcid">PMC6881351</pub-id></element-citation></ref><ref id="B115-cells-13-01071"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Truxova</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kasikova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hensler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Skapa</surname><given-names>P.</given-names></name><name name-style="western"><surname>Laco</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pecen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Belicova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Praznovec</surname><given-names>I.</given-names></name><name name-style="western"><surname>Halaska</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Brtnicky</surname><given-names>T.</given-names></name></person-group><article-title>Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients</article-title><source>J. Immunother. Cancer</source><year>2018</year><volume>6</volume><fpage>139</fpage><pub-id pub-id-type="doi">10.1186/s40425-018-0446-3</pub-id><pub-id pub-id-type="pmid">30526667</pub-id><pub-id pub-id-type="pmcid">PMC6288908</pub-id></element-citation></ref><ref id="B116-cells-13-01071"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verneau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Saut&#233;s-Fridman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C.-M.</given-names></name></person-group><article-title>Dendritic cells in the tumor microenvironment: Prognostic and theranostic impact</article-title><source>Semin. Immunol.</source><year>2020</year><volume>48</volume><fpage>101410</fpage><pub-id pub-id-type="doi">10.1016/j.smim.2020.101410</pub-id><pub-id pub-id-type="pmid">33011065</pub-id></element-citation></ref><ref id="B117-cells-13-01071"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Michea</surname><given-names>P.</given-names></name><name name-style="western"><surname>No&#235;l</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zakine</surname><given-names>E.</given-names></name><name name-style="western"><surname>Czerwinska</surname><given-names>U.</given-names></name><name name-style="western"><surname>Sirven</surname><given-names>P.</given-names></name><name name-style="western"><surname>Abouzid</surname><given-names>O.</given-names></name><name name-style="western"><surname>Goudot</surname><given-names>C.</given-names></name><name name-style="western"><surname>Scholer-Dahirel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vincent-Salomon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Reyal</surname><given-names>F.</given-names></name></person-group><article-title>Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific</article-title><source>Nat. Immunol.</source><year>2018</year><volume>19</volume><fpage>885</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.1038/s41590-018-0145-8</pub-id><pub-id pub-id-type="pmid">30013147</pub-id></element-citation></ref><ref id="B118-cells-13-01071"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wculek</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Cueto</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Mujal</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Melero</surname><given-names>I.</given-names></name><name name-style="western"><surname>Krummel</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Sancho</surname><given-names>D.</given-names></name></person-group><article-title>Dendritic cells in cancer immunology and immunotherapy</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><volume>20</volume><fpage>7</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0210-z</pub-id><pub-id pub-id-type="pmid">31467405</pub-id></element-citation></ref><ref id="B119-cells-13-01071"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waldman</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Fritz</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Lenardo</surname><given-names>M.J.</given-names></name></person-group><article-title>A guide to cancer immunotherapy: From T cell basic science to clinical practice</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><volume>20</volume><fpage>651</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-0306-5</pub-id><pub-id pub-id-type="pmid">32433532</pub-id><pub-id pub-id-type="pmcid">PMC7238960</pub-id></element-citation></ref><ref id="B120-cells-13-01071"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malinowska</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kowalski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Merecz-Sadowska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Paprocka-Zjawiona</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sitarek</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kowalczyk</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zielinska-Blizniewska</surname><given-names>H.</given-names></name></person-group><article-title>PD-1 and PD-L1 Expression Levels as a Potential Biomarker of Chronic Rhinosinusitis and Head and Neck Cancers</article-title><source>J. Clin. Med.</source><year>2023</year><volume>12</volume><elocation-id>2033</elocation-id><pub-id pub-id-type="doi">10.3390/jcm12052033</pub-id><pub-id pub-id-type="pmid">36902820</pub-id><pub-id pub-id-type="pmcid">PMC10004389</pub-id></element-citation></ref><ref id="B121-cells-13-01071"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujita</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yagishita</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hagiwara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yoshioka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kosaka</surname><given-names>N.</given-names></name><name name-style="western"><surname>Takeshita</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fujiwara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tsuta</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nokihara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tamura</surname><given-names>T.</given-names></name><etal/></person-group><article-title>The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer</article-title><source>Mol. Ther.</source><year>2015</year><volume>23</volume><fpage>717</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1038/mt.2015.10</pub-id><pub-id pub-id-type="pmid">25597412</pub-id><pub-id pub-id-type="pmcid">PMC4395779</pub-id></element-citation></ref><ref id="B122-cells-13-01071"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Chao</surname><given-names>S.X.</given-names></name><name name-style="western"><surname>Pelka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Giannakis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hess</surname><given-names>J.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jorgji</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sindurakar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Braverman</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: A phase 2 trial</article-title><source>Nat. Med.</source><year>2023</year><volume>29</volume><fpage>458</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-02181-8</pub-id><pub-id pub-id-type="pmid">36702949</pub-id><pub-id pub-id-type="pmcid">PMC9941044</pub-id></element-citation></ref><ref id="B123-cells-13-01071"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenbaum</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Bledsoe</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Morales-Oyarvide</surname><given-names>V.</given-names></name><name name-style="western"><surname>Huynh</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Mino-Kenudson</surname><given-names>M.</given-names></name></person-group><article-title>PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes</article-title><source>Mod. Pathol.</source><year>2016</year><volume>29</volume><fpage>1104</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2016.95</pub-id><pub-id pub-id-type="pmid">27198569</pub-id></element-citation></ref><ref id="B124-cells-13-01071"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marabelle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Le</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Ascierto</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Di Giacomo</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>De Jesus-Acosta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Delord</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Geva</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gottfried</surname><given-names>M.</given-names></name><name name-style="western"><surname>Penel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>A.R.</given-names></name><etal/></person-group><article-title>Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study</article-title><source>J. Clin. Oncol.</source><year>2020</year><volume>38</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1200/JCO.19.02105</pub-id><pub-id pub-id-type="pmid">31682550</pub-id><pub-id pub-id-type="pmcid">PMC8184060</pub-id></element-citation></ref><ref id="B125-cells-13-01071"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howitt</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Sholl</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Ritterhouse</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Watkins</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Rodig</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stover</surname><given-names>E.</given-names></name><name name-style="western"><surname>Strickland</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>D&#8217;Andrea</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.J.</given-names></name><etal/></person-group><article-title>Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers with Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1</article-title><source>JAMA Oncol.</source><year>2015</year><volume>1</volume><fpage>1319</fpage><lpage>1323</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2015.2151</pub-id><pub-id pub-id-type="pmid">26181000</pub-id></element-citation></ref><ref id="B126-cells-13-01071"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ascierto</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Manzyuk</surname><given-names>L.</given-names></name><name name-style="western"><surname>Motola-Kuba</surname><given-names>D.</given-names></name><name name-style="western"><surname>Penel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cassier</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Bariani</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>De Jesus Acosta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Doi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Longo</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: Updated analysis from the phase II KEYNOTE-158 study</article-title><source>Ann. Oncol.</source><year>2022</year><volume>33</volume><fpage>929</fpage><lpage>938</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2022.05.519</pub-id><pub-id pub-id-type="pmid">35680043</pub-id></element-citation></ref><ref id="B127-cells-13-01071"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bashey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Medina</surname><given-names>B.</given-names></name><name name-style="western"><surname>Corringham</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pasek</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carrier</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vrooman</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lowy</surname><given-names>I.</given-names></name><name name-style="western"><surname>Solomon</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Holland</surname><given-names>H.K.</given-names></name><etal/></person-group><article-title>CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation</article-title><source>Blood</source><year>2009</year><volume>113</volume><fpage>1581</fpage><lpage>1588</lpage><pub-id pub-id-type="doi">10.1182/blood-2008-07-168468</pub-id><pub-id pub-id-type="pmid">18974373</pub-id><pub-id pub-id-type="pmcid">PMC2644086</pub-id></element-citation></ref><ref id="B128-cells-13-01071"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luke</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Blumenschein</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chmielowski</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ulahannan</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Connolly</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Santa-Maria</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bahadur</surname><given-names>S.W.</given-names></name><etal/></person-group><article-title>The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: A phase 1 trial</article-title><source>Nat. Med.</source><year>2023</year><volume>29</volume><fpage>2814</fpage><lpage>2824</lpage><pub-id pub-id-type="doi">10.1038/s41591-023-02593-0</pub-id><pub-id pub-id-type="pmid">37857711</pub-id><pub-id pub-id-type="pmcid">PMC10667103</pub-id></element-citation></ref><ref id="B129-cells-13-01071"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tawbi</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Schadendorf</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lipson</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Ascierto</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Matamala</surname><given-names>L.</given-names></name><name name-style="western"><surname>Castillo Gutierrez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rutkowski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gogas</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Lao</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>De Menezes</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma</article-title><source>N. Engl. J. Med.</source><year>2022</year><volume>386</volume><fpage>24</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2109970</pub-id><pub-id pub-id-type="pmid">34986285</pub-id><pub-id pub-id-type="pmcid">PMC9844513</pub-id></element-citation></ref><ref id="B130-cells-13-01071"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hahn</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Gill</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Pal</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>N.</given-names></name></person-group><article-title>The future of immune checkpoint cancer therapy after PD-1 and CTLA-4</article-title><source>Immunotherapy</source><year>2017</year><volume>9</volume><fpage>681</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.2217/imt-2017-0024</pub-id><pub-id pub-id-type="pmid">28653573</pub-id></element-citation></ref><ref id="B131-cells-13-01071"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>R.-Y.</given-names></name><name name-style="western"><surname>Eppolito</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lele</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shrikant</surname><given-names>P.</given-names></name><name name-style="western"><surname>Matsuzaki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Odunsi</surname><given-names>K.</given-names></name></person-group><article-title>LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>27359</fpage><pub-id pub-id-type="doi">10.18632/oncotarget.4751</pub-id><pub-id pub-id-type="pmid">26318293</pub-id><pub-id pub-id-type="pmcid">PMC4694995</pub-id></element-citation></ref><ref id="B132-cells-13-01071"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guillerey</surname><given-names>C.</given-names></name><name name-style="western"><surname>Harjunp&#228;&#228;</surname><given-names>H.</given-names></name><name name-style="western"><surname>Carri&#233;</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kassem</surname><given-names>S.</given-names></name><name name-style="western"><surname>Teo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Miles</surname><given-names>K.</given-names></name><name name-style="western"><surname>Krumeich</surname><given-names>S.</given-names></name><name name-style="western"><surname>Weulersse</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cuisinier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stannard</surname><given-names>K.</given-names></name></person-group><article-title>TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma</article-title><source>Blood J. Am. Soc. Hematol.</source><year>2018</year><volume>132</volume><fpage>1689</fpage><lpage>1694</lpage><pub-id pub-id-type="doi">10.1182/blood-2018-01-825265</pub-id><pub-id pub-id-type="pmid">29986909</pub-id></element-citation></ref><ref id="B133-cells-13-01071"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Palma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Biziato</surname><given-names>D.</given-names></name><name name-style="western"><surname>Petrova</surname><given-names>T.V.</given-names></name></person-group><article-title>Microenvironmental regulation of tumour angiogenesis</article-title><source>Nat. Rev. Cancer</source><year>2017</year><volume>17</volume><fpage>457</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1038/nrc.2017.51</pub-id><pub-id pub-id-type="pmid">28706266</pub-id></element-citation></ref><ref id="B134-cells-13-01071"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schito</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rey</surname><given-names>S.</given-names></name></person-group><article-title>Hypoxia: Turning vessels into vassals of cancer immunotolerance</article-title><source>Cancer Lett.</source><year>2020</year><volume>487</volume><fpage>74</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2020.05.015</pub-id><pub-id pub-id-type="pmid">32470491</pub-id></element-citation></ref><ref id="B135-cells-13-01071"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schaaf</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Garg</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Agostinis</surname><given-names>P.</given-names></name></person-group><article-title>Defining the role of the tumor vasculature in antitumor immunity and immunotherapy</article-title><source>Cell Death Dis.</source><year>2018</year><volume>9</volume><fpage>115</fpage><pub-id pub-id-type="doi">10.1038/s41419-017-0061-0</pub-id><pub-id pub-id-type="pmid">29371595</pub-id><pub-id pub-id-type="pmcid">PMC5833710</pub-id></element-citation></ref><ref id="B136-cells-13-01071"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J.</given-names></name></person-group><article-title>Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer</article-title><source>OncoTargets Ther.</source><year>2018</year><volume>11</volume><fpage>8605</fpage><lpage>8621</lpage><pub-id pub-id-type="doi">10.2147/OTT.S171724</pub-id><pub-id pub-id-type="pmid">30584320</pub-id><pub-id pub-id-type="pmcid">PMC6287670</pub-id></element-citation></ref><ref id="B137-cells-13-01071"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamaoka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kusumoto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ando</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ohba</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ohmori</surname><given-names>T.</given-names></name></person-group><article-title>Receptor tyrosine kinase-targeted cancer therapy</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><elocation-id>3491</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19113491</pub-id><pub-id pub-id-type="pmid">30404198</pub-id><pub-id pub-id-type="pmcid">PMC6274851</pub-id></element-citation></ref><ref id="B138-cells-13-01071"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>X.-J.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Q.-H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.-M.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Y.-L.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.-D.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.-P.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>S.-L.</given-names></name></person-group><article-title>A phase II study of Endostatin in combination with paclitaxel, carboplatin, and radiotherapy in patients with unresectable locally advanced non-small cell lung cancer</article-title><source>BMC Cancer</source><year>2016</year><volume>16</volume><elocation-id>266</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-016-2234-0</pub-id><pub-id pub-id-type="pmid">27067521</pub-id><pub-id pub-id-type="pmcid">PMC4828797</pub-id></element-citation></ref><ref id="B139-cells-13-01071"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Batchelor</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Sorensen</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>di Tomaso</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.-T.</given-names></name><name name-style="western"><surname>Duda</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Kozak</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Cahill</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>P.-J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>M.</given-names></name></person-group><article-title>AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients</article-title><source>Cancer Cell</source><year>2007</year><volume>11</volume><fpage>83</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2006.11.021</pub-id><pub-id pub-id-type="pmid">17222792</pub-id><pub-id pub-id-type="pmcid">PMC2748664</pub-id></element-citation></ref><ref id="B140-cells-13-01071"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dewhirst</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Secomb</surname><given-names>T.W.</given-names></name></person-group><article-title>Transport of drugs from blood vessels to tumour tissue</article-title><source>Nat. Rev. Cancer</source><year>2017</year><volume>17</volume><fpage>738</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1038/nrc.2017.93</pub-id><pub-id pub-id-type="pmid">29123246</pub-id><pub-id pub-id-type="pmcid">PMC6371795</pub-id></element-citation></ref><ref id="B141-cells-13-01071"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tharkar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Varanasi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chrzanowski</surname><given-names>W.</given-names></name></person-group><article-title>Nano-enhanced drug delivery and therapeutic ultrasound for cancer treat-ment and beyond</article-title><source>Front. Bioeng. Biotechnol.</source><year>2019</year><volume>7</volume><elocation-id>324</elocation-id><pub-id pub-id-type="doi">10.3389/fbioe.2019.00324</pub-id><pub-id pub-id-type="pmid">31824930</pub-id><pub-id pub-id-type="pmcid">PMC6883936</pub-id></element-citation></ref><ref id="B142-cells-13-01071"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Cabral</surname><given-names>H.</given-names></name><name name-style="western"><surname>Stylianopoulos</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>R.K.</given-names></name></person-group><article-title>Improving cancer immunotherapy using nanomedicines: Progress, opportunities and challenges</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2020</year><volume>17</volume><fpage>251</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1038/s41571-019-0308-z</pub-id><pub-id pub-id-type="pmid">32034288</pub-id><pub-id pub-id-type="pmcid">PMC8272676</pub-id></element-citation></ref><ref id="B143-cells-13-01071"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abyaneh</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Regenold</surname><given-names>M.</given-names></name><name name-style="western"><surname>McKee</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gauthier</surname><given-names>M.A.</given-names></name></person-group><article-title>Towards extracellular matrix normalization for improved treatment of solid tumors</article-title><source>Theranostics</source><year>2020</year><volume>10</volume><fpage>1960</fpage><pub-id pub-id-type="doi">10.7150/thno.39995</pub-id><pub-id pub-id-type="pmid">32042347</pub-id><pub-id pub-id-type="pmcid">PMC6993244</pub-id></element-citation></ref><ref id="B144-cells-13-01071"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henke</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nandigama</surname><given-names>R.</given-names></name><name name-style="western"><surname>Erg&#252;n</surname><given-names>S.</given-names></name></person-group><article-title>Extracellular matrix in the tumor microenvironment and its impact on cancer therapy</article-title><source>Front. Mol. Biosci.</source><year>2020</year><volume>6</volume><elocation-id>160</elocation-id><pub-id pub-id-type="doi">10.3389/fmolb.2019.00160</pub-id><pub-id pub-id-type="pmid">32118030</pub-id><pub-id pub-id-type="pmcid">PMC7025524</pub-id></element-citation></ref><ref id="B145-cells-13-01071"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Osterman</surname><given-names>C.J.D.</given-names></name><name name-style="western"><surname>Ozmadenci</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kleinschmidt</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Barrie</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bean</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Sulzmaier</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.L.</given-names></name></person-group><article-title>Abstract A61: FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy</article-title><source>Clin. Cancer Res.</source><year>2020</year><volume>26</volume><fpage>A61</fpage><pub-id pub-id-type="doi">10.1158/1557-3265.OVCA19-A61</pub-id><pub-id pub-id-type="pmcid">PMC6721800</pub-id><pub-id pub-id-type="pmid">31478830</pub-id></element-citation></ref><ref id="B146-cells-13-01071"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mintz</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Sowers</surname><given-names>R.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Hilmer</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Mazza</surname><given-names>B.</given-names></name><name name-style="western"><surname>Huvos</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Meyers</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>LaFleur</surname><given-names>B.</given-names></name><name name-style="western"><surname>McDonough</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Henry</surname><given-names>M.M.</given-names></name></person-group><article-title>An expression signature classifies chemotherapy-resistant pediatric osteosarcoma</article-title><source>Cancer Res.</source><year>2005</year><volume>65</volume><fpage>1748</fpage><lpage>1754</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-2463</pub-id><pub-id pub-id-type="pmid">15753370</pub-id></element-citation></ref><ref id="B147-cells-13-01071"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riaz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sieuwerts</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Look</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Timmermans</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Smid</surname><given-names>M.</given-names></name><name name-style="western"><surname>Foekens</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Martens</surname><given-names>J.W.</given-names></name></person-group><article-title>High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes</article-title><source>Breast Cancer Res.</source><year>2012</year><volume>14</volume><fpage>R123</fpage><pub-id pub-id-type="doi">10.1186/bcr3317</pub-id><pub-id pub-id-type="pmid">22967435</pub-id><pub-id pub-id-type="pmcid">PMC4053101</pub-id></element-citation></ref><ref id="B148-cells-13-01071"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finak</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bertos</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pepin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sadekova</surname><given-names>S.</given-names></name><name name-style="western"><surname>Souleimanova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Omeroglu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Meterissian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Omeroglu</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Stromal gene expression predicts clinical outcome in breast cancer</article-title><source>Nat. Med.</source><year>2008</year><volume>14</volume><fpage>518</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1038/nm1764</pub-id><pub-id pub-id-type="pmid">18438415</pub-id></element-citation></ref><ref id="B149-cells-13-01071"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Provenzano</surname><given-names>P.P.</given-names></name><name name-style="western"><surname>Hingorani</surname><given-names>S.R.</given-names></name></person-group><article-title>Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer</article-title><source>Br. J. Cancer</source><year>2013</year><volume>108</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/bjc.2012.569</pub-id><pub-id pub-id-type="pmid">23299539</pub-id><pub-id pub-id-type="pmcid">PMC3553539</pub-id></element-citation></ref><ref id="B150-cells-13-01071"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Wo</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yeap</surname><given-names>B.Y.</given-names></name><name name-style="western"><surname>Drapek</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Ly</surname><given-names>L.</given-names></name><name name-style="western"><surname>Baglini</surname><given-names>C.V.</given-names></name><name name-style="western"><surname>Blaszkowsky</surname><given-names>L.S.</given-names></name><etal/></person-group><article-title>Total Neoadjuvant Therapy with FOLFIRINOX in Combination with Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial</article-title><source>JAMA Oncol.</source><year>2019</year><volume>5</volume><fpage>1020</fpage><lpage>1027</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2019.0892</pub-id><pub-id pub-id-type="pmid">31145418</pub-id><pub-id pub-id-type="pmcid">PMC6547247</pub-id></element-citation></ref><ref id="B151-cells-13-01071"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lampi</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Reinhart-King</surname><given-names>C.A.</given-names></name></person-group><article-title>Targeting extracellular matrix stiffness to attenuate disease: From molecular mechanisms to clinical trials</article-title><source>Sci. Transl. Med.</source><year>2018</year><volume>10</volume><fpage>eaao0475</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aao0475</pub-id><pub-id pub-id-type="pmid">29298864</pub-id></element-citation></ref><ref id="B152-cells-13-01071"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhome</surname><given-names>R.</given-names></name><name name-style="western"><surname>Goh</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Bullock</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Pillar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Thirdborough</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Mellone</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mirnezami</surname><given-names>R.</given-names></name><name name-style="western"><surname>Galea</surname><given-names>D.</given-names></name><name name-style="western"><surname>Veselkov</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Exosomal microRNAs derived from colorectal cancer-associated fibroblasts: Role in driving cancer progression</article-title><source>Aging</source><year>2017</year><volume>9</volume><fpage>2666</fpage><lpage>2694</lpage><pub-id pub-id-type="doi">10.18632/aging.101355</pub-id><pub-id pub-id-type="pmid">29283887</pub-id><pub-id pub-id-type="pmcid">PMC5764398</pub-id></element-citation></ref><ref id="B153-cells-13-01071"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lytle</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dann</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Ridinger-Saison</surname><given-names>M.</given-names></name><name name-style="western"><surname>DelGiorno</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Antal</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>G.</given-names></name></person-group><article-title>Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring</article-title><source>Nature</source><year>2019</year><volume>569</volume><fpage>131</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1130-6</pub-id><pub-id pub-id-type="pmid">30996350</pub-id><pub-id pub-id-type="pmcid">PMC6565370</pub-id></element-citation></ref><ref id="B154-cells-13-01071"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruzzese</surname><given-names>F.</given-names></name><name name-style="western"><surname>H&#228;ggl&#246;f</surname><given-names>C.</given-names></name><name name-style="western"><surname>Leone</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sj&#246;berg</surname><given-names>E.</given-names></name><name name-style="western"><surname>Roca</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Kiflemariam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sj&#246;blom</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hammarsten</surname><given-names>P.</given-names></name><name name-style="western"><surname>Egevad</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bergh</surname><given-names>A.</given-names></name></person-group><article-title>Local and systemic protumorigenic effects of cancer-associated fibroblast-derived GDF15</article-title><source>Cancer Res.</source><year>2014</year><volume>74</volume><fpage>3408</fpage><lpage>3417</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-2259</pub-id><pub-id pub-id-type="pmid">24780757</pub-id></element-citation></ref><ref id="B155-cells-13-01071"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukumura</surname><given-names>D.</given-names></name><name name-style="western"><surname>Xavier</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sugiura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Park</surname><given-names>E.-C.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Selig</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Taksir</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>R.K.</given-names></name></person-group><article-title>Tumor induction of VEGF promoter activity in stromal cells</article-title><source>Cell</source><year>1998</year><volume>94</volume><fpage>715</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81731-6</pub-id><pub-id pub-id-type="pmid">9753319</pub-id></element-citation></ref><ref id="B156-cells-13-01071"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fearon</surname><given-names>D.T.</given-names></name></person-group><article-title>The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance</article-title><source>Cancer Immunol. Res.</source><year>2014</year><volume>2</volume><fpage>187</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-14-0002</pub-id><pub-id pub-id-type="pmid">24778314</pub-id></element-citation></ref><ref id="B157-cells-13-01071"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lavacchi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Roviello</surname><given-names>G.</given-names></name><name name-style="western"><surname>D&#8217;Angelo</surname><given-names>A.</given-names></name></person-group><article-title>Tumor-Agnostic Treatment for Cancer: When How is Better than Where</article-title><source>Clin. Drug Investig.</source><year>2020</year><volume>40</volume><fpage>519</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1007/s40261-020-00915-5</pub-id><pub-id pub-id-type="pmid">32307639</pub-id></element-citation></ref><ref id="B158-cells-13-01071"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Le</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Durham</surname><given-names>J.N.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>K.N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Aulakh</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kemberling</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wilt</surname><given-names>C.</given-names></name><name name-style="western"><surname>Luber</surname><given-names>B.S.</given-names></name><etal/></person-group><article-title>Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade</article-title><source>Science</source><year>2017</year><volume>357</volume><fpage>409</fpage><lpage>413</lpage><pub-id pub-id-type="doi">10.1126/science.aan6733</pub-id><pub-id pub-id-type="pmid">28596308</pub-id><pub-id pub-id-type="pmcid">PMC5576142</pub-id></element-citation></ref><ref id="B159-cells-13-01071"><label>159.</label><element-citation publication-type="gov"><article-title>FDA Grants Accelerated Approval to Pembrolizumab for First Tissue/Site Agnostic Indication</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-03-26">(accessed on 26 March 2024)</date-in-citation></element-citation></ref><ref id="B160-cells-13-01071"><label>160.</label><element-citation publication-type="gov"><article-title>FDA Approves Pembrolizumab for Adults and Children with TMB-H Solid Tumors</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors" ext-link-type="uri">https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-04-07">(accessed on 7 April 2024)</date-in-citation></element-citation></ref><ref id="B161-cells-13-01071"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hill</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Graf</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>K.</given-names></name><name name-style="western"><surname>Danziger</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Quintanilha</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>Haberberger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Santin</surname><given-names>A.D.</given-names></name><etal/></person-group><article-title>Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer</article-title><source>Int. J. Gynecol. Cancer</source><year>2023</year><volume>33</volume><fpage>504</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1136/ijgc-2022-004026</pub-id><pub-id pub-id-type="pmid">36750267</pub-id><pub-id pub-id-type="pmcid">PMC10086481</pub-id></element-citation></ref><ref id="B162-cells-13-01071"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Reck</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mansfield</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Mok</surname><given-names>T.</given-names></name><name name-style="western"><surname>Scherpereel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Reinmuth</surname><given-names>N.</given-names></name><name name-style="western"><surname>Garassino</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>De Castro Carpeno</surname><given-names>J.</given-names></name><name name-style="western"><surname>Califano</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nishio</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Updated Overall Survival and PD-L1 Subgroup Analysis of Patients with Extensive-Stage Small-Cell Lung Cancer Treated with Atezolizumab, Carboplatin, and Etoposide (IMpower133)</article-title><source>J. Clin. Oncol.</source><year>2021</year><volume>39</volume><fpage>619</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1200/JCO.20.01055</pub-id><pub-id pub-id-type="pmid">33439693</pub-id><pub-id pub-id-type="pmcid">PMC8078320</pub-id></element-citation></ref><ref id="B163-cells-13-01071"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herbst</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Soria</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Kowanetz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fine</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Hamid</surname><given-names>O.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Sosman</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>McDermott</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Powderly</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Gettinger</surname><given-names>S.N.</given-names></name><etal/></person-group><article-title>Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients</article-title><source>Nature</source><year>2014</year><volume>515</volume><fpage>563</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1038/nature14011</pub-id><pub-id pub-id-type="pmid">25428504</pub-id><pub-id pub-id-type="pmcid">PMC4836193</pub-id></element-citation></ref><ref id="B164-cells-13-01071"><label>164.</label><element-citation publication-type="gov"><article-title>FDA Approves Atezolizumab for First-Line Treatment of Metastatic NSCLC with High PD-L1 Expression</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-first-line-treatment-metastatic-nsclc-high-pd-l1-expression" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-first-line-treatment-metastatic-nsclc-high-pd-l1-expression</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-04-07">(accessed on 7 April 2024)</date-in-citation></element-citation></ref><ref id="B165-cells-13-01071"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hodi</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>O&#8217;Day</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>McDermott</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Sosman</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Haanen</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Robert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schadendorf</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hassel</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Improved survival with ipilimumab in patients with metastatic melanoma</article-title><source>N. Engl. J. Med.</source><year>2010</year><volume>363</volume><fpage>711</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1003466</pub-id><pub-id pub-id-type="pmid">20525992</pub-id><pub-id pub-id-type="pmcid">PMC3549297</pub-id></element-citation></ref><ref id="B166-cells-13-01071"><label>166.</label><element-citation publication-type="gov"><article-title>FDA Approves Nivolumab Plus Ipilimumab for First-Line mNSCLC (PD-L1 Tumor Expression &#8805;1%)</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-plus-ipilimumab-first-line-mnsclc-pd-l1-tumor-expression-1" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-plus-ipilimumab-first-line-mnsclc-pd-l1-tumor-expression-1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-04-07">(accessed on 7 April 2024)</date-in-citation></element-citation></ref><ref id="B167-cells-13-01071"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brahmer</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Ciuleanu</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>Bernabe Caro</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nishio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Urban</surname><given-names>L.</given-names></name><name name-style="western"><surname>Audigier-Valette</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lupinacci</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sangha</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pluzanski</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Five-Year Survival Outcomes with Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227</article-title><source>J. Clin. Oncol.</source><year>2023</year><volume>41</volume><fpage>1200</fpage><lpage>1212</lpage><pub-id pub-id-type="doi">10.1200/JCO.22.01503</pub-id><pub-id pub-id-type="pmid">36223558</pub-id><pub-id pub-id-type="pmcid">PMC9937094</pub-id></element-citation></ref><ref id="B168-cells-13-01071"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>S.Q.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>C.</given-names></name><etal/></person-group><article-title>The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients</article-title><source>Cancer Res. Treat.</source><year>2021</year><volume>53</volume><fpage>339</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.4143/crt.2020.790</pub-id><pub-id pub-id-type="pmid">33171025</pub-id><pub-id pub-id-type="pmcid">PMC8053869</pub-id></element-citation></ref><ref id="B169-cells-13-01071"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kerepesi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Abushukair</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Ricciuti</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nassar</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Adib</surname><given-names>E.</given-names></name><name name-style="western"><surname>Alessi</surname><given-names>J.V.</given-names></name><name name-style="western"><surname>Pecci</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rakaee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fadlullah</surname><given-names>M.Z.H.</given-names></name><name name-style="western"><surname>Tokes</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>Association of Baseline Tumor-Specific Neoantigens and CD8(+) T-Cell Infiltration with Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors</article-title><source>JCO Precis. Oncol.</source><year>2024</year><volume>8</volume><fpage>e2300439</fpage><pub-id pub-id-type="doi">10.1200/PO.23.00439</pub-id><pub-id pub-id-type="pmid">38330262</pub-id></element-citation></ref><ref id="B170-cells-13-01071"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atkins</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Chmielowski</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tarhini</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>G.I.</given-names></name><name name-style="western"><surname>Truong</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Davar</surname><given-names>D.</given-names></name><name name-style="western"><surname>O&#8217;Rourke</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stephenson</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients with Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134</article-title><source>J. Clin. Oncol.</source><year>2023</year><volume>41</volume><fpage>186</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1200/JCO.22.01763</pub-id><pub-id pub-id-type="pmid">36166727</pub-id><pub-id pub-id-type="pmcid">PMC9839305</pub-id></element-citation></ref><ref id="B171-cells-13-01071"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falchook</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Long</surname><given-names>G.V.</given-names></name><name name-style="western"><surname>Kurzrock</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Arkenau</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Hamid</surname><given-names>O.</given-names></name><name name-style="western"><surname>Infante</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Millward</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pavlick</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436)</article-title><source>Clin. Cancer Res.</source><year>2014</year><volume>20</volume><fpage>4449</fpage><lpage>4458</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-0887</pub-id><pub-id pub-id-type="pmid">24958809</pub-id></element-citation></ref><ref id="B172-cells-13-01071"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>G.V.</given-names></name><name name-style="western"><surname>Stroyakovskiy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gogas</surname><given-names>H.</given-names></name><name name-style="western"><surname>Levchenko</surname><given-names>E.</given-names></name><name name-style="western"><surname>de Braud</surname><given-names>F.</given-names></name><name name-style="western"><surname>Larkin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garbe</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jouary</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hauschild</surname><given-names>A.</given-names></name><name name-style="western"><surname>Grob</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma</article-title><source>N. Engl. J. Med.</source><year>2014</year><volume>371</volume><fpage>1877</fpage><lpage>1888</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1406037</pub-id><pub-id pub-id-type="pmid">25265492</pub-id></element-citation></ref><ref id="B173-cells-13-01071"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subbiah</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kreitman</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Wainberg</surname><given-names>Z.A.</given-names></name><name name-style="western"><surname>Gazzah</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lassen</surname><given-names>U.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Dietrich</surname><given-names>S.</given-names></name><name name-style="western"><surname>de Jonge</surname><given-names>M.J.A.</given-names></name><name name-style="western"><surname>Blay</surname><given-names>J.Y.</given-names></name><etal/></person-group><article-title>Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: The phase 2 ROAR trial</article-title><source>Nat. Med.</source><year>2023</year><volume>29</volume><fpage>1103</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1038/s41591-023-02321-8</pub-id><pub-id pub-id-type="pmid">37059834</pub-id><pub-id pub-id-type="pmcid">PMC10202803</pub-id></element-citation></ref><ref id="B174-cells-13-01071"><label>174.</label><element-citation publication-type="gov"><article-title>FDA Grants Accelerated Approval to Dabrafenib in Combination with Trametinib for Unresectable or Metastatic Solid Tumors with BRAF V600E Mutation</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-04-07">(accessed on 7 April 2024)</date-in-citation></element-citation></ref><ref id="B175-cells-13-01071"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Dowlati</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brose</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Farago</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Montez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Meric-Bernstam</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Larotrectinib in adult patients with solid tumours: A multi-centre, open-label, phase I dose-escalation study</article-title><source>Ann. Oncol.</source><year>2019</year><volume>30</volume><fpage>325</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdy539</pub-id><pub-id pub-id-type="pmid">30624546</pub-id><pub-id pub-id-type="pmcid">PMC6386027</pub-id></element-citation></ref><ref id="B176-cells-13-01071"><label>176.</label><element-citation publication-type="gov"><article-title>FDA Approves Larotrectinib for Solid Tumors with NTRK Gene Fusions</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions" ext-link-type="uri">https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-04-06">(accessed on 6 April 2024)</date-in-citation></element-citation></ref><ref id="B177-cells-13-01071"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hong</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>DuBois</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Kummar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Farago</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Albert</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Rohrberg</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>van Tilburg</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Nagasubramanian</surname><given-names>R.</given-names></name><name name-style="western"><surname>Berlin</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Federman</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1/2 clinical trials</article-title><source>Lancet Oncol.</source><year>2020</year><volume>21</volume><fpage>531</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(19)30856-3</pub-id><pub-id pub-id-type="pmid">32105622</pub-id><pub-id pub-id-type="pmcid">PMC7497841</pub-id></element-citation></ref><ref id="B178-cells-13-01071"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fischer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ullah</surname><given-names>M.</given-names></name><name name-style="western"><surname>de la Cruz</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Hunsaker</surname><given-names>T.</given-names></name><name name-style="western"><surname>Senn</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wirz</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>B.</given-names></name><name name-style="western"><surname>Draganov</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vazvaei</surname><given-names>F.</given-names></name><name name-style="western"><surname>Donzelli</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: Differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein</article-title><source>Neuro Oncol.</source><year>2020</year><volume>22</volume><fpage>819</fpage><lpage>829</lpage><pub-id pub-id-type="doi">10.1093/neuonc/noaa052</pub-id><pub-id pub-id-type="pmid">32383735</pub-id><pub-id pub-id-type="pmcid">PMC7283026</pub-id></element-citation></ref><ref id="B179-cells-13-01071"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drilon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Siena</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ou</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Farago</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Wheler</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.V.</given-names></name><etal/></person-group><article-title>Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)</article-title><source>Cancer Discov.</source><year>2017</year><volume>7</volume><fpage>400</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-16-1237</pub-id><pub-id pub-id-type="pmid">28183697</pub-id><pub-id pub-id-type="pmcid">PMC5380583</pub-id></element-citation></ref><ref id="B180-cells-13-01071"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ardini</surname><given-names>E.</given-names></name><name name-style="western"><surname>Menichincheri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Banfi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bosotti</surname><given-names>R.</given-names></name><name name-style="western"><surname>De Ponti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pulci</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ballinari</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ciomei</surname><given-names>M.</given-names></name><name name-style="western"><surname>Texido</surname><given-names>G.</given-names></name><name name-style="western"><surname>Degrassi</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications</article-title><source>Mol. Cancer Ther.</source><year>2016</year><volume>15</volume><fpage>628</fpage><lpage>639</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-15-0758</pub-id><pub-id pub-id-type="pmid">26939704</pub-id></element-citation></ref><ref id="B181-cells-13-01071"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Duke</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Bradford</surname><given-names>D.</given-names></name><name name-style="western"><surname>Marcovitz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Amatya</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Mishra-Kalyani</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Price</surname><given-names>L.S.L.</given-names></name><name name-style="western"><surname>Fourie Zirkelbach</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bi</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors</article-title><source>Clin. Cancer Res.</source><year>2023</year><volume>29</volume><fpage>3573</fpage><lpage>3578</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-23-0459</pub-id><pub-id pub-id-type="pmid">37265412</pub-id><pub-id pub-id-type="pmcid">PMC10524590</pub-id></element-citation></ref><ref id="B182-cells-13-01071"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marcus</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lemery</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Keegan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pazdur</surname><given-names>R.</given-names></name></person-group><article-title>FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors</article-title><source>Clin. Cancer Res.</source><year>2019</year><volume>25</volume><fpage>3753</fpage><lpage>3758</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-4070</pub-id><pub-id pub-id-type="pmid">30787022</pub-id></element-citation></ref><ref id="B183-cells-13-01071"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oaknin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tinker</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mathews</surname><given-names>C.</given-names></name><name name-style="western"><surname>Press</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sabatier</surname><given-names>R.</given-names></name><name name-style="western"><surname>O&#8217;Malley</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Samouelian</surname><given-names>V.</given-names></name><name name-style="western"><surname>Boni</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: Interim results from GARNET-a phase I, single-arm study</article-title><source>J. Immunother. Cancer</source><year>2022</year><volume>10</volume><fpage>e003777</fpage><pub-id pub-id-type="doi">10.1136/jitc-2021-003777</pub-id><pub-id pub-id-type="pmid">35064011</pub-id><pub-id pub-id-type="pmcid">PMC8785197</pub-id></element-citation></ref><ref id="B184-cells-13-01071"><label>184.</label><element-citation publication-type="gov"><article-title>FDA Grants Regular Approval to Dostarlimab-Gxly for dMMR Endometrial Cancer</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-dostarlimab-gxly-dmmr-endometrial-cancer" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-dostarlimab-gxly-dmmr-endometrial-cancer</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-03-31">(accessed on 31 March 2024)</date-in-citation></element-citation></ref><ref id="B185-cells-13-01071"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drilon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Laetsch</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Kummar</surname><given-names>S.</given-names></name><name name-style="western"><surname>DuBois</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Lassen</surname><given-names>U.N.</given-names></name><name name-style="western"><surname>Demetri</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Nathenson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Doebele</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Farago</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Pappo</surname><given-names>A.S.</given-names></name><etal/></person-group><article-title>Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>378</volume><fpage>731</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1714448</pub-id><pub-id pub-id-type="pmid">29466156</pub-id><pub-id pub-id-type="pmcid">PMC5857389</pub-id></element-citation></ref><ref id="B186-cells-13-01071"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doebele</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Drilon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Paz-Ares</surname><given-names>L.</given-names></name><name name-style="western"><surname>Siena</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Farago</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Blakely</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Seto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Tosi</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1-2 trials</article-title><source>Lancet Oncol.</source><year>2020</year><volume>21</volume><fpage>271</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(19)30691-6</pub-id><pub-id pub-id-type="pmid">31838007</pub-id><pub-id pub-id-type="pmcid">PMC7461630</pub-id></element-citation></ref><ref id="B187-cells-13-01071"><label>187.</label><element-citation publication-type="gov"><article-title>FDA Approves Entrectinib for NTRK Solid Tumors and ROS-1 NSCLC</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-04-07">(accessed on 7 April 2024)</date-in-citation></element-citation></ref><ref id="B188-cells-13-01071"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimoi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sunami</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tahara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nishiwaki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tanaka</surname><given-names>S.</given-names></name><name name-style="western"><surname>Baba</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kanai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kinoshita</surname><given-names>I.</given-names></name><name name-style="western"><surname>Shirota</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Dabrafenib and trametinib administration in patients with BRAF V600E/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): A multicentre, open-label, and single-arm phase II trial</article-title><source>EClinicalMedicine</source><year>2024</year><volume>69</volume><fpage>102447</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2024.102447</pub-id><pub-id pub-id-type="pmid">38333370</pub-id><pub-id pub-id-type="pmcid">PMC10850114</pub-id></element-citation></ref><ref id="B189-cells-13-01071"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Damodaran</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Deming</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>V.</given-names></name><name name-style="western"><surname>McShane</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Rubinstein</surname><given-names>L.V.</given-names></name><name name-style="western"><surname>Patton</surname><given-names>D.R.</given-names></name><etal/></person-group><article-title>Phase II Study of Copanlisib in Patients with Tumors with PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F</article-title><source>J. Clin. Oncol.</source><year>2022</year><volume>40</volume><fpage>1552</fpage><lpage>1561</lpage><pub-id pub-id-type="doi">10.1200/JCO.21.01648</pub-id><pub-id pub-id-type="pmid">35133871</pub-id><pub-id pub-id-type="pmcid">PMC9084438</pub-id></element-citation></ref><ref id="B190-cells-13-01071"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bouffet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Geoerger</surname><given-names>B.</given-names></name><name name-style="western"><surname>Moertel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Whitlock</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Aerts</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hargrave</surname><given-names>D.</given-names></name><name name-style="western"><surname>Osterloh</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Russo</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Efficacy and Safety of Trametinib Monotherapy or in Combination with Dabrafenib in Pediatric BRAF V600-Mutant Low-Grade Glioma</article-title><source>J. Clin. Oncol.</source><year>2023</year><volume>41</volume><fpage>664</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1200/JCO.22.01000</pub-id><pub-id pub-id-type="pmid">36375115</pub-id><pub-id pub-id-type="pmcid">PMC9870224</pub-id></element-citation></ref><ref id="B191-cells-13-01071"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herbst</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Giaccone</surname><given-names>G.</given-names></name><name name-style="western"><surname>de Marinis</surname><given-names>F.</given-names></name><name name-style="western"><surname>Reinmuth</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vergnenegre</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barrios</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Morise</surname><given-names>M.</given-names></name><name name-style="western"><surname>Felip</surname><given-names>E.</given-names></name><name name-style="western"><surname>Andric</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Geater</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>383</volume><fpage>1328</fpage><lpage>1339</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1917346</pub-id><pub-id pub-id-type="pmid">32997907</pub-id></element-citation></ref><ref id="B192-cells-13-01071"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hellmann</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Paz-Ares</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bernabe Caro</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zurawski</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Carcereny Costa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Park</surname><given-names>K.</given-names></name><name name-style="western"><surname>Alexandru</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lupinacci</surname><given-names>L.</given-names></name><name name-style="western"><surname>de la Mora Jimenez</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer</article-title><source>N. Engl. J. Med.</source><year>2019</year><volume>381</volume><fpage>2020</fpage><lpage>2031</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1910231</pub-id><pub-id pub-id-type="pmid">31562796</pub-id></element-citation></ref><ref id="B193-cells-13-01071"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Narayan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Osgood</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Ricks</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Chiu Yuen Chow</surname><given-names>E.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Namuswe</surname><given-names>F.</given-names></name><etal/></person-group><article-title>FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer</article-title><source>Clin. Cancer Res.</source><year>2021</year><volume>27</volume><fpage>4478</fpage><lpage>4485</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-4557</pub-id><pub-id pub-id-type="pmid">33753456</pub-id><pub-id pub-id-type="pmcid">PMC8570919</pub-id></element-citation></ref><ref id="B194-cells-13-01071"><label>194.</label><element-citation publication-type="gov"><article-title>FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-Nxki for Unresectable or Metastatic HER2-Positive Solid Tumors</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-04-07">(accessed on 7 April 2024)</date-in-citation></element-citation></ref><ref id="B195-cells-13-01071"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Slamon</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Leyland-Jones</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shak</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>H.</given-names></name><name name-style="western"><surname>Paton</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bajamonde</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fleming</surname><given-names>T.</given-names></name><name name-style="western"><surname>Eiermann</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wolter</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pegram</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2</article-title><source>N. Engl. J. Med.</source><year>2001</year><volume>344</volume><fpage>783</fpage><lpage>792</lpage><pub-id pub-id-type="doi">10.1056/NEJM200103153441101</pub-id><pub-id pub-id-type="pmid">11248153</pub-id></element-citation></ref><ref id="B196-cells-13-01071"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Sridhara</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pazdur</surname><given-names>R.</given-names></name></person-group><article-title>FDA drug approval summary: Gefitinib (ZD1839) (Iressa) tablets</article-title><source>Oncologist</source><year>2003</year><volume>8</volume><fpage>303</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.8-4-303</pub-id><pub-id pub-id-type="pmid">12897327</pub-id></element-citation></ref><ref id="B197-cells-13-01071"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Pazdur</surname><given-names>R.U.S.</given-names></name></person-group><article-title>Food and Drug Administration Drug Approval Summary: Conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval</article-title><source>Clin. Cancer Res.</source><year>2005</year><volume>11</volume><fpage>12</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.12.11.1</pub-id><pub-id pub-id-type="pmid">15671523</pub-id></element-citation></ref><ref id="B198-cells-13-01071"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>G.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gobburu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Benson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Leighton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia</article-title><source>Clin. Cancer Res.</source><year>2002</year><volume>8</volume><fpage>935</fpage><lpage>942</lpage><pub-id pub-id-type="pmid">12006504</pub-id></element-citation></ref><ref id="B199-cells-13-01071"><label>199.</label><element-citation publication-type="gov"><article-title>FDA Grants Accelerated Approval to Nivolumab and Ipilimumab Combination for Hepatocellular Carcinoma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-nivolumab-and-ipilimumab-combination-hepatocellular-carcinoma" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-nivolumab-and-ipilimumab-combination-hepatocellular-carcinoma</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-12">(accessed on 12 June 2024)</date-in-citation></element-citation></ref><ref id="B200-cells-13-01071"><label>200.</label><element-citation publication-type="gov"><article-title>FDA Approves Nivolumab and Ipilimumab for Unresectable Malignant Pleural Mesothelioma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-12">(accessed on 12 June 2024)</date-in-citation></element-citation></ref><ref id="B201-cells-13-01071"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakajima</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Vellanki</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Larkins</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chatterjee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mishra-Kalyani</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Bi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Qosa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Biable</surname><given-names>M.</given-names></name><etal/></person-group><article-title>FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma</article-title><source>Clin. Cancer Res.</source><year>2022</year><volume>28</volume><fpage>446</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-21-1466</pub-id><pub-id pub-id-type="pmid">34462287</pub-id><pub-id pub-id-type="pmcid">PMC8810571</pub-id></element-citation></ref><ref id="B202-cells-13-01071"><label>202.</label><element-citation publication-type="gov"><article-title>FDA Grants Regular Approval to Pembrolizumab and Lenvatinib for Advanced Endometrial Carcinoma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-pembrolizumab-and-lenvatinib-advanced-endometrial-carcinoma#:~:text=On%20July%2021%2C%202021%2C%20the,who%20have%20disease%20progression%20following" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-pembrolizumab-and-lenvatinib-advanced-endometrial-carcinoma#:~:text=On%20July%2021%2C%202021%2C%20the,who%20have%20disease%20progression%20following</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-12">(accessed on 12 June 2024)</date-in-citation></element-citation></ref><ref id="B203-cells-13-01071"><label>203.</label><element-citation publication-type="gov"><article-title>FDA Approves Lenvatinib plus Pembrolizumab for Advanced Renal Cell Carcinoma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lenvatinib-plus-pembrolizumab-advanced-renal-cell-carcinoma" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lenvatinib-plus-pembrolizumab-advanced-renal-cell-carcinoma</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-12">(accessed on 12 June 2024)</date-in-citation></element-citation></ref><ref id="B204-cells-13-01071"><label>204.</label><element-citation publication-type="gov"><article-title>FDA Approves Daratumumab and Hyaluronidase-Fihj with Pomalidomide and Dexamethasone for Multiple Myeloma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-pomalidomide-and-dexamethasone-multiple-myeloma" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-pomalidomide-and-dexamethasone-multiple-myeloma</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B205-cells-13-01071"><label>205.</label><element-citation publication-type="gov"><article-title>FDA Approves Isatuximab-Irfc for Multiple Myeloma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-isatuximab-irfc-multiple-myeloma" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-isatuximab-irfc-multiple-myeloma</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B206-cells-13-01071"><label>206.</label><element-citation publication-type="gov"><article-title>FDA Approves Nivolumab plus Cabozantinib for Advanced Renal Cell Carcinoma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-plus-cabozantinib-advanced-renal-cell-carcinoma" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-plus-cabozantinib-advanced-renal-cell-carcinoma</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B207-cells-13-01071"><label>207.</label><element-citation publication-type="gov"><article-title>FDA Approves Pembrolizumab Plus Axitinib for Advanced Renal Cell Carcinoma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-plus-axitinib-advanced-renal-cell-carcinoma" ext-link-type="uri">https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-plus-axitinib-advanced-renal-cell-carcinoma</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B208-cells-13-01071"><label>208.</label><element-citation publication-type="gov"><article-title>FDA Approves Avelumab plus Axitinib for Renal Cell Carcinoma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avelumab-plus-axitinib-renal-cell-carcinoma" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avelumab-plus-axitinib-renal-cell-carcinoma</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B209-cells-13-01071"><label>209.</label><element-citation publication-type="gov"><article-title>FDA Approves Avelumab for Urothelial Carcinoma Maintenance Treatment</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-avelumab-urothelial-carcinoma-maintenance-treatment" ext-link-type="uri">https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-avelumab-urothelial-carcinoma-maintenance-treatment</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B210-cells-13-01071"><label>210.</label><element-citation publication-type="gov"><article-title>FDA Approves Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-plus-bevacizumab-unresectable-hepatocellular-carcinoma" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-plus-bevacizumab-unresectable-hepatocellular-carcinoma</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B211-cells-13-01071"><label>211.</label><element-citation publication-type="gov"><article-title>FDA Approves Atezolizumab with Chemotherapy and Bevacizumab for First-Line Treatment of Metastatic Non-Squamous NSCLC</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/fda-approves-atezolizumab-chemotherapy-and-bevacizumab-first-line-treatment-metastatic-non-squamous" ext-link-type="uri">https://www.fda.gov/drugs/fda-approves-atezolizumab-chemotherapy-and-bevacizumab-first-line-treatment-metastatic-non-squamous</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B212-cells-13-01071"><label>212.</label><element-citation publication-type="gov"><article-title>FDA Approves Atezolizumab for BRAF V600 Unresectable or Metastatic Melanoma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-braf-v600-unresectable-or-metastatic-melanoma" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-braf-v600-unresectable-or-metastatic-melanoma</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B213-cells-13-01071"><label>213.</label><element-citation publication-type="gov"><article-title>FDA Approves Enfortumab Vedotin-Ejfv with Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic-urothelial-cancer" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic-urothelial-cancer</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B214-cells-13-01071"><label>214.</label><element-citation publication-type="gov"><article-title>FDA Approves Tremelimumab in Combination with Durvalumab for Unresectable Hepatocellular Carcinoma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-unresectable-hepatocellular-carcinoma" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-unresectable-hepatocellular-carcinoma</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B215-cells-13-01071"><label>215.</label><element-citation publication-type="gov"><article-title>FDA Approves Carfilzomib and Daratumumab with Dexamethasone for Multiple Myeloma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-carfilzomib-and-daratumumab-dexamethasone-multiple-myeloma" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-carfilzomib-and-daratumumab-dexamethasone-multiple-myeloma</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B216-cells-13-01071"><label>216.</label><element-citation publication-type="gov"><article-title>FDA Grants Accelerated Approval to Tafasitamab-Cxix for Diffuse Large B-Cell Lymphoma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tafasitamab-cxix-diffuse-large-b-cell-lymphoma" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tafasitamab-cxix-diffuse-large-b-cell-lymphoma</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B217-cells-13-01071"><label>217.</label><element-citation publication-type="gov"><article-title>FDA Approves Lenalidomide for Follicular and Marginal Zone Lymphoma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lenalidomide-follicular-and-marginal-zone-lymphoma" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lenalidomide-follicular-and-marginal-zone-lymphoma</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B218-cells-13-01071"><label>218.</label><element-citation publication-type="gov"><article-title>FDA Approves Combination of Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf for HER2-Positive Breast Cancer</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-combination-pertuzumab-trastuzumab-and-hyaluronidase-zzxf-her2-positive-breast-cancer" ext-link-type="uri">https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-combination-pertuzumab-trastuzumab-and-hyaluronidase-zzxf-her2-positive-breast-cancer</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B219-cells-13-01071"><label>219.</label><element-citation publication-type="gov"><article-title>FDA Approves Ramucirumab Plus Erlotinib for First-Line Metastatic NSCLC</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ramucirumab-plus-erlotinib-first-line-metastatic-nsclc" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ramucirumab-plus-erlotinib-first-line-metastatic-nsclc</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B220-cells-13-01071"><label>220.</label><element-citation publication-type="gov"><article-title>FDA Approves Olaparib Plus Bevacizumab as Maintenance Treatment for Ovarian, Fallopian Tube, or Primary Peritoneal Cancers</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-plus-bevacizumab-maintenance-treatment-ovarian-fallopian-tube-or-primary</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B221-cells-13-01071"><label>221.</label><element-citation publication-type="gov"><article-title>FDA Approves Ibrutinib Plus Rituximab for Chronic Lymphocytic Leukemia</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ibrutinib-plus-rituximab-chronic-lymphocytic-leukemia" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ibrutinib-plus-rituximab-chronic-lymphocytic-leukemia</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B222-cells-13-01071"><label>222.</label><element-citation publication-type="gov"><article-title>FDA Approves Encorafenib in Combination with Cetuximab for Metastatic Colorectal Cancer with a BRAF V600E Mutation</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-combination-cetuximab-metastatic-colorectal-cancer-braf-v600e-mutation" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-combination-cetuximab-metastatic-colorectal-cancer-braf-v600e-mutation</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B223-cells-13-01071"><label>223.</label><element-citation publication-type="gov"><article-title>FDA Approves Opdualag for Unresectable or Metastatic Melanoma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-opdualag-unresectable-or-metastatic-melanoma" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-opdualag-unresectable-or-metastatic-melanoma</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B224-cells-13-01071"><label>224.</label><element-citation publication-type="gov"><article-title>FDA Grants Accelerated Approval to Tucatinib with Trastuzumab for Colorectal Cancer</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tucatinib-trastuzumab-colorectal-cancer" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tucatinib-trastuzumab-colorectal-cancer</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B225-cells-13-01071"><label>225.</label><element-citation publication-type="gov"><article-title>FDA Approves Durvalumab with Chemotherapy for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-chemotherapy-mismatch-repair-deficient-primary-advanced-or-recurrent" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-chemotherapy-mismatch-repair-deficient-primary-advanced-or-recurrent</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B226-cells-13-01071"><label>226.</label><element-citation publication-type="gov"><article-title>FDA Approves Durvalumab for Locally Advanced or Metastatic Biliary Tract Cancer</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-locally-advanced-or-metastatic-biliary-tract-cancer" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-locally-advanced-or-metastatic-biliary-tract-cancer</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B227-cells-13-01071"><label>227.</label><element-citation publication-type="gov"><article-title>FDA Approves Durvalumab for Extensive-Stage Small Cell Lung Cancer</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-extensive-stage-small-cell-lung-cancer" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-extensive-stage-small-cell-lung-cancer</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B228-cells-13-01071"><label>228.</label><element-citation publication-type="gov"><article-title>FDA Grants Accelerated Approval to Ponatinib with Chemotherapy for Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-ponatinib-chemotherapy-newly-diagnosed-philadelphia-chromosome" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-ponatinib-chemotherapy-newly-diagnosed-philadelphia-chromosome</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B229-cells-13-01071"><label>229.</label><element-citation publication-type="gov"><article-title>FDA Grants Accelerated Approval to Zanubrutinib for Relapsed or Refractory Follicular Lymphoma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zanubrutinib-relapsed-or-refractory-follicular-lymphoma" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zanubrutinib-relapsed-or-refractory-follicular-lymphoma</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B230-cells-13-01071"><label>230.</label><element-citation publication-type="gov"><article-title>FDA Approves Nivolumab in Combination with Cisplatin and Gemcitabine for Unresectable or Metastatic Urothelial Carcinoma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-combination-cisplatin-and-gemcitabine-unresectable-or-metastatic-urothelial" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-combination-cisplatin-and-gemcitabine-unresectable-or-metastatic-urothelial</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B231-cells-13-01071"><label>231.</label><element-citation publication-type="gov"><article-title>FDA Approves Osimertinib with Chemotherapy for EGFR-Mutated Non-Small Cell Lung Cancer</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-osimertinib-chemotherapy-egfr-mutated-non-small-cell-lung-cancer" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-osimertinib-chemotherapy-egfr-mutated-non-small-cell-lung-cancer</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B232-cells-13-01071"><label>232.</label><element-citation publication-type="gov"><article-title>FDA Approves Pembrolizumab with Chemoradiotherapy for FIGO 2014 Stage III-IVA Cervical Cancer</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemoradiotherapy-figo-2014-stage-iii-iva-cervical-cancer" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemoradiotherapy-figo-2014-stage-iii-iva-cervical-cancer</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B233-cells-13-01071"><label>233.</label><element-citation publication-type="gov"><article-title>FDA Amends Pembrolizumab&#8217;s Gastric Cancer Indication</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-amends-pembrolizumabs-gastric-cancer-indication" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-amends-pembrolizumabs-gastric-cancer-indication</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B234-cells-13-01071"><label>234.</label><element-citation publication-type="gov"><article-title>FDA Approves Pembrolizumab with Chemotherapy for HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemotherapy-her2-negative-gastric-or-gastroesophageal-junction" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemotherapy-her2-negative-gastric-or-gastroesophageal-junction</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B235-cells-13-01071"><label>235.</label><element-citation publication-type="gov"><article-title>FDA Approves Pembrolizumab with Chemotherapy for Biliary Tract Cancer</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemotherapy-biliary-tract-cancer" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-chemotherapy-biliary-tract-cancer</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B236-cells-13-01071"><label>236.</label><element-citation publication-type="gov"><article-title>FDA Approves Pembrolizumab Combination for the First-Line Treatment of Cervical Cancer</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-combination-first-line-treatment-cervical-cancer" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-combination-first-line-treatment-cervical-cancer</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B237-cells-13-01071"><label>237.</label><element-citation publication-type="gov"><article-title>FDA Approves Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-high-risk-early-stage-triple-negative-breast-cancer</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B238-cells-13-01071"><label>238.</label><element-citation publication-type="gov"><article-title>FDA Approves Pembrolizumab for Esophageal or GEJ Carcinoma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-esophageal-or-gej-carcinoma" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-esophageal-or-gej-carcinoma</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B239-cells-13-01071"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larkins</surname><given-names>E.</given-names></name><name name-style="western"><surname>Blumenthal</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>W.</given-names></name><name name-style="western"><surname>He</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sridhara</surname><given-names>R.</given-names></name><name name-style="western"><surname>Subramaniam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Goldberg</surname><given-names>K.B.</given-names></name><etal/></person-group><article-title>FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy</article-title><source>Oncologist</source><year>2017</year><volume>22</volume><fpage>873</fpage><lpage>878</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2016-0496</pub-id><pub-id pub-id-type="pmid">28533473</pub-id><pub-id pub-id-type="pmcid">PMC5507654</pub-id></element-citation></ref><ref id="B240-cells-13-01071"><label>240.</label><element-citation publication-type="gov"><article-title>FDA Approves Encorafenib with Binimetinib for Metastatic Non-Small Cell Lung Cancer with a BRAF V600E Mutation</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-binimetinib-metastatic-non-small-cell-lung-cancer-braf-v600e-mutation" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-encorafenib-binimetinib-metastatic-non-small-cell-lung-cancer-braf-v600e-mutation</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B241-cells-13-01071"><label>241.</label><element-citation publication-type="gov"><article-title>FDA Approves Trifluridine and Tipiracil with Bevacizumab for Previously Treated Metastatic Colorectal Cancer</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-trifluridine-and-tipiracil-bevacizumab-previously-treated-metastatic-colorectal-cancer" ext-link-type="uri">https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-trifluridine-and-tipiracil-bevacizumab-previously-treated-metastatic-colorectal-cancer</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B242-cells-13-01071"><label>242.</label><element-citation publication-type="gov"><article-title>FDA Approves Dostarlimab-Gxly with Chemotherapy for Endometrial Cancer</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-dostarlimab-gxly-chemotherapy-endometrial-cancer" ext-link-type="uri">https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-dostarlimab-gxly-chemotherapy-endometrial-cancer</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B243-cells-13-01071"><label>243.</label><element-citation publication-type="gov"><article-title>FDA Approves Quizartinib for Newly Diagnosed Acute Myeloid Leukemia</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-quizartinib-newly-diagnosed-acute-myeloid-leukemia" ext-link-type="uri">https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-quizartinib-newly-diagnosed-acute-myeloid-leukemia</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B244-cells-13-01071"><label>244.</label><element-citation publication-type="gov"><article-title>FDA Approves Tremelimumab in Combination with Durvalumab and Platinum-Based Chemotherapy for Metastatic Non-Small Cell Lung Cancer</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-and-platinum-based-chemotherapy-metastatic-non" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-and-platinum-based-chemotherapy-metastatic-non</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B245-cells-13-01071"><label>245.</label><element-citation publication-type="gov"><article-title>FDA Approves Brentuximab Vedotin in Combination with Chemotherapy for Pediatric Patients with Classical Hodgkin Lymphoma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brentuximab-vedotin-combination-chemotherapy-pediatric-patients-classical-hodgkin" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brentuximab-vedotin-combination-chemotherapy-pediatric-patients-classical-hodgkin</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B246-cells-13-01071"><label>246.</label><element-citation publication-type="gov"><article-title>FDA Approves Cemiplimab-Rwlc in Combination with Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cemiplimab-rwlc-combination-platinum-based-chemotherapy-non-small-cell-lung-cancer" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cemiplimab-rwlc-combination-platinum-based-chemotherapy-non-small-cell-lung-cancer</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B247-cells-13-01071"><label>247.</label><element-citation publication-type="gov"><article-title>FDA Approves Opdivo in Combination with Chemotherapy and Opdivo in Combination with Yervoy for First-Line Esophageal Squamous Cell Carcinoma Indications</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-opdivo-combination-chemotherapy-and-opdivo-combination-yervoy-first-line-esophageal" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-opdivo-combination-chemotherapy-and-opdivo-combination-yervoy-first-line-esophageal</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B248-cells-13-01071"><label>248.</label><element-citation publication-type="gov"><article-title>FDA Approves Rituximab plus Chemotherapy for Pediatric Cancer Indications</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-rituximab-plus-chemotherapy-pediatric-cancer-indications" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-rituximab-plus-chemotherapy-pediatric-cancer-indications</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B249-cells-13-01071"><label>249.</label><element-citation publication-type="gov"><article-title>FDA Approves Nivolumab in Combination with Chemotherapy for Metastatic Gastric Cancer and Esophageal Adenocarcinoma</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-combination-chemotherapy-metastatic-gastric-cancer-and-esophageal" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-combination-chemotherapy-metastatic-gastric-cancer-and-esophageal</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B250-cells-13-01071"><label>250.</label><element-citation publication-type="gov"><article-title>FDA Approves Margetuximab for Metastatic HER2-Positive Breast Cancer</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-margetuximab-metastatic-her2-positive-breast-cancer" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-margetuximab-metastatic-her2-positive-breast-cancer</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B251-cells-13-01071"><label>251.</label><element-citation publication-type="gov"><article-title>FDA Grants Accelerated Approval to Naxitamab for High-Risk Neuroblastoma in Bone or Bone Marrow</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-naxitamab-high-risk-neuroblastoma-bone-or-bone-marrow" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-naxitamab-high-risk-neuroblastoma-bone-or-bone-marrow</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B252-cells-13-01071"><label>252.</label><element-citation publication-type="gov"><article-title>FDA Approves Nivolumab plus Ipilimumab and Chemotherapy for First-Line Treatment of Metastatic NSCLC</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-plus-ipilimumab-and-chemotherapy-first-line-treatment-metastatic-nsclc" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-plus-ipilimumab-and-chemotherapy-first-line-treatment-metastatic-nsclc</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B253-cells-13-01071"><label>253.</label><element-citation publication-type="gov"><article-title>FDA Approves Tucatinib for Patients with HER2-Positive Metastatic Breast Cancer</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-patients-her2-positive-metastatic-breast-cancer" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tucatinib-patients-her2-positive-metastatic-breast-cancer</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B254-cells-13-01071"><label>254.</label><element-citation publication-type="gov"><article-title>FDA Approves Neratinib for Metastatic HER2-Positive Breast Cancer</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancer" ext-link-type="uri">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-neratinib-metastatic-her2-positive-breast-cancer</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-06-15">(accessed on 15 June 2024)</date-in-citation></element-citation></ref><ref id="B255-cells-13-01071"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geuijen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tacken</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Klooster</surname><given-names>R.</given-names></name><name name-style="western"><surname>van Loo</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mondal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.B.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Condamine</surname><given-names>T.</given-names></name><etal/></person-group><article-title>A human CD137xPD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>4445</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-24767-5</pub-id><pub-id pub-id-type="pmid">34290245</pub-id><pub-id pub-id-type="pmcid">PMC8295259</pub-id></element-citation></ref><ref id="B256-cells-13-01071"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eskiocak</surname><given-names>U.</given-names></name><name name-style="western"><surname>Guzman</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cummings</surname><given-names>C.</given-names></name><name name-style="western"><surname>Milling</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Ophir</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lambden</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bakhru</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gilmore</surname><given-names>D.C.</given-names></name><etal/></person-group><article-title>Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity</article-title><source>JCI Insight.</source><year>2020</year><volume>5</volume><fpage>e133647</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.133647</pub-id><pub-id pub-id-type="pmid">32161196</pub-id><pub-id pub-id-type="pmcid">PMC7141404</pub-id></element-citation></ref><ref id="B257-cells-13-01071"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enell Smith</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fritzell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nilsson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barchan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rosen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>L.</given-names></name><name name-style="western"><surname>Varas</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sall</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rose</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hakansson</surname><given-names>M.</given-names></name><etal/></person-group><article-title>ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1</article-title><source>Cancer Immunol. Immunother.</source><year>2023</year><volume>72</volume><fpage>4145</fpage><lpage>4159</lpage><pub-id pub-id-type="doi">10.1007/s00262-023-03548-7</pub-id><pub-id pub-id-type="pmid">37796298</pub-id><pub-id pub-id-type="pmcid">PMC10700433</pub-id></element-citation></ref><ref id="B258-cells-13-01071"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><etal/></person-group><article-title>A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity</article-title><source>J. Transl. Med.</source><year>2022</year><volume>20</volume><fpage>415</fpage><pub-id pub-id-type="doi">10.1186/s12967-022-03619-w</pub-id><pub-id pub-id-type="pmid">36076251</pub-id><pub-id pub-id-type="pmcid">PMC9461191</pub-id></element-citation></ref><ref id="B259-cells-13-01071"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsurutani</surname><given-names>J.</given-names></name><name name-style="western"><surname>Iwata</surname><given-names>H.</given-names></name><name name-style="western"><surname>Krop</surname><given-names>I.</given-names></name><name name-style="western"><surname>Janne</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Doi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H.</given-names></name><name name-style="western"><surname>Redfern</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tamura</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wise-Draper</surname><given-names>T.M.</given-names></name><etal/></person-group><article-title>Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors</article-title><source>Cancer Discov.</source><year>2020</year><volume>10</volume><fpage>688</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-19-1014</pub-id><pub-id pub-id-type="pmid">32213540</pub-id><pub-id pub-id-type="pmcid">PMC8292921</pub-id></element-citation></ref><ref id="B260-cells-13-01071"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schram</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Odintsov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Espinosa-Cotton</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khodos</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sisso</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Mattar</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Lui</surname><given-names>A.J.W.</given-names></name><name name-style="western"><surname>Vojnic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shameem</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Chauhan</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements</article-title><source>Cancer Discov.</source><year>2022</year><volume>12</volume><fpage>1233</fpage><lpage>1247</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-21-1119</pub-id><pub-id pub-id-type="pmid">35135829</pub-id><pub-id pub-id-type="pmcid">PMC9394398</pub-id></element-citation></ref><ref id="B261-cells-13-01071"><label>261.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogitani</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Aida</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hagihara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>C.</given-names></name><name name-style="western"><surname>Harada</surname><given-names>N.</given-names></name><name name-style="western"><surname>Soma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Okamoto</surname><given-names>H.</given-names></name><name name-style="western"><surname>Oitate</surname><given-names>M.</given-names></name><name name-style="western"><surname>Arakawa</surname><given-names>S.</given-names></name><etal/></person-group><article-title>DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1</article-title><source>Clin. Cancer Res.</source><year>2016</year><volume>22</volume><fpage>5097</fpage><lpage>5108</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-2822</pub-id><pub-id pub-id-type="pmid">27026201</pub-id></element-citation></ref><ref id="B262-cells-13-01071"><label>262.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mukherjee</surname><given-names>N.</given-names></name><name name-style="western"><surname>Katsnelson</surname><given-names>E.</given-names></name><name name-style="western"><surname>Brunetti</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Michel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Couts</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>McCarter</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Norris</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Tobin</surname><given-names>R.P.</given-names></name><etal/></person-group><article-title>MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade</article-title><source>Cell Death Dis.</source><year>2024</year><volume>15</volume><fpage>198</fpage><pub-id pub-id-type="doi">10.1038/s41419-024-06524-w</pub-id><pub-id pub-id-type="pmid">38459020</pub-id><pub-id pub-id-type="pmcid">PMC10923779</pub-id></element-citation></ref><ref id="B263-cells-13-01071"><label>263.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pyonteck</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Akkari</surname><given-names>L.</given-names></name><name name-style="western"><surname>Schuhmacher</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Bowman</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Sevenich</surname><given-names>L.</given-names></name><name name-style="western"><surname>Quail</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>O.C.</given-names></name><name name-style="western"><surname>Quick</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Huse</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Teijeiro</surname><given-names>V.</given-names></name></person-group><article-title>CSF-1R inhibition alters macrophage polarization and blocks glioma progression</article-title><source>Nat. Med.</source><year>2013</year><volume>19</volume><fpage>1264</fpage><lpage>1272</lpage><pub-id pub-id-type="doi">10.1038/nm.3337</pub-id><pub-id pub-id-type="pmid">24056773</pub-id><pub-id pub-id-type="pmcid">PMC3840724</pub-id></element-citation></ref><ref id="B264-cells-13-01071"><label>264.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>B.-Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kitamura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Campion</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Kaiser</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Snyder</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Pollard</surname><given-names>J.W.</given-names></name></person-group><article-title>CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis</article-title><source>Nature</source><year>2011</year><volume>475</volume><fpage>222</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1038/nature10138</pub-id><pub-id pub-id-type="pmid">21654748</pub-id><pub-id pub-id-type="pmcid">PMC3208506</pub-id></element-citation></ref><ref id="B265-cells-13-01071"><label>265.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gholamin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Feroze</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Esparza</surname><given-names>R.</given-names></name><name name-style="western"><surname>Richard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ramaswamy</surname><given-names>V.</given-names></name><name name-style="western"><surname>Remke</surname><given-names>M.</given-names></name></person-group><article-title>Disrupting the CD47-SIRP&#945; anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors</article-title><source>Sci. Transl. Med.</source><year>2017</year><volume>9</volume><fpage>eaaf2968</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aaf2968</pub-id><pub-id pub-id-type="pmid">28298418</pub-id></element-citation></ref><ref id="B266-cells-13-01071"><label>266.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaneda</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Messer</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Ralainirina</surname><given-names>N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Leem</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Gorjestani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Woo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Figueiredo</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Foubert</surname><given-names>P.</given-names></name></person-group><article-title>PI3K&#947; is a molecular switch that controls immune suppression</article-title><source>Nature</source><year>2016</year><volume>539</volume><fpage>437</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1038/nature19834</pub-id><pub-id pub-id-type="pmid">27642729</pub-id><pub-id pub-id-type="pmcid">PMC5479689</pub-id></element-citation></ref><ref id="B267-cells-13-01071"><label>267.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vonderheide</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Glennie</surname><given-names>M.J.</given-names></name></person-group><article-title>Agonistic CD40 antibodies and cancer therapy</article-title><source>Clin. Cancer Res.</source><year>2013</year><volume>19</volume><fpage>1035</fpage><lpage>1043</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-2064</pub-id><pub-id pub-id-type="pmid">23460534</pub-id><pub-id pub-id-type="pmcid">PMC3590838</pub-id></element-citation></ref><ref id="B268-cells-13-01071"><label>268.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>V.</given-names></name><name name-style="western"><surname>Benjamin</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Ko</surname><given-names>E.C.</given-names></name></person-group><article-title>Radiotherapy and immunotherapy combinations for lung cancer</article-title><source>Curr. Oncol. Rep.</source><year>2021</year><volume>23</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.1007/s11912-020-00993-w</pub-id><pub-id pub-id-type="pmid">33215306</pub-id></element-citation></ref><ref id="B269-cells-13-01071"><label>269.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spitler</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cruickshank</surname><given-names>S.</given-names></name><name name-style="western"><surname>Garbe</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H.-Y.</given-names></name><name name-style="western"><surname>Soong</surname><given-names>S.-j.</given-names></name></person-group><article-title>Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II (T4), III, and IV melanoma</article-title><source>J. Immunother.</source><year>2009</year><volume>32</volume><fpage>632</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1097/CJI.0b013e3181a7d60d</pub-id><pub-id pub-id-type="pmid">19483646</pub-id></element-citation></ref><ref id="B270-cells-13-01071"><label>270.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehrotra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Britten</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Chin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Garrett-Mayer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cloud</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Li</surname><given-names>M.</given-names></name><name name-style="western"><surname>Scurti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Salem</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>M.B.</given-names></name></person-group><article-title>Vaccination with poly (IC: LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer</article-title><source>J. Hematol. Oncol.</source><year>2017</year><volume>10</volume><fpage>82</fpage><pub-id pub-id-type="doi">10.1186/s13045-017-0459-2</pub-id><pub-id pub-id-type="pmid">28388966</pub-id><pub-id pub-id-type="pmcid">PMC5384142</pub-id></element-citation></ref><ref id="B271-cells-13-01071"><label>271.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>W.</given-names></name><name name-style="western"><surname>Dang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>J.</given-names></name><name name-style="western"><surname>He</surname><given-names>R.</given-names></name></person-group><article-title>FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3&#8211;CCL2 signaling</article-title><source>Cancer Res.</source><year>2016</year><volume>76</volume><fpage>4124</fpage><lpage>4135</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-2973</pub-id><pub-id pub-id-type="pmid">27216177</pub-id></element-citation></ref><ref id="B272-cells-13-01071"><label>272.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kieffer</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hocine</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Gentric</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pelon</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bernard</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bourachot</surname><given-names>B.</given-names></name><name name-style="western"><surname>Lameiras</surname><given-names>S.</given-names></name><name name-style="western"><surname>Albergante</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bonneau</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guyard</surname><given-names>A.</given-names></name></person-group><article-title>Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer</article-title><source>Cancer Discov.</source><year>2020</year><volume>10</volume><fpage>1330</fpage><lpage>1351</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-19-1384</pub-id><pub-id pub-id-type="pmid">32434947</pub-id></element-citation></ref><ref id="B273-cells-13-01071"><label>273.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahai</surname><given-names>E.</given-names></name><name name-style="western"><surname>Astsaturov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Cukierman</surname><given-names>E.</given-names></name><name name-style="western"><surname>DeNardo</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Egeblad</surname><given-names>M.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Fearon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Greten</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Hingorani</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Hunter</surname><given-names>T.</given-names></name></person-group><article-title>A framework for advancing our understanding of cancer-associated fibroblasts</article-title><source>Nat. Rev. Cancer</source><year>2020</year><volume>20</volume><fpage>174</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1038/s41568-019-0238-1</pub-id><pub-id pub-id-type="pmid">31980749</pub-id><pub-id pub-id-type="pmcid">PMC7046529</pub-id></element-citation></ref><ref id="B274-cells-13-01071"><label>274.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sherman</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Ruth</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Engle</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>N.</given-names></name><name name-style="western"><surname>Atkins</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Tiriac</surname><given-names>H.</given-names></name><name name-style="western"><surname>Collisson</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Connor</surname><given-names>F.</given-names></name><name name-style="western"><surname>Van Dyke</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kozlov</surname><given-names>S.</given-names></name></person-group><article-title>Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy</article-title><source>Cell</source><year>2014</year><volume>159</volume><fpage>80</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.08.007</pub-id><pub-id pub-id-type="pmid">25259922</pub-id><pub-id pub-id-type="pmcid">PMC4177038</pub-id></element-citation></ref><ref id="B275-cells-13-01071"><label>275.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>F.</given-names></name></person-group><article-title>CD10+ GPR77+ cancer-associated fibroblasts promote cancer formation and chemoresistance by sustaining cancer stemness</article-title><source>Cell</source><year>2018</year><volume>172</volume><fpage>841</fpage><lpage>856. e816</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.01.009</pub-id><pub-id pub-id-type="pmid">29395328</pub-id></element-citation></ref><ref id="B276-cells-13-01071"><label>276.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hajdu</surname><given-names>S.I.</given-names></name></person-group><article-title>A note from history: Landmarks in history of cancer, part 3</article-title><source>Cancer</source><year>2012</year><volume>118</volume><fpage>1155</fpage><lpage>1168</lpage><pub-id pub-id-type="doi">10.1002/cncr.26320</pub-id><pub-id pub-id-type="pmid">21751192</pub-id></element-citation></ref><ref id="B277-cells-13-01071"><label>277.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hajdu</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Vadmal</surname><given-names>M.</given-names></name></person-group><article-title>A note from history: Landmarks in history of cancer, Part 6</article-title><source>Cancer</source><year>2013</year><volume>119</volume><fpage>4058</fpage><lpage>4082</lpage><pub-id pub-id-type="doi">10.1002/cncr.28319</pub-id><pub-id pub-id-type="pmid">24105604</pub-id></element-citation></ref><ref id="B278-cells-13-01071"><label>278.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hajdu</surname><given-names>S.I.</given-names></name><name name-style="western"><surname>Vadmal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>P.</given-names></name></person-group><article-title>A note from history: Landmarks in history of cancer, part 7</article-title><source>Cancer</source><year>2015</year><volume>121</volume><fpage>2480</fpage><lpage>2513</lpage><pub-id pub-id-type="doi">10.1002/cncr.29365</pub-id><pub-id pub-id-type="pmid">25873516</pub-id></element-citation></ref><ref id="B279-cells-13-01071"><label>279.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Doroshow</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Doroshow</surname><given-names>J.H.</given-names></name></person-group><article-title>Genomics and the history of precision oncology</article-title><source>Surg. Oncol. Clin.</source><year>2020</year><volume>29</volume><fpage>35</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.soc.2019.08.003</pub-id><pub-id pub-id-type="pmcid">PMC6878897</pub-id><pub-id pub-id-type="pmid">31757312</pub-id></element-citation></ref><ref id="B280-cells-13-01071"><label>280.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adashek</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Subbiah</surname><given-names>V.</given-names></name><name name-style="western"><surname>Kurzrock</surname><given-names>R.</given-names></name></person-group><article-title>From tissue-agnostic to N-of-one therapies:(R) evolution of the precision paradigm</article-title><source>Trends Cancer</source><year>2021</year><volume>7</volume><fpage>15</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2020.08.009</pub-id><pub-id pub-id-type="pmid">33008795</pub-id></element-citation></ref><ref id="B281-cells-13-01071"><label>281.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Redig</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>J&#228;nne</surname><given-names>P.A.</given-names></name></person-group><article-title>Basket trials and the evolution of clinical trial design in an era of genomic medicine</article-title><source>J. Clin. Oncol.</source><year>2015</year><volume>33</volume><fpage>975</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.59.8433</pub-id><pub-id pub-id-type="pmid">25667288</pub-id></element-citation></ref><ref id="B282-cells-13-01071"><label>282.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solomon</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Mok</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.-W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.-L.</given-names></name><name name-style="western"><surname>Nakagawa</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mekhail</surname><given-names>T.</given-names></name><name name-style="western"><surname>Felip</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cappuzzo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Paolini</surname><given-names>J.</given-names></name><name name-style="western"><surname>Usari</surname><given-names>T.</given-names></name></person-group><article-title>First-line crizotinib versus chemotherapy in ALK-positive lung cancer</article-title><source>N. Engl. J. Med.</source><year>2014</year><volume>371</volume><fpage>2167</fpage><lpage>2177</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1408440</pub-id><pub-id pub-id-type="pmid">25470694</pub-id></element-citation></ref><ref id="B283-cells-13-01071"><label>283.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaw</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>de Marinis</surname><given-names>F.</given-names></name><name name-style="western"><surname>Felip</surname><given-names>E.</given-names></name><name name-style="western"><surname>Goto</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mazieres</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.-W.</given-names></name><name name-style="western"><surname>Mok</surname><given-names>T.</given-names></name><name name-style="western"><surname>Polli</surname><given-names>A.</given-names></name></person-group><article-title>First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>383</volume><fpage>2018</fpage><lpage>2029</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2027187</pub-id><pub-id pub-id-type="pmid">33207094</pub-id></element-citation></ref><ref id="B284-cells-13-01071"><label>284.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>G.V.</given-names></name><name name-style="western"><surname>Stroyakovskiy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gogas</surname><given-names>H.</given-names></name><name name-style="western"><surname>Levchenko</surname><given-names>E.</given-names></name><name name-style="western"><surname>De Braud</surname><given-names>F.</given-names></name><name name-style="western"><surname>Larkin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garbe</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jouary</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hauschild</surname><given-names>A.</given-names></name><name name-style="western"><surname>Grob</surname><given-names>J.-J.</given-names></name></person-group><article-title>Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: A multicentre, double-blind, phase 3 randomised controlled trial</article-title><source>Lancet</source><year>2015</year><volume>386</volume><fpage>444</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)60898-4</pub-id><pub-id pub-id-type="pmid">26037941</pub-id></element-citation></ref><ref id="B285-cells-13-01071"><label>285.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mok</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.-L.</given-names></name><name name-style="western"><surname>Kudaba</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kowalski</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Turna</surname><given-names>H.Z.</given-names></name><name name-style="western"><surname>Castro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Srimuninnimit</surname><given-names>V.</given-names></name><name name-style="western"><surname>Laktionov</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Bondarenko</surname><given-names>I.</given-names></name></person-group><article-title>Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial</article-title><source>Lancet</source><year>2019</year><volume>393</volume><fpage>1819</fpage><lpage>1830</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)32409-7</pub-id><pub-id pub-id-type="pmid">30955977</pub-id></element-citation></ref><ref id="B286-cells-13-01071"><label>286.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Robert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Long</surname><given-names>G.V.</given-names></name><name name-style="western"><surname>Brady</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dutriaux</surname><given-names>C.</given-names></name><name name-style="western"><surname>Maio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mortier</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hassel</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Rutkowski</surname><given-names>P.</given-names></name><name name-style="western"><surname>McNeil</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kalinka-Warzocha</surname><given-names>E.</given-names></name></person-group><article-title>Nivolumab in previously untreated melanoma without BRAF mutation</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>372</volume><fpage>320</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1412082</pub-id><pub-id pub-id-type="pmid">25399552</pub-id></element-citation></ref><ref id="B287-cells-13-01071"><label>287.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sikalidis</surname><given-names>A.K.</given-names></name></person-group><article-title>Amino acids and immune response: A role for cysteine, glutamine, phenylalanine, tryptophan and arginine in T-cell function and cancer?</article-title><source>Pathol. Oncol. Res.</source><year>2015</year><volume>21</volume><fpage>9</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1007/s12253-014-9860-0</pub-id><pub-id pub-id-type="pmid">25351939</pub-id></element-citation></ref><ref id="B288-cells-13-01071"><label>288.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larkin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chiarion-Sileni</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Grob</surname><given-names>J.-J.</given-names></name><name name-style="western"><surname>Rutkowski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lao</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Cowey</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Schadendorf</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wagstaff</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dummer</surname><given-names>R.</given-names></name></person-group><article-title>Five-year survival with combined nivolumab and ipilimumab in advanced melanoma</article-title><source>N. Engl. J. Med.</source><year>2019</year><volume>381</volume><fpage>1535</fpage><lpage>1546</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1910836</pub-id><pub-id pub-id-type="pmid">31562797</pub-id></element-citation></ref><ref id="B289-cells-13-01071"><label>289.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rini</surname><given-names>B.I.</given-names></name><name name-style="western"><surname>Plimack</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Stus</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gafanov</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hawkins</surname><given-names>R.</given-names></name><name name-style="western"><surname>Nosov</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pouliot</surname><given-names>F.</given-names></name><name name-style="western"><surname>Alekseev</surname><given-names>B.</given-names></name><name name-style="western"><surname>Souli&#232;res</surname><given-names>D.</given-names></name><name name-style="western"><surname>Melichar</surname><given-names>B.</given-names></name></person-group><article-title>Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma</article-title><source>N. Engl. J. Med.</source><year>2019</year><volume>380</volume><fpage>1116</fpage><lpage>1127</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1816714</pub-id><pub-id pub-id-type="pmid">30779529</pub-id></element-citation></ref><ref id="B290-cells-13-01071"><label>290.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gandhi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Abreu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gadgeel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Esteban</surname><given-names>E.</given-names></name><name name-style="western"><surname>Felip</surname><given-names>E.</given-names></name><name name-style="western"><surname>De Angelis</surname><given-names>F.</given-names></name><name name-style="western"><surname>Domine</surname><given-names>M.</given-names></name><name name-style="western"><surname>Clingan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hochmair</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>S.F.</given-names></name></person-group><article-title>Pembrolizumab plus chemotherapy in metastatic non&#8211;small-cell lung cancer</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>378</volume><fpage>2078</fpage><lpage>2092</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1801005</pub-id><pub-id pub-id-type="pmid">29658856</pub-id></element-citation></ref><ref id="B291-cells-13-01071"><label>291.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bokemeyer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bondarenko</surname><given-names>I.</given-names></name><name name-style="western"><surname>Makhson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Aparicio</surname><given-names>J.</given-names></name><name name-style="western"><surname>De Braud</surname><given-names>F.</given-names></name><name name-style="western"><surname>Donea</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ludwig</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schuch</surname><given-names>G.</given-names></name><name name-style="western"><surname>Stroh</surname><given-names>C.</given-names></name></person-group><article-title>Fluorouracil leucovorin and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer</article-title><source>J. Clin. Oncol.</source><year>2009</year><volume>27</volume><fpage>663</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1200/JCO.2008.20.8397</pub-id><pub-id pub-id-type="pmid">19114683</pub-id></element-citation></ref><ref id="B292-cells-13-01071"><label>292.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palmer</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Sorger</surname><given-names>P.K.</given-names></name></person-group><article-title>Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy</article-title><source>Cell</source><year>2017</year><volume>171</volume><fpage>1678</fpage><lpage>1691.e1613</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.11.009</pub-id><pub-id pub-id-type="pmid">29245013</pub-id><pub-id pub-id-type="pmcid">PMC5741091</pub-id></element-citation></ref><ref id="B293-cells-13-01071"><label>293.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsimberidou</surname><given-names>A.-M.</given-names></name><name name-style="western"><surname>Iskander</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Wheler</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Falchook</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Piha-Paul</surname><given-names>S.</given-names></name><name name-style="western"><surname>Naing</surname><given-names>A.</given-names></name><name name-style="western"><surname>Janku</surname><given-names>F.</given-names></name><name name-style="western"><surname>Luthra</surname><given-names>R.</given-names></name></person-group><article-title>Personalized medicine in a phase I clinical trials program: The MD Anderson Cancer Center initiative</article-title><source>Clin. Cancer Res.</source><year>2012</year><volume>18</volume><fpage>6373</fpage><lpage>6383</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-1627</pub-id><pub-id pub-id-type="pmid">22966018</pub-id><pub-id pub-id-type="pmcid">PMC4454458</pub-id></element-citation></ref><ref id="B294-cells-13-01071"><label>294.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hainsworth</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Meric-Bernstam</surname><given-names>F.</given-names></name><name name-style="western"><surname>Swanton</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hurwitz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Spigel</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Sweeney</surname><given-names>C.</given-names></name><name name-style="western"><surname>Burris</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bose</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>A.</given-names></name></person-group><article-title>Targeted therapy for advanced solid tumors on the basis of molecular profiles: Results from MyPathway, an open-label, phase IIa multiple basket study</article-title><source>J. Clin. Oncol.</source><year>2018</year><volume>36</volume><fpage>536</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1200/JCO.2017.75.3780</pub-id><pub-id pub-id-type="pmid">29320312</pub-id></element-citation></ref><ref id="B295-cells-13-01071"><label>295.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsimberidou</surname><given-names>A.-M.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cartwright</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wheler</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Falchook</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Naing</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Piha-Paul</surname><given-names>S.</given-names></name><name name-style="western"><surname>Janku</surname><given-names>F.</given-names></name></person-group><article-title>Initiative for molecular profiling and advanced cancer therapy (IMPACT): An MD Anderson precision medicine study</article-title><source>JCO Precis. Oncol.</source><year>2017</year><volume>1</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1200/PO.17.00002</pub-id><pub-id pub-id-type="pmid">29082359</pub-id><pub-id pub-id-type="pmcid">PMC5659750</pub-id></element-citation></ref><ref id="B296-cells-13-01071"><label>296.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sicklick</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>S.</given-names></name><name name-style="western"><surname>Okamura</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schwaederle</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>De</surname><given-names>P.</given-names></name><name name-style="western"><surname>Krie</surname><given-names>A.</given-names></name><name name-style="western"><surname>Piccioni</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>V.A.</given-names></name></person-group><article-title>Molecular profiling of cancer patients enables personalized combination therapy: The I-PREDICT study</article-title><source>Nat. Med.</source><year>2019</year><volume>25</volume><fpage>744</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0407-5</pub-id><pub-id pub-id-type="pmid">31011206</pub-id><pub-id pub-id-type="pmcid">PMC6553618</pub-id></element-citation></ref><ref id="B297-cells-13-01071"><label>297.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sicklick</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>S.</given-names></name><name name-style="western"><surname>Okamura</surname><given-names>R.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nikanjam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fanta</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>De</surname><given-names>P.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guido</surname><given-names>J.</given-names></name></person-group><article-title>Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-na&#239;ve study</article-title><source>Genome Med.</source><year>2021</year><volume>13</volume><fpage>155</fpage><pub-id pub-id-type="doi">10.1186/s13073-021-00969-w</pub-id><pub-id pub-id-type="pmid">34607609</pub-id><pub-id pub-id-type="pmcid">PMC8491393</pub-id></element-citation></ref><ref id="B298-cells-13-01071"><label>298.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Soria</surname><given-names>J.-C.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>R.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Rubin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kugel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tsimberidou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Saintigny</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ackerstein</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bra&#241;a</surname><given-names>I.</given-names></name></person-group><article-title>Genomic and transcriptomic profiling expands precision cancer medicine: The WINTHER trial</article-title><source>Nat. Med.</source><year>2019</year><volume>25</volume><fpage>751</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0424-4</pub-id><pub-id pub-id-type="pmid">31011205</pub-id><pub-id pub-id-type="pmcid">PMC6599610</pub-id></element-citation></ref><ref id="B299-cells-13-01071"><label>299.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaya</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kato</surname><given-names>S.</given-names></name><name name-style="western"><surname>Adashek</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fanta</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Botta</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Sicklick</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Kurzrock</surname><given-names>R.</given-names></name></person-group><article-title>Personalized matched targeted therapy in advanced pancreatic cancer: A pilot cohort analysis</article-title><source>NPJ Genom. Med.</source><year>2023</year><volume>8</volume><fpage>1</fpage><pub-id pub-id-type="doi">10.1038/s41525-022-00346-5</pub-id><pub-id pub-id-type="pmid">36670111</pub-id><pub-id pub-id-type="pmcid">PMC9860045</pub-id></element-citation></ref><ref id="B300-cells-13-01071"><label>300.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fountzilas</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tsimberidou</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Vo</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Kurzrock</surname><given-names>R.</given-names></name></person-group><article-title>Clinical trial design in the era of precision medicine</article-title><source>Genome Med.</source><year>2022</year><volume>14</volume><fpage>101</fpage><pub-id pub-id-type="doi">10.1186/s13073-022-01102-1</pub-id><pub-id pub-id-type="pmid">36045401</pub-id><pub-id pub-id-type="pmcid">PMC9428375</pub-id></element-citation></ref><ref id="B301-cells-13-01071"><label>301.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dienstmann</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rodon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tabernero</surname><given-names>J.</given-names></name></person-group><article-title>Optimal design of trials to demonstrate the utility of genomically-guided therapy: Putting precision cancer medicine to the test</article-title><source>Mol. Oncol.</source><year>2015</year><volume>9</volume><fpage>940</fpage><lpage>950</lpage><pub-id pub-id-type="doi">10.1016/j.molonc.2014.06.014</pub-id><pub-id pub-id-type="pmid">25081646</pub-id><pub-id pub-id-type="pmcid">PMC5528747</pub-id></element-citation></ref><ref id="B302-cells-13-01071"><label>302.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bogin</surname><given-names>V.</given-names></name></person-group><article-title>Master protocols: New directions in drug discovery</article-title><source>Contemp. Clin. Trials Commun.</source><year>2020</year><volume>18</volume><fpage>100568</fpage><pub-id pub-id-type="doi">10.1016/j.conctc.2020.100568</pub-id><pub-id pub-id-type="pmid">32395664</pub-id><pub-id pub-id-type="pmcid">PMC7205752</pub-id></element-citation></ref><ref id="B303-cells-13-01071"><label>303.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Offin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Drilon</surname><given-names>A.</given-names></name></person-group><article-title>Tumor-agnostic drug development</article-title><source>American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting</source><publisher-name>NIH Public Access</publisher-name><publisher-loc>Bethesda, MD, USA</publisher-loc><year>2018</year><fpage>184</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/EDBK_200831</pub-id><pub-id pub-id-type="pmcid">PMC7506519</pub-id><pub-id pub-id-type="pmid">30231313</pub-id></element-citation></ref><ref id="B304-cells-13-01071"><label>304.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simon</surname><given-names>R.</given-names></name><name name-style="western"><surname>Roychowdhury</surname><given-names>S.</given-names></name></person-group><article-title>Implementing personalized cancer genomics in clinical trials</article-title><source>Nat. Rev. Drug Discov.</source><year>2013</year><volume>12</volume><fpage>358</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1038/nrd3979</pub-id><pub-id pub-id-type="pmid">23629504</pub-id></element-citation></ref><ref id="B305-cells-13-01071"><label>305.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stewart</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Kurzrock</surname><given-names>R.</given-names></name></person-group><article-title>Fool&#8217;s gold, lost treasures, and the randomized clinical trial</article-title><source>BMC Cancer</source><year>2013</year><volume>13</volume><elocation-id>193</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2407-13-193</pub-id><pub-id pub-id-type="pmid">23587187</pub-id><pub-id pub-id-type="pmcid">PMC3639810</pub-id></element-citation></ref><ref id="B306-cells-13-01071"><label>306.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tabatabaei</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>M.</given-names></name></person-group><article-title>Enzyme-Linked Immunosorbent Assay (ELISA)</article-title><source>Methods Mol. Biol.</source><year>2022</year><volume>2508</volume><fpage>115</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1007/978-1-0716-2376-3_10</pub-id><pub-id pub-id-type="pmid">35737237</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="cells-13-01071-f001" orientation="portrait"><label>Figure 1</label><caption><p>Historical timeline of the development of our understanding of human neoplasms.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cells-13-01071-g001.jpg"/></fig><fig position="float" id="cells-13-01071-f002" orientation="portrait"><label>Figure 2</label><caption><p>Schematic overview of the principle of the next-generation sequencing methodology. NGS uses libraries of short segments of DNA or RNA tagged by adapter sequences for bidirectional bridge amplification. Sequencing is accomplished using the amplified fragments using fluorescently labeled nucleotides of which emission wavelengths and intensity are continuously recorded upon the simultaneous synthesis along millions of templates. This leads to the read of hundreds to thousands of fragment clusters at the same time. Sequence information is finally lined up to reference genome sequences.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cells-13-01071-g002.jpg"/></fig><fig position="float" id="cells-13-01071-f003" orientation="portrait"><label>Figure 3</label><caption><p>Schematic overview of the roles of characteristic tumor-agnostic biomarkers in cell cycle control.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cells-13-01071-g003.jpg"/></fig><fig position="float" id="cells-13-01071-f004" orientation="portrait"><label>Figure 4</label><caption><p>Schematic overview of the prototype immune checkpoint inhibitors. Engaging the immune checkpoint effector PD-1 receptor of T-lymphocytes by the PD-L1 ligand of dendritic cells results in suppression of both the innate and adaptive immunity. Cancer cells can exert this immune paralysis by the expression of PD-L1. This interaction can be blocked by the PD-1 monoclonal antibody (PD-1 mAb). In addition to PD-1/PDL-1, the cytotoxic T-lymphocyte antigen-4 (CTLA-4) ligation by its ligand B7, expressed on antigen-presenting cells, triggers an inhibitory response of T-lymphocyte activity. CTLA-4 targeting monoclonal antibodies (CTLA-4 mAb) can disrupt this interaction. Thus, pharmacological targeting of the PD-1/PD-L1 and CTLA-4/B7 complexes is believed to deliberate T-cell activity from cancer-mediated paralysis and serve as a potential tumor-agnostic targets.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="cells-13-01071-g004.jpg"/></fig><table-wrap position="float" id="cells-13-01071-t001" orientation="portrait"><object-id pub-id-type="pii">cells-13-01071-t001_Table 1</object-id><label>Table 1</label><caption><p>Summary of the next generation sequencing-based oncopanels currently in use in clinical practice and in research. NSCLC: non-small-cell lung cancer.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Panel</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"># of Genes</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Neoplasms</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<sc>FDA </sc>
</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Manufacturer</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">FoundationOne CDx</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">324</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">NSCLC, melanoma, breast cancer, colorectal cancer, and ovarian cancer</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Foundation medicine</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B47-cells-13-01071" ref-type="bibr">47</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Oncomine Dx Target Test</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">23</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Original use: NSCLC<break/>Current use: NSCLC, colon cancer, melanoma, gastric and ovarian cancer</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Thermo Fisher scientific</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B48-cells-13-01071" ref-type="bibr">48</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Omniseq Advance</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">144</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Solid tumors</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Labcorp oncology</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B49-cells-13-01071" ref-type="bibr">49</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Omniseq Insight</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">523</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Solid tumors</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Labcorp oncology</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B50-cells-13-01071" ref-type="bibr">50</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancerplex</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">435</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Solid tumors</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">KEW</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B51-cells-13-01071" ref-type="bibr">51</xref>]</td></tr></tbody></table></table-wrap><table-wrap position="float" id="cells-13-01071-t002" orientation="portrait"><object-id pub-id-type="pii">cells-13-01071-t002_Table 2</object-id><label>Table 2</label><caption><p>Programmed death ligand 1 immunohistochemistry assays used to identify programmed death ligand 1-positive cancers. NSCLC, non-small-cell lung cancer.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Stain</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antibody</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">FDA Approval</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Supplier</th><th align="center" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">22C3</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">pembrolizumab</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes for NSCLC</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Agilent DAKO</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B52-cells-13-01071" ref-type="bibr">52</xref>,<xref rid="B55-cells-13-01071" ref-type="bibr">55</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">28-8</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">nivolumab</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes for NSCLC, Squamous cell carcinoma of the head and neck and melanoma</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Agilent DAKO</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B52-cells-13-01071" ref-type="bibr">52</xref>,<xref rid="B56-cells-13-01071" ref-type="bibr">56</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">SP142</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">atezolizumab</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes for NSCLC and urothelial carcinoma</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Ventana Roche</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B52-cells-13-01071" ref-type="bibr">52</xref>,<xref rid="B57-cells-13-01071" ref-type="bibr">57</xref>]</td></tr><tr><td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">SP263</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">durvalumab</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes for NSCLC</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Ventana Roche</td><td align="center" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B52-cells-13-01071" ref-type="bibr">52</xref>,<xref rid="B58-cells-13-01071" ref-type="bibr">58</xref>]</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>